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This study evaluated the epidemiological relationship between diabetes and 
incident depression, as well as antidepressant medication utilization among indigent care 
patients diagnosed with diabetes. Medical data for 2,886 subjects receiving care in a 
public indigent care provider network were utilized for this study. Diagnoses of diabetes, 
depression, and other comorbid medical conditions were identified from the electronic 
medical record. Prescription claims data from the clinic pharmacy network were used to 
evaluate medication-taking behaviors. Clinical laboratory data were extracted, as 
available, from the electronic clinic records. 
After controlling for the influence of age, gender, race/ethnicity, marital status 
classification, and Charlson score, a diagnosis of diabetes was associated with a 42 
percent reduction in odds of new-onset depression (p = 0.021). In the a priori analysis of 
factors associated with new-onset depression among diabetic patients, none of the risk 
factors evaluated were associated with incident depression at a statistically significant 
 vi 
level. Post-hoc exploratory analyses revealed that female gender and White non-Hispanic 
race/ethnicity were associated with increased odds of a prevalent diagnosis of depression 
among diabetic patients. Patients with diabetes were more likely to be prescribed 
selective serotonin reuptake inhibitors (SSRIs) as their initial antidepressant medication 
compared to non-SSRIs. Diagnosis of diabetes was not associated with antidepressant 
switch, discontinuation, or 6-month antidepressant adherence; however, diagnosis of 
diabetes was associated with a higher level of 12-month antidepressant adherence (p = 
0.024). Diagnosis of diabetes was also associated with a higher level of 3-month 
antidepressant persistence (p = 0.004), but not 12-month persistence. There were no 
statistically significant relationships observed between initial class of antidepressant 
medication prescribed and any of the medication-taking behaviors evaluated. For subjects 
with available data (n = 106), glycemic control was evaluated in terms of hemoglobin 
A1c. Increased antidepressant medication adherence was associated with higher 
hemoglobin A1c values during follow-up. 
Results suggest that prevalent diabetes is associated with a reduced risk of 
diagnosis of new-onset depression in indigent care patients. Further research is necessary 
to evaluate the effect that chronic comorbid medical conditions such as diabetes may 
have on antidepressant medication-taking behaviors, and the relationship between 
antidepressant exposure and glycemic control. 
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 1 
Chapter 1: Introduction and Literature Review 
PROBLEM STATEMENT 
As clinicians increasingly embrace a holistic approach to understanding the health 
status of their patients, greater attention has been given to the interaction between chronic 
medical conditions and comorbid psychiatric disorders. Of particular interest to many has 
been the effect of comorbid mood disorders on chronic diseases such as hypertension, 
cardiovascular disease, and diabetes mellitus. A number of studies have indicated that 
chronic medical conditions may be exacerbated when comorbid depression is present. 
Patients with concurrent psychiatric and chronic medical conditions utilize more 
healthcare resources, experience greater loss of productivity, and display increased 
functional impairment compared to their non-depressed counterparts. While recent 
attention has focused on the complex interactions between mental illness and a variety of 
chronic medical conditions, relatively little research has been conducted focusing on the 
implications of medical and psychiatric comorbidity on psychotropic utilization patterns, 
psychotropic medication adherence and persistence, and other factors related to 
medication treatment in these patients. The purpose of this research is to evaluate the 
relationship between diabetes and new-onset depression, and to explore the potential 
implications that comorbid diabetes and depression may have on medication-taking 
behaviors and patient clinical status. 
  
 2 
INTRODUCTION 
The notion that a relationship exists between psychiatric disorders, emotional 
well-being, and physical health is not a new concept. “A cheerful heart is good medicine, 
but a crushed spirit dries up the bones” writes the author of the Biblical text Proverbs, 
noting the link between emotional and physical well-being.
1
 In the 3
rd
 century CE, the 
Roman philosopher and physician Galen speculated that physical and psychological 
maladies were related to a common etiology. He suggested that melancholic disposition 
and breast cancer in women were related to a common underlying imbalance in black 
bile.
2
 The 12
th
 century Rabbi Moshe ben Maimon comments in his work, Regimen of 
Health, that the “passions of the psyche produce changes
 
in the body that are great, 
evident, and manifest to all”.
3
 Further, Maimonides suggests that a primary role of the 
physician is to address these psychological barriers to wellness. In more recent times, 
Thomas Willis, the originator of the term diabetes mellitus in the late 17
th
 century, noted 
the association between glycosuria and mood. Willis suggested that diabetes resulted 
from “sadness or long sorrow and other depression and disorders”.
4
  
Despite historical recognition of the relationships between the mind, emotional 
well-being, and the body, modern medicine is only beginning to fully appreciate the 
biological basis of these associations and their clinical consequences. In the 300 years 
since Willis’ observation, scientific research focused on the relationship between diabetes 
and depression has been scarce. Indeed, most of the scientific literature on the subject has 
only emerged in the last 20 years. This chapter will provide a brief overview of major 
depressive disorder and diabetes mellitus, including a review of the epidemiology, 
diagnosis, and treatment of each disorder. This chapter will also summarize the current 
understanding of the relationship between depression and diabetes, and review the 
 3 
research evaluating clinical outcomes among individuals with diabetes and comorbid 
depression.  
 4 
MAJOR DEPRESSIVE DISORDER 
Epidemiology 
Major Depressive Disorder (MDD, referred to simply as depression hereafter) is a 
severe and disabling psychiatric mood disorder affecting approximately 6 percent of 
Americans each year.
5
 According to the National Comorbidity Survey Replication study, 
the lifetime prevalence of MDD is approximately 16 percent.
6
 Risk factors for depression 
include female gender, younger age, family history of mood disorder, and personal 
history of mood disorder.
7,8
 Women appear to be especially susceptible to depression, 
with a risk approximately two-fold greater than their male counterparts.
9
 Unmarried 
marital status, unemployment, less than 12 years of education, and living in or near 
poverty have also been identified as risk factors for depression in Americans.
10
 
 
Morbidity and Mortality 
Major depression can be a particularly disabling psychiatric condition. The World 
Health Organization (WHO) has identified depression as a leading cause of disability and 
disease burden world-wide.
11
 Individuals with depression may be at as much as a five-
fold increased risk of disability.
12
 In older individuals, depression is associated with 
increased risk of disability, impairment in activities of daily living, and decreased 
mobility.
13-16
 The level of functional impairment associated with depression is 
comparable to or greater than disability associated with a number of medical disorders, 
including hypertension, diabetes, and arthritis.
17
 A recent WHO survey found that 
depression was associated with the lowest overall health status among chronic medical 
conditions including asthma, angina, arthritis, and diabetes.
18
 
 5 
In addition to profound effect on functional impairment and disability, depression 
is a significant risk factor for suicide-related mortality. The risk of suicide associated with 
depression varies across different populations of patients. In a meta-analysis of patients 
with depressive disorders, Bostwick and Pankratz found a “stair-step” progression in 
suicide risk based on treatment setting and the presence of specific suicidal thoughts or 
actions.
19
 (see Figure 1.1). Patients treated in the outpatient setting had the lowest 
probability of suicide (2.2%), patients treated in the inpatient setting displayed a higher 
probability of suicide (4.0%), and inpatients admitted after a suicide attempt or with 
suicidal ideation had the highest probability for completed suicide (8.6%). 
 
  
 6 
Figure 1.1 Lifetime risk of suicide for individuals with depression by treatment site and 
in the general population 
 
Data from Bostwick and Pankratz,2000 19  
 
  
 7 
Clinical Course 
In over 70 percent of cases, depression is recurrent and episodic.
20
 The incidence 
of depression increases rapidly in the mid-teens, after which the incidence rate is steady 
within a given age cohort.
20
 The median age at onset of depression is in the mid-30s.
6
 
Left untreated, depression spontaneously remits in approximately 89 percent of 
individuals within two years.
21
 If spontaneous remission of depression is to occur, it 
typically occurs in the first 3-4 months of the depressive episode. For those who do not 
remit in this timeframe, the chances of spontaneously remitting later are significantly 
lower.
21
 
According to the American Psychiatric Association, treatment of depression is 
conceptualized as following three phases: acute, continuation, and maintenance.
22
 The 
goal of the acute phase of treatment is to achieve remission of depressive symptoms. 
Remission is defined as a return to a baseline, pre-morbid level of symptom severity and 
global functioning. The period of time associated with the acute phase treatment of 
depression is patient-specific, but typically lasts 8-12 weeks.  
Once remission of depression is achieved, continuation phase treatment is 
initiated. The purpose of continuation phase treatment is to prevent the return of 
depressive symptoms. Continuation phase treatment consists of continuing the treatment 
and dosage of medication that was successful in achieving remission for an additional 16-
20 weeks.
22
 Following successful continuation phase treatment and sustained remission 
of depressive symptoms, an individual is considered to have recovered from the initial 
episode of depression. A return of depressive symptoms during the continuation phase of 
treatment is considered a relapse.
23
 The return of depressive symptoms after the 
completion of continuation treatment (i.e., after recovery) is considered recurrence.
23
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Recurrence is indicative of a new and separate episode of depression, distinct from the 
initial episode. 
Recurrence rates are high among patients with a history of depression. 
Approximately one-half of individuals will experience a recurrent episode of depression 
after their first episode, and the risk of recurrence increases with each subsequent episode 
of depression.
24
 By the time an individual has experienced three past episodes of 
depression, the probability of recurrence is 90 percent.
24
 The presence of residual 
depressive symptoms is also associated with significantly increased risk of recurrent 
depression. An individual with residual depressive symptoms following acute treatment 
for depression has an approximately 3.5-fold increased risk for recurrent depression, and 
will relapse approximately 3 times faster than patients who achieve complete symptom 
remission.
25
 For patients at high risk of recurrence, long-term maintenance phase 
treatment may be indicated. Factors which should be considered when determining the 
suitability of maintenance treatment for an individual include: the risk of recurrence, 
severity of previous episodes of depression, side effects experienced during treatment, 
and patient preference.
22
 Maintenance phase treatment consists of long-term continuation 
of treatment with the primary objective of preventing future recurrence of depression.
22
 
 
Economic Impact 
The economic impact of depression is significant, and was estimated to amount to 
$83.1 billion dollars in 2000.
26
 Much of the economic burden of depression is attributed 
to costs associated with workplace absenteeism and decreased workplace productivity. Of 
these costs, $51.5 billion were attributed to workplace costs, $26.1 billion to direct 
treatment costs, and $5.4 billion to suicide-related costs.
26
 (see Figure 1.2). Druss et al. 
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found that patients with depression used, on average, a significantly greater number of 
sick days per year compared to patients with diabetes (9.86 vs. 7.17, p=0.04), heart 
disease (7.47, p=0.01), hypertension (5.39, p<0.001), or back problems (7.21, p=0.04).
27
 
 
Figure 1.2 Total economic burden of depression, 2000 
 
           Data from Greenberg, et al., 2003 26 
 
 
In addition to decreased productivity, individuals with major depression consume 
substantially greater healthcare resources than non-depressed patients. In a study of 
healthcare utilization among Canadians in Nova Scotia, patients with depression were 50 
percent more likely to utilize a high amount of physician services, more likely to be 
hospitalized, have a hospitalization over three days, and have higher healthcare costs than 
non-depressed individuals.
28
 Increased healthcare utilization translates into increased 
healthcare costs. Even after controlling for the influence of chronic medical conditions on 
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health care utilization, healthcare costs are higher among patients with depression 
compared to the non-depressed.
29
  
 
Pathophysiology 
The causes of depression are not well understood, but the etiology is likely 
complex and multi-factorial with genetics, environmental, and biological factors all 
contributing. Genetic factors are thought to account for approximately 40 percent of the 
risk for depression.
30,31
 Studies indicate that depression tends to be familial,
32-35
 with first 
degree family members of individuals with depression having an approximately three-
fold increased risk for being diagnosed with depression.
30
 Some research suggests that 
individuals who are at high familial risk for depression tend to have more severe and 
recurrent depression, with longer duration of depressive episodes, high levels of 
depression-related impairment, and recurrent thoughts of death or suicide.
36
 Despite 
evidence of the genetic basis for affective disorders, researchers have been unsuccessful 
at identifying specific genes which confer risk. The reality of the heterogeneity and 
complexity of psychiatric disorders is such that it is unlikely that a single genetic risk 
factor will be isolated.
37
 Rather, it is more likely that the genetic risk factors for 
depression are extremely complex, involving interactions between multiple genes, and 
interactions with environmental risk factors.
31
  
The fundamental principle of biological psychiatry is that the physiological 
functioning of the human body and the brain can be used to explain the symptoms and 
experience of mental illness. Attempts have been made to “deconstruct” the symptoms 
associated with major depressive disorder and their associated neurophysiological circuits 
(See Table 1.1). A number of brain regions have been proposed to play a significant role 
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in the pathophysiology of depression including the prefrontal and cingulate cortex, 
hippocampus, striatum, amygdala, and thalamus.
38
 
 
Table 1.1 Hypothetical topography of symptoms of major depressive disorder.  
 
Adapted from Stahl, et al. 38 
 
 
While recent animal and human research has shed some light on potential brain 
regions involved in depression, historically much of what we know regarding the 
biological basis of depression is a result of the serendipitous discovery of 
pharmacological agents with effects on mood. In the 1950s and 1960s, researchers began 
to unravel the complex web of pharmacological, animal, and human clinical data 
describing the role of monoamines in mood disorders. Research uncovering the 
antidepressant activity of iproniazid and imipramine, as well as the potential for 
Symptom(s)
Depressed mood and sadness
Sleep disturbances
Problems concentrating
Change in weight or appetite
Fatigue and anergia
Anhedonia
Amygdala, anterior cingulate cortex, medial 
prefrontal cortex, orbitofrontal cortex
Striatum, cerebellum  
Medial prefrontal cortex, anterior cingulate cortex, 
orbitofrontal cortex
Neural circuit(s)
Feelings of worthlessness or 
guilt and thoughts of suicide
Psychomotor agitation or 
retardation
Hypothalamic sleep-wake switch, brainstem sleep 
centers
Dorsolateral prefrontal cortex
Hypothalamus
Striatum, cerebellum, spinal cord
Hypothalamus, nucleus accumbens
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medications such as reserpine and tetrabenazine to elicit depressive symptoms, resulted in 
initial formulation of the monoamine hypothesis of depression.
39
 
The monoamine hypothesis of depression, as expressed in 1965 by Schildkraut, 
states that “depressions are associated with an absolute or relative decrease in 
cathecholamines, particularly norepinephrine, available at central adrenergic receptor 
sites. Elation, conversely, may be associated with an excess of such amines.”
40
 The 
monoamine hypothesis of depression as originally formulated was focused on the role of 
catecholamines, specifically norepinephrine, in the etiology of depression. Alec Coppen, 
publishing his review in the British Journal of Psychiatry two years after Schildkraut, 
argued for a role of serotonin in the etiology of depression.
41
 In the 1970s, dopamine was 
added to the discussion of monoamines with potential relevance to depression.
39
 
While the monoamine hypothesis of depression has an elegant and 
straightforward explanatory value (depletion of monoamines cause depression, 
restoration of monoamine levels corrects this deficiency and alleviates symptoms of 
depression), it is overly simplistic and does not account for a number of clinical 
observations. Most notably, the monoamine hypothesis does not adequately account for 
the observation that the onset of action of antidepressant medication is delayed over a 
period of weeks after starting treatment. While some treatment-emergent adverse effects 
such as nausea, irritability, and insomnia may appear acutely following administration of 
antidepressant medications, initial clinical resolution of depressive symptoms typically 
occurs over a prolonged period of time, typically two to four weeks.
22
 This observation 
has led much of the current research to focus on potential mechanisms of action away 
from the synapse and actual monoamine levels, to distal sites of action. Some researchers 
have proposed that the delayed effectiveness of antidepressant medications may be due to 
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“time lag” related to gene expression and protein transcription at these distant sites of 
action.
31,42,43
 
In addition to genetic and biological factors, non-genetic factors such as stress, 
traumatic life events, and environmental exposures are thought to be involved in the 
etiology of depression. The role of stress in the development of depression has garnered 
special attention. One of the mechanisms by which the human body responds to 
emotional or physical stress is by activation of the hypothalamic-pituitary-adrenal (HPA) 
axis.
43
 HPA activation ultimately results in an increase in glucocorticoid secretion.  In 
patients with depression, dysregulation of the HPA axis is thought to be related to 
alteration of glucocorticoid receptor expression and activity, and hypersecretion of 
corticotropin-releasing hormone.
44,45
 Chronic hypercortisolemia may result in neural 
damage, especially in the areas of the brain such as the hippocampus and the amygdala 
which are associated with mood, cognition, and emotional regulation.
43
 
Another area that has received recent attention is the role of neurotrophic factors 
in depression. Neurotropins are proteins that regulate the growth and differentiation of 
neural cells during development, as well as plasticity and survival of developed neuronal 
networks in the adult brain. Of particular interest is the role of brain-derived neurotrophic 
factor (BDNF) in the pathophysiology of depression. Via a number of different 
mechanisms, stress results in a reduction of BDNF in the central nervous system, and 
deficiencies of BDNF may play a role in central nervous system pathology, specifically 
in the hippocampus.
43
 Interestingly, administration of antidepressant medication is 
associated with increased production of BDNF in the hippocampus.
46
 Theoretically, an 
increase in BDNF production and other neurotrophins may have neuroprotective and 
neurorestorative effects, which may account for the therapeutic effects of antidepressant 
medications.
43,46
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Our understanding of the biological basis of depression is clearly limited. As 
researchers continue their quest to understand the genetic, biological and environmental 
factors involved in psychiatric mood disorders, their advances pave the way for novel 
pharmacological treatments for depression. Clinical research involving agents affecting 
the HPA axis, BDNF activity, and other biological targets are ongoing and may yield 
future novel treatments that not only improve the lives of individuals suffering from 
depression, but continue to enhance our understanding the complex biological 
mechanisms underlying depression. 
 
Diagnosis 
Depression is characterized by depressed mood and/or anhedonia occurring in the 
presence of a constellation of other symptoms including sleep changes, appetite changes, 
amotivation, anergia, impaired concentration, and feelings of guilt or worthlessness.
24
 
The Diagnostics and Statistical Manual-IV Text Revision (DSM-IV TR) is the gold 
standard in the United States for the diagnosis of mental disorders.
24
 The DSM-IV TR 
criteria for major depressive disorder require the presence of five or more depressive 
symptoms, with either a depressed mood and/or anhedonia, being present (see Table 1.2). 
It should be noted that diagnosis of depression is not based on objective 
diagnostic tests (e.g., blood chemistry, imaging, etc.). Rather, a diagnosis of depression is 
based on the presence of a collection of symptoms. As discussed previously, the 
underlying physiological activities that result in the symptoms associated with depression 
are likely diverse and heterogeneous across individuals. Therefore, what we characterize 
as depression is most appropriately conceptualized as a syndromatic umbrella under 
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Table 1.2 Diagnostic and Statistical Manual IV - Text Revision criteria for the diagnosis 
of Major Depressive Episode 
 
Adapted from American Psychiatric Association, 2000 
24
 
 
 
which a variety of distinct or related pathophysiological processes fall. It is perhaps this 
complexity and heterogeneity that underlies the variable clinical presentation and 
unpredictable nature of treatment response in patients diagnosed with major depressive 
disorder. 
 
(3) significant weight loss when not dieting or weight gain, or decrease or increase in appetite 
nearly every day
A. Five or more of the following symptoms have been present during the same 2-week period and 
represent a change from previous functioning: at least one of the symptoms is either (1) 
depressed mood or (2) loss of interest or pleasure.
B. Symptoms do not meet criteria for a Mixed Episode.
E. The symptoms are not better accounted for by Bereavement.
(9) recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide 
attempt or a specific plan for committing suicide
(2) markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day (as indicated by either subjective account or observation made by others)
(1) Depressed mood most of the day, nearly every day, as indicated by either subjective report 
(e.g. feels sad or empty) or observation made by others (e.g. appears tearful)
(4) insomnia or hypersomnia nearly every day
(5) psychomotor agitation or retardation nearly every day
(6) fatigue or loss of energy nearly every day
(7) feelings of worthlessness or excessive or inappropriate feelings of guilt nearly every day
(8) diminished ability to think or concentrate, or indecisiveness, nearly every day
C. The symptoms cause clinically significant distress or impairment in social, occupational, or other 
important areas of functioning.
D. The symptoms are not due to the directy physiological effects of a substance, or a general 
medical condition.
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Diagnostic Coding 
According to the DSM-IV TR nosology, the diagnostic codes 296.2x and 296.3x 
are used to indicate a diagnosis of major depressive disorder (see Table 1.3). The DSM-
IV TR code 311 may also be used to code depressive disorder, not otherwise specified.
24
 
For 296.2x and 296.3x, the fourth digit may be used to indicate whether the current 
episode of depression is the initial episode, or whether the current episode of depression 
is a recurrent episode (296.2x, single episode; 296.3x, recurrent). According to DSM-IV 
TR, an episode of MDD is considered to have ended when there exists a period of two 
months or more during which there is either complete resolution of depressive symptoms 
or depressive symptoms no longer meet the full diagnostic criteria. Note that the duration 
of sustained symptom remission indicative of recovery according to the DSM-IV TR 
differs from the APA treatment guidelines previously discussed. A return of depressive 
symptoms prior to a sustained two-month period of remission would be considered a 
relapse, and a continuation of the initial major depressive episode (coded as 296.2x). A 
return to syndromatic depression after sustained remission of depressive symptoms would 
be indicative of a recurrence of MDD, i.e., a new and distinct major depressive episode, 
and would be coded with DSM code 296.3x. 
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Table 1.3 Diagnostic and Statistical Manual IV - Text Revision diagnostic codes for 
major depressive disorder and related fourth and fifth digit specifiers 
 
 
 
In addition to the fourth digit codes, the DSM-IV TR coding schema allow for the 
use of a number of other specifiers to provide information about the psychiatric 
presentation of an individual with major depression (see Table 1.3). The DSM-IV TR 
fifth digit specifiers may be used to indicate either the current clinical status of an episode 
of depression or the severity of current presentation. If the individual meets the full 
diagnostic criteria for MDD at the time of assessment, the fifth digit is used to indicate 
the severity of the current episode. If the full diagnostic criteria for MDD are not met at 
the time of assessment, the fifth digit indicates the level of remission (i.e., in partial 
remission or in full remission). In addition to these specifiers captured in the diagnostic 
coding, the DSM-IV TR describes a number of other specifiers that are not coded. These 
specifiers include: chronic, with catatonic features, with melancholic features, with 
atypical features, and with postpartum onset. The International Statistical Classification 
Code Description
296.2x Major Depressive Disorder, Single Episode
296.3x Major Depressive Disorder, Recurrent
311 Depressive Disorder, Not Otherwise Specified
Fifth digit specifiers
If full criteria for Major Depressive Disorder are met:
296.x1 Mild 
296.x2 Moderate
296.x3 Severe without psychotic features
296.x4 Severe with psychotics features
If full criteria for Major Depressive Disorder are NOT met:
296.x5 In partial remission
296.x6 In full remission
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of Diseases and Related Health Problems, 9
th
 revision clinical modification (ICD-9 CM) 
diagnostic codes for major depressive disorder correspond to the DSM-IV TR diagnostic 
codes.
47
 
 
Treatment 
Treatment Goals 
The goals of treatment for depression are to achieve complete and sustained 
remission of depressive symptoms, complete functional recovery, and to prevent further 
episodes of depression.
22
 Remission is defined as a return to premorbid normalcy, the 
complete absence of depressive symptoms, and the restoration of function.
48
 Remission is 
distinct from treatment response in that response is, in practical terms, considered a 
significant but incomplete improvement in depressive symptomatology, whereas 
remission is the complete resolution of depressive symptoms. In clinical trials, treatment 
response is defined as a 50 percent reduction in the score of a depression-specific 
psychiatric rating scale.
48,49
 In these studies, remission is defined in terms of a threshold 
score on the rating scale (e.g., 17-item Hamilton Depression Rating Scale score < 7).
48,49
 
In clinical practice patient-rated assessments of depression severity, such as the 9-
item Patient Health Questionnaire (PHQ-9), may be used to assess and track the severity 
of depression during the course of treatment.
50
 The PHQ-9 is derivative from the Primary 
Care Evaluation of Mental Disorders (PRIME-MD) Patient Health Questionnaire 
instrument.
51
 The PHQ-9 consists of the 9 items from the depression module of the 
broader Patient Health Questionnaire.
50,51
 Each item included in the PHQ-9 is tied to one 
of the DSM-IV criteria for depression. Patients are asked to score each item based on the 
frequency of experiencing specific symptoms within the past 2 weeks (scoring: 0, not at 
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all; 1, several days; 2, more than half the days; 3, nearly every day). Therefore, PHQ-9 
scores range from 0-27, with higher scores indicating increasing severity of depression 
symptoms. Breakpoints for interpreting PHQ-9 scores are provided in Table 1.4. 
 
Table 1.4 Interpretation of Patient Health Questionnaire-9 scores 
 
Adapted from Kroenke et al., 2001 50 
 
 
Pharmacotherapy 
The discovery of the antidepressant effects of iproniazid and imipramine, along 
with the discovery of the antipsychotic chlorpromazine, marked the advent of modern 
psychopharmacology. Imipramine and iproniazid were the unexpected result of unrelated 
research on antihistamine and anti-tubercular agents, respectively.
39
 Following the 
discovery of the antidepressant effects of these agents, a number of related medication 
therapies were developed, giving rise to the monoamine oxidase inhibitors (MAOIs) and 
the other tricyclic antidepressants (TCAs). Despite their effectiveness as antidepressant 
agents, these early agents were plagued by poor tolerability and safety concerns. The 
MAOIs interact with many other medications as well as some food products to cause a 
hypertensive reaction, while the TCAs are associated with significant adverse effects, 
cardiovascular toxicity, and can be lethal in overdose situations.
52-54
 Based on an 
PHQ-9 score Depression severity
1 to 4 None
5 to 9 Mild
10 to 14 Moderate
15 to 19 Moderately Severe
20 to 27 Severe
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understanding of the pharmacodynamics of these early antidepressant medications, a 
number of novel compounds were developed beginning in the late 1970s and early 1980s. 
These novel compounds include the selective serotonin reuptake inhibitors, the serotonin-
norepinephrine reuptake inhibitors, as well as a number of other agents. While these 
newer medications have a more favorable tolerability and safety profile than the older 
agents, no significant advances in terms of antidepressant effectiveness have been 
made.
55
 
Antidepressant therapy is the mainstay of medication treatment for depression. A 
number of medication alternatives are available for the treatment of depression; the most 
commonly used medications currently include: Selective Serotonin Reuptake Inhibitors 
(SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic 
Antidepressants (TCAs), and the atypical antidepressants (bupropion, mirtazapine) (see 
Table 1.5). These medications are considered equally effective for the treatment of 
uncomplicated major depression; however, they differ greatly with regards to their safety 
and tolerability profiles.
22
 The SSRIs are the most commonly prescribed class of 
antidepressant medication in the United States, likely due to their favorable safety and 
tolerability profile. In addition to efficacy as antidepressant treatments, these medications 
are used in a variety of other psychiatric conditions, including anxiety disorders. 
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Table 1.5 Classification of commonly used antidepressant agents 
 
Generic name Brand name
SSRIs
Fluoxetine Prozac®
Sertraline Zoloft®
Paroxetine Paxil®, Paxil CR®, Pexeva ®
Citalopram Celexa®
Escitalopram Lexapro®
Fluvoxamine Luvox®, Luvox CR®
SNRIs
Venlafaxine Effexor®, Effexor XR®
Duloxetine Cymbalta®
Desvenlafaxine Pristiq®
Bupropion Wellbutrin®, Wellbutrin SR®, Wellbutrin XL®
Mirtazapine Remeron®
Tricyclic Antidepressants
Amitriptyline Elavil®
Clomipramine Anafranil®
Desipramine Norpramin®
Doxepin Sinequan®
Imipramine Tofranil®
Nortriptyline Pamelor®
Protriptyline Vivactil®
Trimipramine Surmontil®
Atypical Antidepressants
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake 
inhibitor; TCA, tricyclic antidepressant
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The mechanism of action for each of the modern antidepressant medications 
varies by class. All U.S. Food and Drug Administration (FDA)-approved antidepressant 
medications act either directly or indirectly on monoamine neurotransmission. The SSRI 
antidepressants are so named due to their selective inhibition of the serotonin reuptake 
transport protein located on presynaptic neurons.
56
 The most commonly prescribed SSRI 
antidepressants for depression are fluoxetine, sertraline, paroxetine, citalopram, and 
escitalopram. SNRI medications exert their action by inhibiting the activity of both 
serotonin and norepinephrine reuptake transport proteins.
57
 FDA-approved SNRI 
medications include venlafaxine, duloxetine and desvenlafaxine. The TCA medications 
exert their antidepressant effect by inhibiting norepinephrine and serotonin reuptake to 
extents that vary according to the pharmacodynamic profile of each individual tricyclic 
agent.
58
 The antidepressant medication bupropion is thought to exert its antidepressant 
activity through its affinity for norepinephrine and dopamine transport proteins; however, 
bupropion displays a relatively low affinity for the serotonin transport protein.
59
 This 
unique mechanism of action is thought to explain the side effect profile of bupropion, 
with relatively low rates of sexual dysfunction reported during treatment.
60
 The 
antidepressant medication mirtazapine has a complex mechanism of action whereby it 
increases noradrenergic and serotonergic neurotransmission indirectly by blocking 
presynaptic α2 receptors. Simultaneous to α2 blockade, mirtazapine alters neurotransmitter 
activity at the level of postsynaptic receptors by blocking 5-HT2 and 5-HT3 receptors.
61
 
Of particular interest to clinicians is how to best utilize the wide variety of 
antidepressant medications available for the treatment of depression. A number of 
organizations have released evidence-based consensus guidelines and treatment 
algorithms to inform clinical decision making in the treatment of depression.
22,62
 The 
Texas Medication Algorithm Project treatment guidelines recommend a stepwise 
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approach to treatment of depression, beginning with antidepressant monotherapy and 
branching to a variety of augmentation and switch strategies as the individual clinical 
situation dictates.
62
 Results from the STAR*D effectiveness study indicate that if a 
sequential algorithm for the treatment of depression is optimally implemented, remission 
rates of up to 70 percent are achievable.
63
 
 
Summary 
Depression is a serious and debilitating mental illness that affects a significant 
number of Americans. The course of depression is typically chronic and recurrent. 
Depression is associated with significant morbidity, mortality, and economic costs. The 
biological phenomena underlying depression are not completely understood, but 
depression is thought to be related to a combination of genetic, biological, and 
environmental factors. A number of medications including SSRIs, SNRIs, and other 
antidepressant medications have demonstrated efficacy for the treatment of depression. 
Remission is the goal of treatment for depression, and is associated with improved 
functioning and decreased risk for recurrence of depression. Remission is achieved by 
approximately one-third of subjects in acute treatment trials with antidepressant 
medications. Sequential treatment strategies based on evidence-based algorithms may 
increase remission rates to as high as two-thirds. 
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DIABETES MELLITUS 
Epidemiology 
Diabetes mellitus (DM, referred to simply as diabetes hereafter) is an endocrine 
disorder characterized by impaired glycemic control and hyperglycemia. According to 
National Health and Nutrition Examination Survey (NHANES) data from 1999-2000, the 
prevalence of diabetes in the United States is just over 9 percent, and affects nearly 20 
million Americans.
64
 The prevalence of diagnosed diabetes increases with older age and 
varies by race (see Figure 1.3). Diagnosed diabetes is more common among non-Hispanic 
blacks (11.0%) and Mexican-Americans (10.4%), with prevalence among these 
ethnicities approximately two-fold higher than that of non-Hispanic whites (5.2%).
64
 Of 
particular concern, 2.8 percent of Americans have undiagnosed diabetes.
64
 Also alarming 
is the high overall prevalence of impaired fasting glucose (26.0%), indicating that a 
significant number of Americans are at high risk for development of diabetes and for 
cardiovascular disease. 
64
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Figure 1.3 Prevalence of diagnosed diabetes mellitus by age and race 
 
         Data from Cowie et al., 2006 64  
 
Risk factors for diabetes and prediabetes are summarized in Table 1.6. The risk of 
type 2 diabetes increases with age and lack of physical activity.
65
 Diabetes is also more 
common among people with a family history of diabetes, and women with a history of 
gestational diabetes.
65
 Obesity is a well recognized risk factor for diabetes, increasing risk 
over seven-fold.
66
 The prevalence of diabetes, as discussed earlier, is higher among 
certain ethnic groups. Specifically, Hispanic, non-Hispanic black, Asian American, 
Native American, or Pacific Islander ethnicities are considered a risk factor for diabetes.
65
 
Individuals with hypertension, dyslipidemia, cardiovascular disease, and a history of 
impaired fasting blood glucose or impaired glucose tolerance are also at an increased risk 
for later developing diabetes.
65
 Exposure to certain medications, such as atypical 
antipsychotics
67
 and corticosteroids,
68
 may increase the risk of hyperglycemia and 
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diabetes. Polycystic ovarian syndrome and psychiatric illness are other recognized risk 
factors for diabetes mellitus.
65
 
 
Table 1.6 Risk factors for diabetes and prediabetes 
 
       Adapted from Rodbard et al., 2007 65 
 
Classification 
Diabetes can be classified into four types: Type 1, Type 2, gestational, or diabetes 
due to other causes (e.g., drug induced).
69
 Type 1 diabetes mellitus (T1DM) accounts for 
5-10 percent of all cases of diabetes, is characterized by the complete absence of insulin 
production, and is thought to be the result of an autoimmune response resulting in 
destruction of the insulin-producing beta cells in the pancreas.
65,69
 Type 2 diabetes 
mellitus (T2DM) is a complex metabolic condition thought to be related to decreased 
physiological sensitivity to insulin, decreased insulin production, and/or increased hepatic 
glucose production.
65,69
 Type 2 diabetes accounts for approximately 90-95 percent of all 
cases of diabetes.
69
 Gestational diabetes mellitus is characterized by glucose intolerance 
Risk Factors
Family history of diabetes
Cardiovascular disease
Overweight or obesity
Sedentary lifestyle
Impaired glucose tolerance or impaired fasting glucose
Hypertension
Dyslipidemia
History of gestational diabetes
Polycystic ovary syndrome
Psychiatric illness
Hispanic, non-Hispanic black, Asian American, Native American, or 
Pacific Islander ethnicity
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with onset during pregnancy, and affects approximately 4 percent of all pregnancies.
69
 
Diabetes may also be associated with a number of other specific causes, including 
medications and other medical conditions. In recent years, the American Diabetes 
Association has also recognized the category of “pre-diabetes.”
69
 Individuals who meet 
criteria for pre-diabetes are at high risk for developing diabetes.
65,69
 
 
Pathophysiology 
Diabetes is associated with hyperglycemia due to reduced production of insulin, a 
decrease in insulin’s physiological effects, increased hepatic glucose production, or a 
combination of these factors. The etiology of diabetes is multi-factorial in nature, 
influenced by both genetic and environmental factors. While development of T1DM is 
not genetically predestined, genetic factors can increase risk of developing this condition. 
Human leukocyte antigen (HLA) DR and HLA-DQ appear to have a strong association 
with diabetes
69
, with other HLA components likely playing a significant role as well.
70
 
Autoimmune destruction of the insulin-producing beta cells of the pancreas leads to 
insulin deficiency, hyperglycemia, and the hallmark characteristics of diabetes. 
Autoimmune antibodies indicative of this process are present in up to 90% of individuals 
with T1DM.
69
 
The etiology of T2DM is fundamentally related to pathological changes in insulin 
secretion and activity, and hepatic production of glucose.
65
 Adiposity plays a pivotal role 
in the development of T2DM. Increases in adiposity lead to decreases in sensitivity to 
insulin and increased circulating glucose levels.
65
 This hyperglycemia leads to further 
insulin desensitization and increased insulin production, perpetuating a cycle of insulin 
resistance and increased production, compounding the problem of glycemic 
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dysregulation. Ultimately, repeat hyperglycemia, as well as the actions of cytokines, 
leptin, and dyslipidemia result in pancreatic beta cell burn-out.
71
 
 
Diagnosis 
Diabetes can be diagnosed by fasting blood glucose (FBG), causal blood glucose 
measurement, or by oral glucose tolerance test (OGTT) .
65,69
 The diagnostic criteria must 
be met on two separate occasions, on different days, in order for a diagnosis of diabetes 
to be made.
69
 In a broadening of the concept of glycemic abnormalities, the category of 
pre-diabetes was introduced in 2003 by the American Diabetes Association. Pre-diabetes 
is identified by the presence of either an impaired FBG or an impaired OGTT, and is a 
risk factor for the development of diabetes and future cardiovascular disease.
69
 The 
American Diabetes Association criteria for diagnosis of diabetes and pre-diabetes are 
presented in Table 1.7. 
 
Table 1.7 American Diabetes Association diagnostic criteria for diabetes mellitus 
 
Diagnosis Criteria
Diabetes FBG ≥ 126mg/dl
Casual BG > 200mg/dl and symptoms of hyperglycemia
2-h post OGTT plasma glucose level ≥ 200mg/dl
Pre-diabetes FBG 100-125 mg/dl
2-h post OGTT plasma glucose level 140-199 mg/dl
FBG, fasting blood glucose; OGTT, oral glucose tolerance test
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Diagnostic Coding 
The ICD-9 CM codes 250.0x to 250.9x are used to code diabetes (see Table 
1.8).
47
 The ICD-9 CM code 250.0 is used to indicate a diagnosis of diabetes mellitus 
without further specification for the presence of complications or classification. The ICD-
9 CM fourth digit may be used to indicate the presence of diabetic complications 
including ketoacidosis (250.1), renal complications (250.4), and ophthalmic 
complications (250.5). A fifth digit code may be used to identify the particular 
classification of diabetes (i.e., type 1 vs. type 2) and the level of glycemic control 
(controlled or uncontrolled).  
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Table 1.8 International Statistical Classification of Diseases and Related Health 
Problems, 9th Revision clinical modification codes for diabetes and related disorders  
 
  
ICD-9 CM code Description
Diabetes codes
250.0 Diabetes mellitus without mention of complication
250.1 Diabetes with ketoacidosis
250.2 Diabetes with hyperosmolarity
250.3 Diabetes with other coma
250.4 Diabetes with renal manifestations
250.5 Diabetes with ophthalmic manifestations
250.6 Diabetes with neurological manifestations
250.7 Diabetes with peripheral circulatory disorders
250.8 Diabetes with other specified manifestations
250.9 Diabetes with unspecified complication
250.x0 Diabetes mellitus type 2 or unspecified type
250.x1 Diabetes mellitus type 1
250.x2 Diabetes mellitus type 2 or unspecified type, uncontrolled
250.x3 Diabetes mellitus type 1, uncontrolled
Other related codes
251.0 Hypoglycemic coma
251.1 Other specified hypoglycemia
251.2 Hypoglycemia unspecified
277.7 Dysmetabolic syndrome x
362.0x Diabetic retinopathy*
366.41 Diabetic cataract
357.2 Polyneuropathy in diabetes
585.x Chronic kidney disease
*added in 2006
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Treatment 
Treatment Goals 
The goals of treatment for diabetes are to effectively manage glycemic control 
and to prevent complications associated with diabetes. Glycemic control is evaluated in 
terms of FBG and glycosylated hemoglobin (hemoglobin A1c or HbA1c). Fasting blood 
glucose values indicate a “snapshot” of an individual’s glucose level at a moment in time, 
whereas HbA1c levels reflect the average glycemic levels over a period of time 
approximating 120 days.
72
 According to the American Diabetes Association guidelines, 
HbA1c is the primary target for glycemic control and the lab test should be obtained 
initially and routinely during the course of care.
73
 In order to make the concept of HbA1c 
easier for patients to integrate into their self-monitoring practices, the American Diabetes 
Association has recommended the use of the term estimated average glucose (eAG) to 
express the equivalence between HbA1c and mean plasma glucose levels.
73
 (see Table 
1.9). In addition to having utility for evaluating glycemic control over a period of months, 
HbA1c has also been shown to be predictive of diabetic complications and outcomes 
associated with chronic diabetes.
74
  
A summary of the American Diabetes Association recommendations for 
achieving glycemic control in adults with diabetes is presented in Table 1.10.
73
 Notably, 
while the American Diabetes Association indicates that the target HbA1c for patients 
with diabetes should be < 7 percent, other organizations recommend more aggressive 
targets for HbA1c. The American Association of Clinical Endocrinologists recommends 
a target HbA1c of < 6.5 percent for patients with diabetes.
65
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Table 1.9 Relationship between hemoglobin A1c level and estimated average glucose.  
 
       Adapted from American Diabetes Association, 2009 73 
 
Table 1.10 Summary of American Diabetes Association glycemic goals for adults with 
diabetes 
 
       Adapted from Stratton, 2000 73 
 
Non-pharmacological Treatment 
Successful management of diabetes typically requires both lifestyle interventions 
as well as medication treatment. The American Diabetes Association recommends that 
any treatment plan for diabetes incorporates diabetes self-management education 
including instruction for proper self-monitoring of blood glucose (SMBG) and education 
on medical nutritional therapy.
73
 Self-monitoring of blood glucose can be used to 
evaluate the effectiveness of medication treatment and to prevent hyper- and 
hypoglycemia.
73
 Self-monitoring allows patients to monitor their level of glycemic 
control on an ongoing basis, is useful to inform treatment decisions, and may help in 
preventing hypoglycemia.
73
 In patients with diabetes receiving insulin treatment, SMBG 
HbA1c value (%) eAG (mg/dl)
6.0 126
7.0 154
8.0 183
9.0 212
10.0 240
11.0 269
12.0 298
HbA1c, hemoglobin A1c; eAG, estimated average glucose
Goal
< 7.0%
70-130 mg/dl
< 180 mg/dl
Pre-prandial plasma glucose
Peak post-prandial plasma glucose
HbA1c
Assessment
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is especially important, and the American Diabetes Association recommends SMBG at 
least three times daily for these patients.
73
 Self-monitoring of blood glucose may be 
useful, as well, in patients with T2DM not receiving insulin treatment. Research suggests 
that SMBG is associated with a reduction of 0.4 percent in HbA1c when SMBG is 
included in the treatment plan of individuals with T2DM.
75
 
Medical nutrition therapy (MNT) is the primary non-pharmacological therapy for 
the treatment, prevention, and control of diabetes.
65,73,76
 The goal of MNT is to reduce the 
risk of diabetes and cardiovascular disease through nutritional choices and physical 
activity. Specifically, the goals of MNT are to achieve glycemic control within the 
normal range, to achieve a lipid profile that reduces cardiovascular risk, to maintain 
blood pressure control, to prevent or slow the development of diabetic complications, and 
to address nutritional needs.
76
 Research indicate that MNT can have a profound impact 
on glycemic control, reducing HbA1c by 1-2 percent.
77
 MNT is also effective for 
preventing the development of diabetes in individuals at high risk for the disease.
77
 
 
Pharmacological Treatment 
Medication treatment for diabetes varies according to the classification of 
diabetes. Due the lack of insulin production characteristic of T1DM, medication 
treatment for T1DM consists of insulin replacement therapy.
65,69
 The American Diabetes 
Association recommends a general insulin replacement strategy consisting of multiple 
daily dosage of basal and prandial insulin, or continuous subcutaneous insulin infusion 
(insulin pump therapy).
73
 A variety of human insulin formulations have been developed 
to optimally mimic the normal physiological profile of insulin and to achieve glycemic 
control (see Table 1.11). 
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Table 1.11 Insulin formulations used for the treatment of diabetes mellitus 
 
         Adapted from Dipiro et al. 78 
 
 
Medication treatment for T2DM consists of oral antidiabetic agents, injectable 
antidiabetic agents, and insulin replacement therapy. Selection of specific treatment for 
T2DM is guided by consideration of the glycemic effects, non-glycemic effects, safety 
and tolerability, and ease of use of the individual agents.
79
 Five classes of oral 
antidiabetic medications are available for the treatment of T2DM: sulfonylureas (SU), 
meglitinides, biguanides, thiazolidinediones (TZD), and alpha-glucosidase inhibitors. 
Examples of each of these medication classes are provided in Table 1.12. A number of 
combination formulations of these agents are also available (see Table 1.13). 
 
Insulin Formulation Onset Peak Duration
Rapid-acting
Insulin aspart 5-15 min 1-2 h 3-5 h
Insulin lispro 5-15 min 1-2 h 3-4 h
Insulin glulisine 5-15 min 1-2 h 3-4 h
Short-acting
Regular 30-60 min 2-3 h 3-6 h
Intermediate, basal
NPH 2-4 h 4-6 h 8-12 h
Lente 3-4 h 6-12 h 12-18 h
Long-acting, basal
Insulin ultralente 6-10 h 10-16 h 18-20 h
Insulin glargine 4-5 h N/A 22-24 h
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Table 1.12 Oral antidiabetic medications for the treatment of type 2 diabetes mellitus 
 
  
Medication Initial Dosage Maximum Dosage
Sulfonylureas
Glyburide 1.25-5 mg/day 20 mg/day
Glipizide 2.5-5 mg/day 40 mg/day
Glimepiride 1-2 mg/day 8 mg/day
Meglitinides
Repaglinide 0.5mg TID 16 mg/day
Nateglinide 60-120 mg TID 360 mg/day
Biguanides
Metformin 500-850 mg/day 2550 mg/day
Thiazolidinediones
Pioglitazone 15-30 mg/day 45 mg/day
Rosiglitazone 4 mg/day 8 mg/day
DPP inhibitors Potentiate incretin effects.
Sitagliptin
Alpha-glucosidase inhibitors
Acarbose 25mg TID 300 mg/day
Miglitol 25 mg TID 300 mg/day
Delay carbohydrate absorption, 
decreasing post-prandial hyperglycemia.
Mechanism of action
Stimulate insulin release. Administered 
once daily.
Stimulate insulin secretion. Short acting 
agents adminstered 15-30 minutes 
before each meal.
Inhibit hepatic glucose production. First 
line agent for T2DM.
Increase insulin sensitivity.
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Table 1.13 Combination oral antidiabetic medications for the treatment of type 2 diabetes 
mellitus 
 
  
Medication Available Dosages Maximum Dosage
Metformin + pioglitazone 500mg/15mg 2550mg/45mg per day
800mg/15mg
Metformin + rosiglitazone 500mg/1mg 2000mg/8mg per day
500mg/2mg
500mg/4mg
1000mg/2mg
1000mg/4mg
Metformin + glyburide 250mg/1.25mg 2000mg/20mg per day
500mg/2.5mg
500mg/5mg
Metformin + glipizide 250mg/2.5mg 2000mg/20mg per day
500mg/5mg
500mg/5mg
Metformin + repaglinide 500mg/1mg 2500mg/10mg
500mg/1mg
Metformin + sitagliptin 500mg/50mg 2000mg/100mg per day
1000mg/50mg
Rosiglitazone + glimepiride 4mg/1mg 8mg/4mg per day
4mg/2mg
4mg/4mg
8mg/2mg
8mg/4mg
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The comparative effectiveness and safety of oral hypoglycemic medications for 
the treatment of type 2 diabetes was evaluated systematically by Bolen and colleagues.
80
 
They reviewed clinical data from 216 trials and 2 systematic reviews involving oral 
hypoglycemic medications and performed a variety of assessments of comparative 
effectiveness (including control of HbA1c, blood pressure, and lipid levels) and safety 
(hypoglycemia and other adverse events). In light of the lack of substantial clinical 
research involving other agents, analyses and conclusions focused primarily on 
comparisons of metformin, SUs, and TZDs. In terms of glycemic control, monotherapy 
with TZDs, second generation SUs, and metformin was associated with similar absolute 
reductions in HbA1c of approximately 1 percent. Combination hypoglycemic treatment 
(metformin + TZD, metformin + SU, or SU + TZD) was more effective than 
monotherapy, and was associated with approximately a 1 percent reduction in HbA1c 
over monotherapy. The absolute effect of all oral hypoglycemic medications on blood 
pressure was minimal, and there were no statistically significant differences found 
between any of the treatments. In terms of low density lipoprotein (LDL) cholesterol, 
metformin was associated with a 10 mg/dL decrease, TZDs were associated with a 10 
mg/dL increase, and SUs had minimal effect on LDL levels. Thiazolidinediones, either in 
combination or monotherapy, were associated with an increase in high density lipoprotein 
(HDL) cholesterol of 3-5 mg/dL, while SUs and metformin had no effect on HDL levels. 
In terms of safety, hypoglycemia was more common with SUs, while gastrointestinal 
disturbances were more common with metformin. Higher risk for edema was associated 
with TZDs compared to metformin and SUs.  
Individuals typically begin treatment for T2DM with lifestyle intervention and 
medication monotherapy. Medication treatment may progress to combination therapy if 
necessary, based on response to initial treatment. The American Diabetes Association 
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recommends initiation of metformin in addition to lifestyle interventions for initial 
treatment of type 2 diabetes.
79
 If an individual is unable to achieve or maintain adequate 
glycemic control with metformin monotherapy, the American Diabetes Association 
recommends that augmentation with either an SU or basal insulin should be implemented 
within a period of 2-3 months. If combination oral treatment (metformin + SU) is not 
able to achieve glycemic control, than combination treatment with metformin + insulin is 
indicated. Alternatively, second-tier treatment strategies with less evidence include other 
two-drug combinations (i.e., metformin + pioglitazone or metformin + exenatide) and 
may be preferred in certain patients. Triple combination oral treatment (metformin + 
pioglitazone + SU) may also be considered in some patients. 
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Medication-taking Behaviors in Patients with Diabetes 
Medication-taking can be particularly challenging for individuals with diabetes. A 
number of retrospective and prospective studies have evaluated medication-taking 
behaviors in diabetic patients, and attempted to identify barriers to optimal medication 
adherence. While no studies have specifically evaluated antidepressant medication-taking 
behavior among patients with diabetes, significant research has been conducted 
evaluating antidiabetic medication adherence and persistence among patients with 
diabetes.
81-100
 Key components and findings of these studies are summarized in Appendix 
A. 
Antidiabetic medication adherence in patients with diabetes may be affected by 
the complexity of the medication regimens involved, the cost of treatment, emotional 
well-being, as well as knowledge about the disease state and medication.
101
 Additionally, 
a number of barriers unique to insulin treatment, such as fear of needles, inconvenience, 
and physician resistance have been identified.
102
 In medication adherence studies 
involving patients with diabetes on oral antidiabetic medication treatment, age, gender, 
medication factors, medication regimen complexity, medical comorbidity, and 
psychological factors have all been associated with diabetic medication non-
adherence.
81,84-86,88,89,92,96,99,100
 These findings are summarized in Table 1.15. 
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Table 1.14 Factors associated with antidiabetic medication non-adherence in studies 
using pharmacy claims data 
Author, year n Medications studied Factors associated with nonadherence
Venturini, 1999 786 SU Age
Medication class
Number of daily doses of medication
Self-reported compliance
New start vs. continuing treatment
Dailey, 2002 23400 ODM and/or insulin Polytherapy
Dezii, 2002 992 Glipizide Younger age
Dosage regimen
Donnan, 2002 2849 SU or MET SU:
Age
Daily number of tablets
No. of other medications
Social Deprivation
MET:
No. of other medications
Mellkian, 2002 1815 SU+MET Age >55
Total nubmer of tablets per day
Morningstar, 2002 3358 SU or MET Age
Gender
Drug class
Days in hospital
Balkrishnan, 2003 775 ODM, insulin, or combination Use of insulin or combination
ER visit in preceding year
Higher Charlson comorbidity score
Hertz, 2005 6090 SU, MET, MEG, TZD, AGI, insulin Adherence:
Age
Hypertenstion
Dyslipidemia
Average number of rx
Non-persistence:
Age
Gender
Drug class
History of Depression
Type of insurance plan
Average number of rx (neg assn)
Adams, 2008 1806 oral hypoglycemics Black ethnicity
Rozenfeld, 2008 2741 SU, MET, AGI, TZD, MEG Younger age
Lower chronic disease score
Lower medication burden
n, number of subjects; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglidinide ; ODM, 
any oral diabetic medication
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A high level of adherence to antidiabetic medication treatment is essential to 
achieving optimal medical outcomes. A number of studies have evaluated the clinical and 
economic outcomes associated with poor adherence to pharmacological treatment of 
diabetes (see Appendix B).
90,95,97,99,100,103,104
 While most studies have utilized the 
medication possession ratio (MPR) or a similar calculation to measure medication 
adherence,
90,95,97,99,100
 two prospective studies utilized patient self-report or the 4-item 
Morisky survey to evaluate medication adherence.
103,104
  
Higher level of adherence to oral antidiabetic medication treatment is consistently 
associated with improved glycemic control. In retrospective studies, the relationship 
between medication adherence and glycemic control is consistently inverse,
90,95,97,99,100
 
with a modest magnitude (a 10 percent increase in medication adherence is associated 
with a 0.1-0.14 percent absolute reduction in HbA1c).
90,95,100
 In an evaluation involving 
810 indigent care patients, Schectman et al. found that a 10 percent increase in 
medication adherence was associated with an absolute reduction in HbA1c of 0.16 
percent.
90
 Improved metabolic control was associated with increased age, White 
race/ethnicity, and medication adherence. Pladevall et al. found a similar relationship 
between medication adherence and glycemic control in their retrospective evaluation of 
pharmacy claims and medical clinic data.
95
 Among 677 subjects with T2DM, they found 
that a 10 percent decrease in medical adherence was associated with an absolute increase 
in HbA1c of 0.14 percent. Rozenfeld et al. reinforced the apparent relationship and 
magnitude of the association between medication adherence and HbA1c, reporting that a 
10 percent increase in medication adherence was associated with a 0.1 percent absolute 
decrease in HbA1c in their retrospective evaluation.
100
 While the magnitude of the 
relationship between antidiabetic medication adherence and HbA1c may appear 
numerically modest, evidence suggests that a decrease in HbA1c of any magnitude is 
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associated with a clinically significant reduction in risk for clinical complications of 
diabetes.
74
 
In studies evaluating antidiabetic medication adherence via patient self-report, the 
association between medication adherence and glycemic control is not as consistent as in 
studies using objective measures. While some studies suggest a negative association 
between adherence and HbA1c,
103,104
 other earlier studies have not found an association 
between self-reported medication adherence and glycemic control.
105-108
 Patient self-
report may not be a valid or reliable measure of actual medication adherence. Indeed, an 
analysis comparing an electronic measure of medication adherence (MEMS cap), patient 
self-reported adherence, and physician-reported adherence for a sample of diabetic 
patients receiving treatment found that both patient- and physician-reported medication 
adherence was much higher compared to the electronic measure of medication 
adherence.
109
 Similar trends in medication adherence assessment have been reported in a 
variety of other chronic disease states.
110-113
 
A number of studies have evaluated the associations between antidiabetic 
medication adherence and economic and service utilization outcomes (See Table 
1.17).
92,94,98,114
 Research suggests that poor diabetic medication adherence is associated 
with increased risk of hospitalization and increased mortality rates. In a study involving 
data for 11,532 patients with diabetes, Ho et al. found that poor diabetic medication 
adherence was associated with increased HbA1c, as well as increased rates of all-cause 
hospitalization and all-cause mortality.
98
 Likewise, Lau et al. found that the odds of 
hospitalization was over 2-fold higher for subjects non-adherent to their diabetic 
medications compared to those who were adherent.
94
 While poor adherence is associated 
with increased service utilization, the economic consequences associated with poor 
diabetic medication adherence are not clear. Balkrishnan et al. found that a 10 percent 
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increase in MPR was associated with an 8.6 percent decrease in total healthcare costs, 
while other research suggests that medical care cost-savings associated with medication 
adherence may be offset by increased medication-related costs.
92
 In a study involving 
57,687 patients with diabetes, Hepke et al. found that lower rates of medication 
adherence was associated with increased emergency department visits and increased 
medical care costs; however, from the perspective of the managed care organization, total 
healthcare costs were unaffected due to increased medication costs.
114
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Table 1.15 Studies evaluating the relationship between antidiabetic medication adherence and economic and service utilization 
outcomes for patients with diabetes 
Author, year n Design Outcomes Evaluated Findings
Balkrishnan, 2003 775 Prospective cohort
Hepke, 2004 775 Retrospective cohort
Lau, 2004 900 Retrospective cohort
Ho, 2007 11532 Retrospective cohort All-cause hospitalization, 
all-cause mortality
Medication non-adherence was associated 
with increased risk for all-cause 
hospitalization (OR 1.38) and all-cause 
mortality (OR 1.39).  A 25% increase in 
adherence associated with 0.05% 
reduction in HbA1c.
n, number of subjects;  MPR, medication possession ratio; ED, emergency department; DM, diabetes mellitus; 
CVD,cardiovascular disease; OR, odds ratio; ODM, oral diabetic medication
Total healthcare costs 10% increase in MPR associated with 8.6% 
decrease in total annual healthcare costs 
(p<0.001)
Total healthcare costs, 
use of ED services, 
inpatient admission
Increased levels of medication adherence 
associated with increased total healthcare 
costs and decreased ED utilization.
DM or CVD-related 
hospitalizaion
Increased risk of hospitalization (OR 2.53) 
with poor ODM adherence (MPR <80%).
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Summary 
Diabetes is an endocrine disorder affecting nearly 20 million Americans, a 
significant number of who may be undiagnosed. Diabetes and complications associated 
with diabetes result in significant morbidity and mortality and related economic costs. 
The mainstay of treatment for type 1 diabetes mellitus is insulin replacement therapy. For 
patients with type 2 diabetes mellitus, oral antidiabetic medications are first-line 
treatments. Regardless of the type of diabetes, diabetes self-management education, 
lifestyle interventions, and medical nutrition therapy are essential facets of diabetes 
management. While a number of medications have demonstrated effectiveness for the 
treatment of diabetes, barriers such as poor medication adherence remain a significant 
obstacle. Medication non-adherence in patients with diabetes is associated with poor 
glycemic control, increased healthcare services utilization, and increased morbidity and 
mortality. 
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COMORBID DIABETES MELLITUS AND MAJOR DEPRESSIVE DISORDER 
Epidemiology 
In studies evaluating the prevalence of depression among diabetic patients, the 
estimated prevalence of depression ranges from 3.8 percent to 60.7 percent, with an 
aggregate prevalence of 25.3 percent.
115
 These estimates appear to be influenced by a 
number of factors, including gender, the type of diabetes, the method used to evaluate 
depression, as well as the site of recruitment for epidemiology study participants. In 
individuals with diabetes the prevalence of depression is higher among women than men 
(28% vs. 18%), and among patients with T2DM compared to those with T1DM (27% vs. 
21%). Patients evaluated with self-reported symptom questionnaires report a higher 
prevalence of elevated depressive symptoms compared to those evaluated with a 
standardized diagnostic interview (31% vs. 11%). This is likely due to the limited 
specificity of self-report measures of depression (i.e., these instruments may pick up 
symptoms unrelated to depression, but related to some other disorder). Recruitment site 
also appears to effect prevalence estimates, with patients recruited from clinical settings 
displaying higher rates of depression compared to subjects recruited from the community 
(32% vs. 20%). 
While prevalence estimates vary greatly across the previously discussed factors, 
the ratio of the odds for experiencing depression with comorbid diabetes to the odds of 
depression among non-diabetics is relatively stable across these factors.
115
 Overall, the 
odds of experiencing depression are approximately two-fold higher for individuals with 
diabetes compared to non-diabetics, and the odds ratio appears consistent across gender, 
diabetes type, community- vs. clinic-based sampling, or the assessment method utilized.  
This seems to indicate that the risk factors for depression in diabetes are similar to the 
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risk factors for depression among non-diabetic patients; however, the presence of 
depression magnifies the effect of these risk factors two-fold. In light of the high 
prevalence of depression among patients with diabetes and the profound implications that 
depression can have on the clinical course of diabetes, the high rate of undiagnosed 
depression in this population is particularly worrisome. It has been estimated that up to 
two-thirds of patients with diabetes and comorbid depression have their mood disorder go 
undiagnosed and untreated.
116
 
Scarce research has evaluated the epidemiology of depression and comorbid 
diabetes in underserved populations. Research from the early 1990s found no increased 
prevalence of depression among Hispanic men or women with diabetes, when compared 
to those without diabetes.
117
 Other research by Black et al. found a high prevalence of 
depressive symptoms among a sample of older Hispanic patients, and the prevalence was 
higher among subjects with diabetes compared to those without diabetes (31% vs. 
24%).
118
 The presence of significant depressive symptoms in this study was also 
associated with significant risk for diabetic complications, functional disability, and 
greater health service use. In a cross-sectional study of 209 Hispanics with diabetes, 33.5 
percent had comorbid depression.
119
 Subjects with moderate to severe depression were 
more likely to be younger in age, female, and living alone, when compared to their non-
depressed counterparts. In a community-based sample of 126 Hispanic women receiving 
treatment for diabetes, the prevalence of depression was high at 40.6 percent.
120
 
Alarmingly, only 3.1 percent had been previously assessed for depression, indicating 
significant under-recognition and treatment of depression in this patient population.  
Research also suggests that there may be differences in the types and rates of 
treatment for depression in various ethnic groups with diabetes. De Groot et al. evaluated 
depression treatment patterns in a multicultural sample of patients with diabetes.
121
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African-Americans were found to be less likely to receive treatment for depression. They 
were also less likely to receive antidepressant treatment, as well as treatment provided by 
a mental health specialist, when compared to Whites. There were no significant 
differences in treatment observed between Hispanics and Whites in this study. 
 
Clinical Course 
The clinical course of depression in patients with diabetes tends to be chronic and 
recurrent. In a 5-year follow-up study involving 25 diabetics with an index event of 
depression, depression recurred in 80 percent of subjects after 1 year and 92 percent of 
patients after 5 years.
116
 During the follow-up period, the average number of episodes of 
major depression was 4.8, and the average duration of the longest episode of depression 
during the follow-up period was 16.1 months. Further, in this small longitudinal study, 
active depression was associated with worsened glycemic control. These findings are 
consistent with an earlier follow-up study of 37 subjects with depression and diabetes.
122
 
In that study, 79 percent of patients had a recurrent mood disorder during 5 years of 
follow-up, and the mean number of mood disorder episodes during the follow-up period 
was 4.2. The 5-year incidence of depression among diabetic patients without a previous 
depressive episode was only 10 percent, potentially indicating a significant difference in 
the risk for recurrence compared to new-onset depression among diabetic patients.  
The temporal course and the interrelationship between depression and diabetes are 
complex and appear to be bidirectional. Research appears to suggest that a prevalent case 
of either disorder increases the risk for an incident case of the other. Golden and 
colleagues utilized longitudinal patient data in a study evaluating the directional 
associations between depression and diabetes.
123
 The overall study cohort was separated 
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into two groups, one with prevalent depression but not diabetes, and one with prevalent 
diabetes but not depression. Study participants were followed for up to 5 years and the 
incidence of diabetes and depression were calculated for each group, respectively. 
Subjects with prevalent depression were found to have a 37 percent increased risk for 
incident diabetes compared to their non-depressed counterparts. On the other side, 
subjects with prevalent diabetes receiving treatment had a 52 percent increased risk of 
incident depression. Interestingly, individuals with untreated diabetes displayed no 
increase in risk of depression (OR 0.73; CI 0.41-1.30). Likewise, subjects with impaired 
fasting glucose did not have an increased odds of depression (OR 0.80; CI 0.63-1.02). 
Potential explanations for this observation may be related to psychological stress 
associated with complex treatment regimens, or higher level of disease state severity and 
complications among those who are being treated for diabetes. 
The mechanism by which mood and diabetes are related may be biological, 
psychological, or a combination of both. Depression is associated with a number of 
biological alterations that may increase the vulnerability of an individual to 
hyperglycemia and diabetic complications.
124
 Increased release of hormones such as 
cortisol, glucagon, growth hormone, and catecholamines are associated with stress. These 
hormones act to increase blood levels of glucose, thus potentially altering glycemic 
control. Immunomodulatory cytokines, such as interleukin-6 and tumor necrosis factor 
alpha, are expressed in increased levels in diabetic patients and are associated with 
“sickness behavior,” a collection of symptoms with great similarity to the symptoms of 
depression. Psychosocial factors, such as stress associated with a chronic medical 
condition, may also result in mood alterations. This is supported by research suggesting 
that simple awareness of a diagnosis of diabetes is associated with an increased risk of 
depression when compared to individuals who meet criteria for diabetes but are unaware 
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of their condition.
125
 The destabilizing effect of depression on glycemic control may also 
be mediated through self-care behaviors and healthy lifestyle activities related to diet and 
exercise.
126
 
 
Outcomes Associated with Depression in Patients with Diabetes 
Depression is associated with increased healthcare utilization, increased 
healthcare costs, symptom amplification, disability, and increased mortality associated 
with a variety of other chronic medical conditions.
18,127-132
 In patients with diabetes, 
depressive symptoms are associated with impaired glycemic control, poor treatment 
adherence, lower functional status, and increased mortality. 
 
Glycemic Control 
Depression is associated with hyperglycemia in patients with both T1DM and 
T2DM.
55
 Meta-analysis of data from 24 cross-sectional studies indicates a modest 
correlation between depression and hyperglycemia (r = 0.17; CI 0.13 - 0.21). This 
correlation was similar among subjects with both type 1 and type 2 diabetes (r = 0.19; CI 
0.12 - 0.25 vs. r = 0.16; CI 0.09 - 0.22). The correlation between depression and 
hyperglycemia appears to be greater when a structured diagnosis of depression is used, 
rather than self-rated assessment (r = 0.28; CI 0.20 - 0.36 vs. r = 0.15; CI 0.11 - 0.19). 
While the absolute value of this correlation is modest at best, in practical terms treatment 
of depression could result in a 17 percent increase in the proportion of diabetic patients 
achieving glycemic treatment goals.
55
 
The causal directionality of the association between depression and glycemic 
control in patients diagnosed with diabetes is not clear. Much of the research in this area 
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has been cross-sectional in nature; the prospective studies that do exist indicate that the 
relationship is bidirectional - that depression causes hyperglycemia and hyperglycemia 
exacerbates depression.
133
 Some research indicates that the influence of depression on 
glycemic control is mediated through self-care behaviors. This research suggests that 
patients with depression are less likely to adhere to self-care behaviors such as diet, 
exercise, and self monitoring, and this ultimately results in poorer glycemic control.
126
  
 
Diabetic Complications 
Diabetes is associated with a number of significant medical complications 
including nephropathy, retinopathy, neuropathy and an increased risk for heart attack and 
stroke. A meta-analysis by de Groot et al. evaluated the association between depression 
and diabetic complications across 27 studies published between 1979 and 1999.
134
  While 
no temporal relationship (i.e., the direction of the causal relationship) could be 
established, depression was correlated with retinopathy (r = 0.17, p < 0.001), 
nephropathy (r = 0.25, p < 0.001), neuropathy (r = 0.28, p < 0.001), sexual dysfunction 
(r = 0.32, p < 0.001), and macrovascular complications (r = 0.20, p < 0.001). The overall 
correlation between depression and all complications combined was significant (r = 0.25; 
p < 0.001). In addition to being associated with the presence of a diabetic complication, 
depression was also associated with an increased number and increased severity of 
complications. Of note, the strongest correlation between depression and a diabetic 
complication was seen with sexual dysfunction. It is unclear whether this correlation is 
due to a destabilizing effect of depression on glycemic control, or whether this correlation 
is intrinsically related to depression or depression treatment. Notably, sexual dysfunction 
(especially decreased interest) may be associated with depression in the absence of 
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treatment.
135
 In addition, many antidepressant treatments are associated with sexual 
dysfunction (especially anorgasmia and/or impotence).
136
 Moderate correlations were 
also seen between depression and nephropathy, neuropathy, and macrovascular 
complications. 
 
Treatment Adherence  
Depression has a well established association with poor treatment adherence 
across a variety of disease states.
137
 A number of studies specifically evaluating the 
influence of depressive symptomatology on diabetic medication adherence have been 
performed (See Table 1.18).
138-144
 This research suggests that the presence of depression 
is associated with a small (~5%), but statistically significant reduction in diabetic 
medication adherence. This small reduction in adherence to diabetic medications is 
clinically significant in light of the overall poor level of medication adherence exhibited 
by patients on oral hypoglycemic, and the significant clinical and financial consequences 
of suboptimal levels of medication adherence in this population.
86,92,94,103,145
  
A major limitation is that most of these studies were not designed to evaluate the 
directional effects between depression and medication adherence. That is to say, they 
were not designed to evaluate whether depression caused poor diabetic medication 
adherence, or whether poor diabetic medication adherence resulted in diabetic 
complications which ultimately led to the development of depression. 
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Table 1.16 Studies evaluating association between depression and diabetic medication adherence. 
 
Author, year n Design Adherence Measure
Ciechanowski, 2000 367 Cross-sectional HSCL-20
Lin, 2004 4463 Cross-sectional PHQ-9 Percentage of days lacking medication Non-depressed Depressed
18.8%‡ 24.50%
Kilbourne, 2005* 203 Prospective/Retrospective PHQ-9
Nau, 2005* 1454 Retrospective Medication possession ratio
Kalsekar, 2006 1326 Retrospective ICD-9 code Medication possession ratio Non-depressed Depressed
73%†† 66%
Gonzalez, 2007 879 Cross-sectional HANDS
Nau, 2007* 391 Cross-sectional PHQ-8 SR medication use behaviors
*, results reported herein based on abstract
†, indicates high severity group significantly greater proportion of days in interruption compared to low severity group, p=0.04
††, statistically different from depressed group with a p <0.001
EMC: percent of days with correct 
number of doses; CPR, percent of days 
with with adequate medication
Depression associated with lower adherence by SR and 
CPR.  EMC and PR adherence were similar amoung 
depressed and non-depressed patients.
Adequate AD treatment assocaited with higher MPR 
when compared to inadequate AD treatment and no AD 
treatment.
Depression 
Measure
Influence of Depression on Adherence
Percentage of days in treatment 
interruption
High depression symptom severity:          14.9%†
Medium depression symptom severity:     9.3%
Low depression symptom severity:              7.1%
Depression associated with significantly worse 
medication adherence
Antidepressant 
use
‡, statistically different from depressed group after controlling for covariates: age, sex, marital status, education, ethnicity, medical comorbidity, diabetic complications, 
treatment intensity, and primary care physician
2.3-fold increase in odds of missing dose of DM 
medication; Each 1 pt increase in HANDS score 
associated with 1.12-fold increase in odds of missing 
Dichotomized response to question 
about missed medication doses in past 
7 days
n, number of subjects; HMO, health maintenance organization; HSCL-20, Hopkins Symptom Checklist-20; PHQ, Patient Health Questionnaire; CPR, computerized pharmacy 
records, EMC, electronic monitoring caps; SR, self-report; PR, physician report; MPR, medication possession ratio; HANDS, Harvard National Depression Screening Scale; NI, not 
indicated
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Morbidity and Disability 
Depression is associated with an increased number of diabetic symptoms and 
symptom amplification in patients with diabetes. The presence of a psychiatric diagnosis 
(most commonly depression or anxiety) was associated with a nearly 2-fold increase in 
the number of diabetic symptoms reported by a group of 144 patients with diabetes.
146
 In 
a study involving 407 subjects with diabetes, presence of depression was associated with 
increased diabetic symptom reporting after controlling for important covariates including 
comorbidity, diabetic complications, and diabetes type.
147
 In a survey of 4168 subjects 
with diabetes, Ludman et al. found that after controlling for clinical and demographic 
covariates, an elevated PHQ-9 score was associated with increased reporting of diabetic 
symptoms when compared to subjects without depressive symptoms.
148
 In this study, 
there was a clear relationship between the number of depressive symptoms and the 
number of diabetic symptoms, with incrementally increasing PHQ-9 scores closely 
associated with increased number of diabetic symptoms. 
A recent survey conducted by the World Health Organization illustrates the 
relationship between depression and overall health status for patients with a variety of 
chronic medical conditions, including diabetes.
18
 Based on a survey administered to 
254,404 patients from 60 countries worldwide, depression was found to be present in 9.3 
percent of respondents with diabetes. Based on composite health status score, comorbid 
depression and diabetes were associated with greater health impairment than that which 
would be expected from the individual contributions of each disease state separately, 
suggesting a synergism between the two diseases in terms of effect on overall health 
status. 
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Mortality 
Depression is associated with increased mortality in patients with a number of 
chronic medical conditions, including coronary artery disease, myocardial infarction, and 
stroke.
127-130
 As in these other chronic disease states, depression appears to increase the 
risk for mortality among patients with diabetes.
149-154
 The mortality hazard ratio 
independently attributable to depression ranges from 1.33 to 1.63, indicating a 33-63 
percent increased risk of mortality in diabetic patients who also have depression over 
diabetes alone. The presence of even relatively low levels of depressive symptomatology 
(subsyndromal minor depression) is associated with increased risk of mortality in patients 
with diabetes.
151
 Some research suggests that increased risk for mortality among patients 
with diabetes and comorbid depression may be mediated through diabetic complications; 
however, a number of studies that controlled for the presence of diabetic complications 
found that depression is an independent risk factor for mortality in patients with 
diabetes.
149,151,153,155
 
 
Treatment of Depression in Patients with Diabetes 
Non-pharmacological Treatment 
One controlled study of psychotherapy for the treatment of depression in the 
presence of comorbid DM has been reported in the literature.
156
 In this study, a 10-week 
course of Cognitive Behavioral Therapy (CBT) plus diabetes education was compared to 
diabetes education alone. Cognitive Behavioral Therapy resulted in better response and 
remission rates at the end of treatment compared to the education only group (response: 
66.6% vs. 29.6%, p < 0.001; remission: 70.8% vs. 22.2%, p < 0.001). Results at a 6-
month follow-up assessment were similarly in favor of CBT. In regards to glycemic 
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control, no statistically significant reduction in HbA1c was seen at the end of 10 weeks of 
CBT treatment; however, HbA1c levels were decreased by 0.7 percent in the CBT group 
and increased by 0.9 percent in the control group at the 6-month follow-up (p = 0.04). 
The level of treatment response appeared to have an effect on glycemic control, as 
remission of depressive symptoms with CBT was associated with significantly lower 
mean HbA1c at the end of treatment and at the 6-month follow-up. Finally, and 
somewhat unexpectedly, participation in the CBT group was associated with a decline in 
self-monitoring of blood glucose levels over time. 
 
Pharmacological Treatment 
A number of clinical studies have evaluated the pharmacological treatment of 
depression in patients with diabetes (See Table 1.19). Studies of the antidepressant 
medications nortriptyline
157
 and bupropion,
158
 as well as the SSRIs sertraline,
159
 
fluoxetine,
160,161
 paroxetine,
161
 and escitalopram
162
 suggest that these medications are 
effective acute-phase treatments for depression associated with diabetes. 
While the clinical literature supports the efficacy of antidepressant medications 
for the treatment of depression in patients with diabetes, the effect of antidepressant 
treatment on clinical measures of glycemic control is less clear. No consistent effect of 
treatment for depression on outcomes associated with diabetes has been demonstrated. In 
an early study by Lustman et al., path analysis was conducted to evaluate the direct and 
indirect effects (mediated through improvement in depressive symptoms) of nortriptyline 
on glycemic control.
157
 While nortriptyline treatment improved depressive symptoms, 
and this improvement was associated with improvement in glycemic control, a direct 
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hyperglycemic effect of nortriptyline negated the indirect positive effect on glycemic 
control. 
In the only placebo-controlled acute-phase treatment trial involving an SSRI, no 
significant improvement in glycemic control was observed with fluoxetine treatment.
160
 
The lack of significant findings regarding improved glycemic control may be related to 
the short duration of observation in acute-phase depression treatment trials and/or 
insufficient statistical power. HbA1c reflects the average level of glycemic control over a 
period of up to 120 days, and therefore, might not reflect changes in glycemic control 
over the course of a typical 8-12 week acute-phase clinical trial. In addition, these studies 
tend to be small and underpowered to detect modest changes in glycemic control. 
Only one long-term, placebo-controlled, maintenance-phase study involving SSRI 
treatment of depression in patients with diabetes has been published.
163
 This placebo-
controlled study evaluated the maintenance efficacy of sertraline over 52 weeks 
following acute response. As expected, sertraline maintenance treatment was effective for 
preventing depression recurrence after acute response was achieved. In the 16-week acute 
phase open-label portion of the study, glycemic control improved (mean change in 
HbA1c -0.4% +/- 1.5%, p=0.002); however, no further improvement in glycemic control 
was seen during the maintenance phase, and the improvements in glycemic control seen 
during the acute phase persisted equally in both the active and placebo maintenance 
groups. No post-recurrence HbA1c values were obtained in order to evaluate the potential 
consequences of depressive recurrence on glycemic control in this study. 
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Table 1.17 Studies of antidepressant treatment for depression in patients with diabetes 
Author, year Treatment phase Intervention n Duration Depression outcomes Diabetes outcomes
Goodnick, 1997 Acute open-label SER, 50 mg/day 28 10 weeks
Lustman, 1997 Acute NOR, level: 50-150 ng/mL 14 8 weeks Favored NOR (ΔBDI: -10.2 vs. -5.8, p=0.03)
Placebo 14
Lustman, 2000 Acute FLU, up to 40 mg/day 27 8 weeks No difference in ΔHbA1C
Placebo 27
Gulseren, 2005 Acute FLU, 20 mg/day 11 12 weeks
PAR, 20 mg/day 9
Amsterdam, 2006 Acute open-label ESC, 10-20 mg/day 14 16 weeks No effect on HbA1C or FBG
Lustman, 2006 Maintenance SER, mean dose=117.9 mg/day 79 52 weeks
Placebo 73
Improvement in HAMD (22.6 ±3.4 to 4.9 ±5.9, 
p<0.001) and BDI (21.9 ±10.5 to 12.7 ±8.3, 
p<0.001)
Improved dietary compliance, reduction in 
HbA1C in 76% of subjects with baseline 
HbA1C >8.0 (p=0.018)
Path analysis indicates that NOR associated 
with worsened HbA1C
Favored FLU (ΔBDI: -14.0 vs. -8.8, p<0.03; 
ΔHAMD: -10.7 vs. -5.2, p=0.01)
FLU and PAR associated with within-group 
reductions in HAMD, no difference in 
between-groups ΔHAMD.
No difference within- or between-groups in 
ΔHbA1C
ESC associated with significant 
improvements in HAMD, CGI-S and CGI-I
SER associated with longer time to relapse of 
depression (>365 days vs. 251 days, p=0.02)
Reduction in HbA1C seen during open-label 
acute-phase of trial, however no additional 
reduction during maintenance treatment.
n, number of sujects; DM, diabetes mellitus; HAMD, Hamilton Depression Rating Scale; BDI, Beck Depression Inventory; NOR, nortryptiline; CBT, cognitive behavioral therapy; BGM, 
blood glucose monitoring; FLU, fluoxetine; PAR, paroxetine; ESC, escitalopram; SER, sertraline; CGI-S, clinical global impression-severity; CGI-I, clinical global impression-
improvement
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In an open-label study of the atypical antidepressant bupropion, remission of 
depression was observed for 87.3 percent of subjects during acute-phase treatment (10 
weeks).
158
 Of those who remitted during acute-phase treatment, 100 percent who 
completed the maintenance-phase (24 weeks) remained depression-free. Remission of 
depressive symptoms was associated with a 0.6 percent (± 1.1%) reduction in HbA1c 
(p<0.001), compared to a 0.1 percent (± 1.3%) reduction in patients who did not achieve 
remission (p=0.7) in the acute-phase of the study. As in the sertraline maintenance study, 
improvements in glycemic control during the acute-phase persisted throughout the 
depression-free maintenance period. Further, regression analyses indicate that 
improvement in depressive symptoms had a significant and independent effect on 
reducing HbA1c after controlling for baseline HbA1c and changes in self-care behaviors, 
monitoring, and body mass index during the course of the study. No subjects in this study 
who entered the maintenance phase experienced a recurrence of depressive symptoms, 
making it impossible to determine the nature of any association between recurrence of 
depressive symptoms and glycemic control. 
 
Effect of Treatment on Diabetic Medication Adherence 
Katon et al. evaluated the influence of antidepressant adherence on medication 
adherence in a number of chronic disease states, including diabetes.
164
 Adherence with 
antidepressant treatment was defined as: a) Medication Possession Ratio (MPR) ≥ 80 
percent; and b) No evidence of a medication gap ≥ 15 days during the first 90 days of 
antidepressant treatment. Diabetic medication adherence was evaluated by MPR, with an 
MPR ≥ 80 percent being identified as adherent. Logistic regression analysis, including 
age, sex, insurance plan type, psychiatric services, anxiety or depression diagnosis, pre-
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index medication adherence, and antidepressant dosing as covariates, was used to 
evaluate the effect of antidepressant adherence on diabetic medication adherence.  
Katon and colleagues analyzed pharmacy prescription data for 8,040 patients, 
2,518 of whom were receiving treatment for diabetes. In the 6-month period prior to 
initiation of antidepressant medication, 77 percent of subjects with diabetes were 
adherent to their diabetic medication regimen. In the year after initiation of antidepressant 
medication, diabetic medication adherence dropped to 64.4 percent. During the period of 
concomitant treatment, antidepressant medication adherence was lower than diabetic 
medication adherence (36.3% vs. 64.4%). After controlling for the covariates mentioned 
previously, adherence to antidepressant treatment was associated with a 1.82-fold 
increase in the odds of adherence to diabetic medications. Notably, the influence of 
depression symptom severity was not accounted for in this study. It is unclear whether 
the association between antidepressant treatment and diabetic medication adherence was 
related to patient-specific medication-taking behaviors, or whether the association was 
mediated through reduction or resolution of depressive symptoms with antidepressant 
treatment.  
 
Collaborative Care Programs 
Multi-disciplinary collaborative care has gained increasing attention as a possible 
intervention to improve clinical outcomes associated with a range of medical and 
psychiatric conditions. The outcomes associated with a collaborative care program 
consisting of nurse-administered education and support of depression treatment for 
patients with depression and diabetes was reported by Katon and colleagues.
165
 When 
compared to treatment as usual, enhanced care was associated with greater improvements 
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in adequacy of antidepressant treatment, antidepressant medication adherence, and 
depressive symptoms. Although enhanced care was associated with better depression 
treatment outcomes, no effect on diabetes self-care activities or glycemic control over 12 
months was seen.
166
 In addition, enhanced care had no significant effect on 
antihypertensive and lipid-lowering medication adherence. Interestingly, hypoglycemic 
medication adherence was actually lower in the intervention group compared to controls, 
perhaps suggesting that patients were overburdened by the enhanced care intervention. 
Notably, enhanced care in this study was focused on support and guidance for treatment 
of depression, and no diabetes-specific interventions were conducted. 
These results are similar to those found during a subgroup analysis of another 
collaborative care intervention in older patients with depression.
167
 Collaborative 
depression care in this study resulted in improvements in depression outcomes, but 
diabetes self-care behaviors (with the exception of weekly exercise days) and glycemic 
control were unaffected. Similar discouraging results have been found in studies 
evaluating psychoeducational interventions for patients with diabetes and subsyndromal 
depression, as well as collaborative care programs among a cohort of predominantly 
Hispanic patients with diabetes and depression.
168,169
 
It is not clear why these enhanced depression care programs have failed to 
demonstrate significant effects on diabetes care behaviors, diabetes medication 
adherence, and glycemic control. It has been suggested that concurrent intensive 
depression and diabetes treatment regimens might overwhelm these patients, and self-
care activities such as glucose monitoring, exercise, and medication adherence might 
suffer as a result. 
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Antidepressant Exposure and Risk of New-onset Diabetes  
A number of recent studies have evaluated antidepressant medication exposure 
and its association with diabetes. Brown et al. evaluated the relationship between 
antidepressant medication exposure and new-onset diabetes over a 10-year period.
170
 
SSRI monotherapy was associated with lower risk of observing new-onset diabetes 
compared to TCA monotherapy (OR 0.76, 95% CI 0.63 – 0.91); however, an increased 
risk of new-onset diabetes diagnosis was observed for individuals taking SSRI/TCA 
combination therapy compared to individuals receiving TCA monotherapy (OR, 1.88, 
95% CI 1.37 – 2.59). There was no association observed between use of other 
combinations of antidepressant medication and risk of diabetes, compared to patients 
receiving TCAs only.  
Rubin et al. evaluated antidepressant medication exposure as a risk factor for 
developing diabetes among a group of subjects at high risk for developing diabetes.
171
 
Baseline antidepressant use was associated with a 3.48-fold increased in the odds of 
diagnosis of diabetes over a mean follow-up period of 3.2 years. Intermittent 
antidepressant exposure was not associated with a statistically significant increase in odds 
of diabetes diagnosis, while continuous antidepressant use was associated with a 2.6-fold 
increase in risk. These data suggest that increased levels of antidepressant medication 
exposure may be associated with increased risk for development of diabetes. 
Research conducted by Andersohn et al. would likewise suggest that the extent of 
antidepressant exposure is a key factor in risk of diabetes associated with antidepressant 
exposure.
172
 Like Rubin, Andersohn found that higher levels of exposure to 
antidepressant treatment (in this case, ≥ 24 months of moderate to high dose treatment) 
were associated with increased risk of diabetes, but not shorter periods or lower dosages. 
Of note, Brown, Rubin, and Andersohn evaluated new-onset diabetes and did not 
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evaluate the association between antidepressant exposure and glycemic control among 
diabetic patients. 
A case-control study conducted by Derijks et al. reiterates the role that duration of 
medication exposure may play in the relationship between antidepressant exposure and 
diabetes.
173
 Derijks and colleagues found that antidepressant exposure was associated 
with spontaneous adverse event reporting of diabetes and other forms of hyperglycemia 
(OR 1.52, 95% CI 1.20 – 1.93). In addition, longer term antidepressant use (> 1 year) was 
associated with hyperglycemia, while short-term treatment (0 - 1 year) was not. 
The association between antidepressant use and new-onset diabetes may be 
associated with metabolic side effects associated with antidepressant treatment. Raeder et 
al. found that SSRI use was associated with obesity and hypercholesterolemia.
174
 
Subgroup analyses revealed that the association was heterogeneous among the specific 
SSRI agents. Paroxetine, but not citalopram, was associated with obesity. Sertraline, 
fluoxetine, and fluvoxamine (analyzed as a single group) were associated with obesity 
and hypercholesterolemia. Citalopram appeared to have the most favorable metabolic 
profile among the agents evaluated. 
Some antidepressant medications may be associated with a more direct 
deleterious effect on glycemic control. Imipramine, but not fluoxetine, was associated 
with an increase in fasting blood glucose levels in an evaluation of the relationship 
between short-term antidepressant use (8 weeks) and glycemic control.
175
 A number of 
animal studies suggest the possibility of a direct hyperglycemic effect for a variety of 
antidepressant medications; however, these findings have not been consistently replicated 
in human subjects.
176,177
 As discussed previously, treatment of depression with 
antidepressant medications has been associated with improved glycemic control in some 
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studies, but in those studies improvement in glycemic control was evaluated in 
relationship to treatment response, rather than simple medication exposure.  
 
Summary 
Diabetes and depression are individually significant public healthcare problems in 
the United States. The combination of the two is common, and the presence of a 
diagnosis of diabetes has been associated with a 2-fold increase in the odds of an 
individual being diagnosed with depression or experiencing significant depressive 
symptoms. Comorbid depression is associated with worsened outcomes associated with 
diabetes, including hyperglycemia, lower rates of medication adherence, and increased 
risk of diabetic complications and death. Some research suggests that antidepressant 
exposure may be associated with new-onset diabetes. While a number of effective 
treatments for depression in this population exist, research has yet to demonstrate that 
treatment and resolution of depression in this patient population has a significant 
influence on glycemic control, diabetes treatment adherence, and complications 
associated with depression.  
  
 65 
MEDICATION ADHERENCE AND PERSISTENCE 
Optimal medication-taking is essential to achieving the intended therapeutic 
outcome. Medication-taking behaviors have been shown to be important factors 
associated with clinical and economic outcomes for a wide variety of medical conditions 
including hypertension, human immunodeficiency virus infection, hepatitis C, 
schizophrenia, as well as diabetes and depression, as previously discussed.
178-184
 The 
purpose of this section is to discuss terminology and definitions for the constructs related 
to medication-taking behavior that will be evaluated in this study. 
 
Pharmacy Claims Data 
Medication-taking behavior can been evaluated in a number of ways including 
patient self-report, clinician assessment, pharmacy refill records, electronic monitoring, 
and serum blood levels. This study utilized pharmacy refill records to evaluate 
medication-taking behaviors in patients with diabetes and depression. The primary 
benefit to using pharmacy claims data for evaluations of medication adherence and 
persistence in large populations is the relative efficiency compared to other methods.
185
 
Prescription claims data may also provide longitudinal data on medication refill patterns 
that might otherwise not be available. 
The use of pharmacy claims data to evaluate medication adherence has been 
validated against other measures of medication adherence such as patient self-report, pill 
count, and biological measures of drug consumption.
186
 The use of prescription claims 
data as a proxy for medication adherence is predicated on the assumption that obtaining a 
medication from the pharmacy is a valid marker for medication consumption. While this 
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might not always be the case, research suggests that medication acquisition is associated 
with drug consumption as measured by drug levels and physiological effect.
186
 
For pharmacy claims data to be a valid marker for medication adherence, it is 
necessary that the dataset contain complete medication data for an individual subject. If 
an individual has multiple sources of medications, such as multiple third-party 
prescription plans or physician samples in addition to pharmacy-dispensed medications, 
pharmacy claims data may be an inaccurate reflection of medication acquisition and 
availability. In addition, if a patient pays out-of-pocket for some of their medications, 
those data may not be captured in secondary pharmacy claims datasets. With those 
limitations in mind, if the data are complete and there is a low likelihood of subjects 
obtaining medications from sources not captured in the database, pharmacy claims data 
can be useful for identifying non-adherence with high specificity.
185
 
 
Defining and Operationalizing Medication-taking Behaviors 
Two constructs can been used to describe medication-taking behavior: medication 
adherence (synonym: compliance), and medication persistence. The following sections 
discuss issues related to medication adherence and persistence, with a particular focus on 
medication possession ratio as a measure of adherence, and evaluation of medication 
persistence. 
 
Medication Adherence 
Medication adherence is defined as “the extent to which a patient acts in 
accordance with the prescribed interval and dose of a dosing regimen.”
187
 Medication 
adherence is measured in terms of a time period and should be reported as a 
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percentage.
188
 In studies utilizing pharmacy claims records to evaluate medication 
adherence, adherence is commonly operationalized by the medication possession ratio 
(MPR). The MPR is calculated using the days’ supply information from pharmacy claims 
data. 
The MPR is essentially the ratio of the sum of the days of medication supplied 
divided by the number of days of observation.
185,188,189
 A number of variations in 
methodology have been used to calculate the MPR, with variability in the methodology 
being related primarily to calculation of the denominator. The denominator of the MPR 
has been determined using a fixed time interval, or alternatively, by using a variable time 
period based on refill intervals. In a review of 136 studies utilizing medication adherence 
measures, the MPR was reported in 57 percent (n=77) of published articles.
185
 Among 
these studies, the majority (55%, n = 42) utilized a fixed interval to calculate the 
denominator for the MPR calculation. Thirty nine percent (n = 30) used a denominator 
calculated on the basis of refill intervals. Hess et al. compared a variety of adherence 
measures including a fixed-interval MPR and an MPR calculation based on the refill 
interval (in this case, termed the MPRm).
189
 The fixed interval MPR returned adherence 
estimates that were similar to a number of other prescription claims-based adherence 
measures (e.g. Continuous measure of medication acquisition, proportion of days 
covered), while the MPRm returned a higher estimate of adherence. In addition the 
MPRm was found to be particularly sensitive to attrition and instances when only a single 
prescription refill is obtained. 
A formal taxonomy of methods for assessing medication adherence with 
pharmacy refill data has been described by Steiner and Prochazka.
186
 According to their 
taxonomy, methods of calculating medication adherence can be characterized on the basis 
of three attributes: the nature of the adherence variable (Continuous or Dichotomous); the 
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number of refill intervals in the observation period (Single or Multiple); and, whether the 
variable measures the presence or absence of access to medication (Available or Gap). 
Using this taxonomy, medication adherence measures can be notated by using a single 
letter to describe the variable on each of the three attributes. For example, a CMA 
measure of medication adherence would be a continuous variable evaluating medication 
availability over multiple refill intervals. The MPR is, therefore, a CMA measure of 
medication adherence when it is calculated based on pharmacy claims data over an 
observation period covering multiple refill intervals. 
In addition to being treated as a continuous measure of adherence, the MPR value 
may also be dichotomized (i.e., compliant vs. non-compliant), based on comparison of an 
individual subject’s MPR with a threshold MPR. A commonly used MPR threshold for 
dichotomizing medication adherence data is 0.80 (i.e., MPR ≥ 0.80 = compliant; MPR < 
0.80 = non-compliant). This value of an MPR threshold has been used in a number of 
studies in a variety of chronic disease states such as diabetes and hypertension,
94,96,98,100
 
while studies in other disease states (e.g., HIV infection, hepatitis c infection) have used 
higher MPR thresholds to operationally define dichotomized medication adherence.
179,180
 
 
Medication Persistence 
ISPOR defines medication persistence as: “the duration of time from initiation to 
discontinuation of therapy”.
187
 Medication persistence is essentially a measure of the 
length of time that an individual stays on an initial treatment. A common method of 
evaluating medication persistence with pharmacy claims data involves calculation of a 
“permissible gap”.
187
 A subject’s pattern of prescription refills are followed 
longitudinally until the length of time between prescription refills exceeds the 
 69 
predetermined permissible gap.
190
 A common timeframe used for the permissible gap is 
1.5 times the days’ supply of preceding prescription, although a variety of multiples 
ranging from 1.5 to 3.0 have been used.
190,191
 Alternatively, fixed-intervals ranging from 
15 to 120 days have been used to identify non-persistence.
190-193
 Medication persistence 
is measured as a continuous variable in terms of whole days. A strength of this method of 
evaluating medication persistence is that it lends itself to methods of survival analysis, 
such as Kaplan-Meier analysis and Cox survival regression analysis.
188,191
 This 
continuous measure can also be dichotomized into persistent and non-persistent, 
indicating a person’s persistence status at a given point in time (e.g., 3- or 12-month 
persistence). 
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STUDY RATIONALE 
The overall objective of this research is to evaluate the relationship between 
diabetes and depression, with a specific focus on antidepressant medication-taking 
patterns in patients with diabetes. First, this study will seek to evaluate diabetes as a risk 
factor for the development of new-onset depression among a cohort of indigent care 
patients. Risk factors for incident cases of depression among patients with prevalent 
diabetes will also be identified. In addition to factors related to the diagnosis of 
depression, the pharmacoepidemiology of antidepressant use in patients with comorbid 
depression and diabetes will be evaluated. This study will provide insight into 
antidepressant medication utilization patterns among patients with diabetes and 
depression, the relationship between a diagnosis of diabetes and antidepressant 
medication adherence, and the relationship between antidepressant treatment adherence 
and glycemic outcomes in patients with diabetes. 
These areas as outlined represent understudied topics in the health services and 
medical outcomes literature. It is hoped that by addressing these research topics, the 
results of the current study will aid healthcare providers in helping to inform their 
provision of medical care for patients with co-occurring diabetes and depression. 
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OBJECTIVES AND HYPOTHESES 
The objectives and related hypotheses of this study are presented in the following 
section.  
Objective 1 
Objective 1 is to evaluate diabetes as a risk factor for depression in a population 
of indigent primary care patients. 
 
H0 1.1: There is no statistically significant association between diabetes diagnostic 
status and incident depression diagnostic status among indigent primary care 
patients. 
H0 1.2: After controlling for age, gender, ethnicity, marital status, and Charlson score 
there is no statistically significant association between diabetes diagnostic 
status and incident depression diagnostic status among indigent primary care 
patients. 
 
Objective 2 
Objective 2 is to evaluate risk factors for an incident diagnosis of depression 
among patients with diabetes. 
 
H0 2.1: After controlling for the influence of covariates, there is no statistically 
significant association between age and depression diagnostic status in patients 
with a diagnosis of diabetes. 
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H0 2.2: After controlling for the influence of covariates, there is no statistically 
significant association between gender and depression diagnostic status in 
patients with a diagnosis of diabetes. 
H0 2.3: After controlling for the influence of covariates, there is no statistically 
significant association between race/ethnicity and depression diagnostic status 
in patients with a diagnosis of diabetes. 
H0 2.4: After controlling for the influence of covariates, there is no statistically 
significant association between marital status and depression diagnostic status 
in patients with a diagnosis of diabetes. 
H0 2.5: After controlling for the influence of covariates, there is no statistically 
significant association between baseline HbA1c level and depression 
diagnostic status in patients with a diagnosis of diabetes. 
H0 2.6: After controlling for the influence of covariates, there is no statistically 
significant association between number of diabetic complications and 
depression diagnostic status in patients with a diagnosis of diabetes. 
H0 2.7: After controlling for the influence of covariates, there is no statistically 
significant association between the Charlson score and depression diagnostic 
status in patients with a diagnosis of diabetes. 
 
Objective 3 
Objective 3 is to evaluate the association between diabetes diagnostic status and 
antidepressant medication utilization patterns. 
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H0 3.1: There is no statistically significant relationship between diabetes diagnostic 
status and class of initial antidepressant (i.e., SSRI, non-SSRI) prescribed for 
patients with depression. 
H0 3.2: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant switch 
status in patients with depression. 
H0 3.3: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 
discontinuation status in patients with depression. 
H0 3.4: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 6-month 
MPR. 
H0 3.5: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 12-month 
MPR. 
H0 3.6: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and time to antidepressant 
non-persistence status. 
H0 3.7: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and 3-month antidepressant 
persistence status. 
H0 3.8: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and 12-month antidepressant 
persistence status. 
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Objective 4 
Objective 4 is to evaluate the association between class of initial antidepressant 
medication treatment and antidepressant medication-taking behaviors in patients with 
diabetes. 
 
H0 4.1: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 
antidepressant switch status after controlling for appropriate covariates. 
H0 4.2: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 
antidepressant discontinuation status after controlling for appropriate 
covariates. 
H0 4.3: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 6-month 
antidepressant MPR after controlling for appropriate covariates. 
H0 4.4: Among subjects with diabetes, there is no statistically significant between type 
of initial antidepressant medication treatment and 12-month antidepressant 
MPR after controlling for appropriate covariates. 
H0 4.5: Among subjects with diabetes, there is no statistically significant between type 
of initial antidepressant medication treatment and time to antidepressant non-
persistence status after controlling for appropriate covariates. 
H0 4.6: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 3-month 
antidepressant persistence status after controlling for appropriate covariates. 
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H0 4.7: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 12-month 
antidepressant persistence status after controlling for appropriate covariates. 
 
Objective 5 
Objective 5 is to evaluate the relationship between antidepressant medication 
adherence and glycemic control (measured by HbA1c) in patients with diabetes and 
comorbid depression. 
 
H0 5.1: After controlling for appropriate covariates, there is no statistically significant 
relationship between 6-month antidepressant medication MPR and HbA1c 
during follow-up. 
H0 5.2: After controlling for appropriate covariates, there is no statistically significant 
relationship between 12-month antidepressant medication MPR and HbA1c 
during follow-up. 
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Chapter 2: Methodology 
CHAPTER OVERVIEW 
The purpose of this chapter is to describe the design and methods of this research 
including institutional review board approval, study design, description of the data 
sources, study population, study variables, and statistical analyses. 
 
INSTITUTIONAL REVIEW BOARD APPROVAL 
This study was approved by The University of Texas at Austin Institutional 
Review Board (IRB) (study identification number: 2008-06-0007). The study met the 
requirements for expedited review and was initially approved on 06/17/2008. We 
requested and received waivers of informed consent and HIPAA authorization from the 
IRB. These waivers were authorized on the basis that all data collected and analyzed for 
this study were pre-existing and were already maintained as a part of the participants’ 
existing medical records. In addition, waiver of HIPAA authorization was granted 
because: 1) there will be minimal risk to the patients; 2) contacting and obtaining HIPAA 
consent from subjects would be impractical; and 3) obtaining HIPAA consent from 
patients no longer treated in the CommUnityCare clinic network (formerly Austin Travis 
County Community Healthcare Clinics) would be impossible. 
 
STUDY DESIGN 
This study is a retrospective database study. Patient-level data was extracted from 
a variety of administrative and clinical databases for individuals who met study inclusion 
criteria. Demographic information, such as age, gender, ethnicity, and marital status, as 
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well as clinical information, including diagnosis codes, laboratory results, and 
prescription records, were utilized as available. 
 
DATA SOURCES 
This study utilized data obtained from a number of administrative and clinical 
data sources. These data sources and the related data elements are summarized in 
Appendix C. Data for this study consisted of administrative and clinical data obtained 
during the course of usual care in a community indigent care network. The primary 
source of data for this project is the NextGen Healthcare Information System (NHIS). 
Prescription claims data and laboratory data were obtained from pharmacy and laboratory 
datasets and linked to the primary data source. A brief description of each of the data 
sources follows. 
 
Administrative and Clinical Data 
The NHIS system is the practice management and electronic health record system 
utilized by CommUnityCare, a nonprofit organization providing healthcare services for 
indigent patients in Austin and Travis County, TX. The NHIS system contains 
information related to practice management (appointments, billing information, etc.), as 
well as clinical documentation and charting for service encounters occurring within the 
clinic system. There are two primary subsystems within the NHIS as implemented by the 
clinics, the Enterprise Practice Management system (EPM) and the Electronic Medical 
Record system (EMR).  
The EPM is the administrative management system used to schedule patient 
appointments and to facilitate billing. The EMR is the clinical management system used 
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in community healthcare centers and contains patient-level medical data. Data elements 
available through NHIS which will be used for this study include demographic 
information, service eligibility data, medical encounter data and clinical laboratory data. 
 
Pharmacy Data 
Prescription claims data were collected from two sources. During the period of 
time covered by this study, the clinic network operated onsite class A pharmacies located 
within some of the community health clinics. Pharmacy services are also provided by a 
chain community pharmacy. Patients receive their prescriptions at a reduced rate if they 
obtain them through the onsite or participating community pharmacies. These pharmacy 
data sources were utilized to obtain prescription claim records for study subjects. 
Data elements associated with pharmacy claims include: a unique and de-
identified study identification number, prescriber name, dispense date, date the 
prescription was written, national drug code, dispensed quantity, prescription quantity, 
and days supply of medication. These data elements were used as described in subsequent 
sections to facilitate evaluation of medication-taking behaviors.  
 
Laboratory Data 
Laboratory services are provided for the community health centers by the 
Laboratory Corporation of America (also known as LabCorp). Data elements included in 
the laboratory table include: study identification number, type of test, date of test, 
laboratory test result, result description, result units, and ordering provider. Laboratory 
data were extracted from the EMR with supplementary data obtained, as necessary, from 
archived laboratory data maintained in a separate LabCorp data table. These 
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supplementary data were identified and incorporated into the final database by clinic 
information technology personnel at the request of the researcher. 
 
STUDY POPULATION 
Data were extracted only for adults receiving medical care within the 
CommUnityCare clinic network. This study utilized data for both male and female 
patients, as well as patients of all ethnicities. No data was systematically excluded from 
the data extraction on the basis of any demographic or clinical factors, other than those 
detailed in the inclusion and exclusion criteria.  
 
Inclusion Criteria 
Data were initially extracted for individuals meeting the following criteria: 
1) Subject has one or more medical encounter(s) in one of the CommUnityCare 
clinics between October 1, 2004 and September 30, 2008; and, 
2) Age between 18 and 64 years. 
 
Exclusion Criteria 
Patients meeting any of the following criteria were excluded from the data extraction: 
1) Medicare benefits coverage; 
2) Medicaid benefits coverage; or 
3) Clinic eligibility determination as homeless. 
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Rationale for Inclusion and Exclusion Criteria 
 The inclusion and exclusion criteria implemented for this study are based on a 
number of practical and methodological considerations. The preliminary case 
identification screen was conducted by clinic personnel based on the study inclusion and 
exclusion criteria. Subjects with Medicare or Medicaid coverage were excluded due to 
the lack of available prescription claims data within the clinic health information 
infrastructure for these individuals. Homeless subjects were excluded from this study due 
to the way in which the clinic assigns service eligibility to these clients. Service 
eligibility for these clients is intermittent and assigned in short-term increments. 
 
TIME FRAME 
This study utilized data collected during clinic visits occurring between October 
1, 2004 and September 30, 2008. This study period was chosen based on a number of 
factors including the implementation status of the NHIS in the clinics, data availability, 
and study requirements. 
 
 DATA MANAGEMENT 
This study utilized administrative and clinical data obtained from multiple data 
sources. The NHIS is considered the primary data resource for this research. Data were 
managed using Microsoft Office Access 2007. Microsoft Office Excel 2007 was used as 
a secondary data management system in order to perform certain calculations or data 
manipulations, as necessary. All statistical modeling and analyses were conducted using 
PASW version 18.0. 
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STUDY VARIABLES 
The purpose of this section is to provide the operational definition for each of the 
dependent and independent study variables. The operational definitions for each of the 
variables of interest, as well as covariates included in the analyses are described in the 
following section. The study variables, variable coding, variable type, and source are 
summarized in Appendix D. 
 
Primary Variables of Interest 
Diagnosis of Depression 
A diagnosis of depression was identified using diagnostic information obtained 
from computerized medical records. Depression was identified on the basis of 
International Statistical Classification of Diseases and Related Health Problems, 9
th
 
revision clinical modification (ICD-9 CM) diagnostic codes 296.2x, 296.3x, or 311.xx. 
The presence of a diagnosis of depression was coded as 1 in the analytic dataset, while 
the absence of a diagnosis of depression was coded as 0. In the final dataset, separate 
indicator variables were used to identify the presence of depression during the screening 
period (if applicable) and the follow-up period, based on the analytic strategy detailed 
later in this chapter. 
 
Diagnosis of Diabetes Mellitus 
The presence of a diagnosis of diabetes was determined based on clinical 
diagnostic data. ICD-9 CM diagnostic code 250.xx was used to identify the presence of a 
diagnosis of diabetes. The presence of a diagnosis of diabetes was coded as 1 in the 
analytic dataset, while the absence of a diagnosis of diabetes was coded as 0. As with 
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depression indicator coding, in the final dataset separate indicator variables were used to 
identify the presence of diabetes during the screening period and the follow-up period, 
based on the analytic strategy detailed later in this chapter. 
 
Medication Adherence and Persistence 
Medication Adherence 
Medication adherence was evaluated as a continuous measure of medication 
adherence using the medication possession ratio (MPR). The MPR was used as a CMA 
(continuous, multiple period, medication available) method of measuring medication 
adherence, according to the taxonomy proposed by Steiner and Prochazka.
186
 The MPR is 
defined as the sum of the number of days of medication supplied during a time interval 
divided by the number of days during the interval.
188
 In the current study, the MPR was 
calculated for the index antidepressant medication using a fixed observation time frame 
for the observation interval. Observation time frames of 6 and 12 months were used, 
depending on the specific hypothesis being tested. Calculations of MPR resulting in 
values greater than 1.00 for individual subjects were truncated at 1.00 prior to analysis. 
 
Medication Persistence 
Medication-taking behavior was also measured as a function of persistence, or the 
length of time that the subject remains on continuous therapy once treatment is initiated. 
Medication persistence is an important component of medication adherence that attempts 
to capture continuity of medication exposure, a factor that is not captured in the MPR.
188
 
This is done by evaluating the temporal gaps between medication refills. Persistence was 
evaluated in terms of both continuous and dichotomous measures. Time to non-
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persistence was the continuous measure of persistence, and was measured in days. 
Persistence in this study was evaluated according to the “permissible gap” method 
described by Sikka and colleagues.
190
 This methodology identifies subjects as non-
persistent when a predetermined length of time between the end of the last supply of 
medication and the time of refilling the subsequent prescription is exceeded. For the 
purposes of this study, the predetermined period of “permissible gap” time allowed 
between refills was 15 days. 
When an individual subject displayed a gap in medication availability of greater 
than 15 days, the date of expiration of the days supply associated with the previous 
prescription fill was considered the conversion to non-persistence, and the period of time 
between the initiation of the index prescription and this conversion date was calculated in 
days (Figure 2.1). Continuous time to non-persistence data were used to create 
dichotomous variables indicating persistence status at 3 and 12 months. Subjects who 
displayed a total number of persistent days greater than or equal to 90 days were coded as 
being persistent at 3 months. If the total number of persistent days was equal to or greater 
than 365 days, patients were coded as being persistent at 12 months.
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Figure 2.1 Examples of medication persistence calculation based on four prescription fill 
patterns. 
 
Solid line indicates days supply period associated with prescription fill; dashed line indicates time period 
during which days supply from previous fill has expired (i.e. gap); index, index prescription claim; rf, refill;   
p, persistence time calculated in days 
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Antidepressant Medication Class 
Pharmacy prescription claims data were utilized to evaluate the frequency of type 
of initial antidepressant medication prescribed for individuals receiving treatment for 
depression. The original intent was to categorize antidepressant medications according to 
their pharmacological classification as either a serotonin reuptake inhibitor (SSRI), a 
serotonin-norepinephrine reuptake inhibitor (SNRI), or an atypical antidepressant. 
However, based on preliminary analysis of the available data, the initial antidepressant 
medication was coded as a dichotomous variable; SSRI antidepressant medications were 
coded as 0 and SNRI or atypical antidepressant medications were coded as 1. Based on 
preliminary evaluation of medication utilization patterns observed with tricyclic 
antidepressant medications, prescription claims for tricyclic antidepressant medications 
were not included in any of the study analyses. Prescription claims for tricyclic 
antidepressant medications were generally indicative of low-dose use for indications 
other than depression. 
 
Antidepressant Discontinuation and Switch 
Pharmacy prescription claims data were utilized to evaluate medication utilization 
patterns. Specifically, this study evaluated rates of antidepressant discontinuation and 
switch among patients with depression. Discontinuation and switch rates for subjects with 
diabetes were compared to the rates of discontinuation and switch for subjects without 
diabetes. Analysis of discontinuation and switch rates by initial class of antidepressant 
treatment were also conducted. 
Antidepressant discontinuation was operationalized as the absence of a pharmacy 
claim for an antidepressant medication for a continuous period of 60 days following the 
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expiration of the days supply associated with the previous antidepressant prescription 
claim. Individuals who were identified as discontinuing antidepressant medication 
treatment according to this definition were coded as 1 in the analytic dataset, while 
subjects who did not meet this definition of discontinuation were coded as 0. 
Discontinuation is distinct from medication non-persistence (discussed earlier), in that 
discontinuation is indicative of a long-term cessation of medication treatment, whereas 
non-persistence is indicative of intermittent, short-term cessation of medication treatment 
that may or may not be followed by a resumption of the index treatment. 
Antidepressant switch was operationalized as the absence of a subsequent claim 
for the index antidepressant medication for a continuous period of 60 days after the 
expiration of medication supply, during which period of time a claim for an alternative 
antidepressant medication was observed. Individuals who met this definition of 
antidepressant switch were coded as 1 in the analytic dataset, while individuals who did 
not meet this definition were coded as 0. This definition of antidepressant switch attempts 
to capture individuals who initiate treatment on an antidepressant medication, discontinue 
their initial treatment for any reason, and switch to an alternate treatment without a 
substantial lapse in treatment indicative of treatment discontinuation. 
 
Glycemic Control 
Glycemic control was evaluated by inspection of HbA1c values at time points 
described in the analysis section of this chapter, and as available from the laboratory 
dataset. HbA1c is reported as a percentage and is treated as a continuous variable in 
analyses related to Objective 5. 
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Covariates 
A number of covariates were included in statistical analyses to control for 
potential confounding due to various demographic, medication, and clinical factors. 
Descriptions and operational definitions of the variables which were used as covariates in 
the various regression models and have not previously been described are presented in 
the following section. 
 
Demographic Variables 
Age 
Age was incorporated as a continuous variable, and was obtained from the NHIS. 
For analyses under Objective 1 and Objective 2, the reference age was the age in years at 
the start date for the screening period. For all other objectives, the reference age was the 
age in years at the time of the index antidepressant prescription fill. 
 
Gender 
Gender was incorporated as a dichotomous categorical variable and was obtained 
from the NHIS. For the purposes of all analyses, gender was coded as:  female = 0; male 
= 1. On the basis of this coding, female gender served as the reference comparator group 
for all regression analyses. 
 
Race/ethnicity 
Race/ethnicity was entered into the regression models as a categorical variable. 
Due to the low frequency of some reported race/ethnicity categories, the following 
race/ethnicity categories were collapsed to a single “other or unknown” category: Asian, 
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American Indian/Alaskan, Native Hawaiian, Other Pacific Islander-Not Hawaiian, 
unreported, and unknown. Therefore, the classification and coding of the race/ethnicity 
variable was as follows: White-Hispanic = 0; White-non-Hispanic = 1; African-American 
= 2; other or unknown = 3. While the general convention for incorporating race/ethnicity 
into statistical modeling is to use dummy coding such that the comparator group is White 
non-Hispanic, due to the fact that the overwhelming majority of subjects included in this 
study were classified as White Hispanic, this group was used as the comparator for all 
other ethnic classifications. 
Due to modeling considerations for analyses related to Objective 4, and after 
preliminary inspection of the frequency distribution of the race/ethnicity variable for 
subjects included in these analyses, the race/ethnicity classification for these models were 
further collapsed to two groups: White Hispanic = 0; and non-White Hispanic = 1. This 
allowed for removal of two variables from the Objective 4 statistical models, increasing 
the stability of the regression solution. 
 
Marital Status 
Marital status was incorporated into the regression models as a categorical 
variable. Due to the low frequency of some reported marital status categories, the 
following marital status categories were collapsed to a single category labeled “Other or 
unknown”: divorced, widowed, legally separated, and unknown. The coding of the 
marital status variable is as follows:  single = 0; married = 1; divorced, widowed, other or 
unknown = 2. On the basis of this coding, marital status of single was the reference 
comparator group in the regression models for all other marital status classifications. 
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Clinical Variables 
Comorbidity Index 
The Charlson comorbidity index (CCI) was developed to predict risk of 1-year 
mortality attributable to medical comorbidity.
194
 Romano and colleagues adapted the CCI 
for use with ICD-9 CM diagnostic codes.
195
 The Charlson score has been used in a 
variety of epidemiological studies as a continuous marker of comorbidity.
196-198
 The 
Romano implementation of the CCI was used to adjust for comorbidity via inclusion as 
the Charlson score in the statistical tests. The Charlson score was treated as a continuous 
variable for the purposes of this study. ICD-9 CM codes were converted to Charlson 
scores based on the classifications proposed by Romano. These classifications are 
presented in Appendix E. 
 
Diabetic Complications 
The presence of diabetic complications (e.g., retinopathy, nephropathy, etc.) was 
determined based on ICD-9 CM diagnostic codes. The presence of individual 
complications was coded in the analytic dataset according to the ICD-9 CM diagnostic 
codes presented in Appendix F. A separate indicator variable was coded 0 or 1 based on 
the presence of a diagnostic code for the specific complication. Individual indicator 
variables were constructed for retinopathy, nephropathy, neuropathy, cardiovascular 
disease, cerebrovascular disease, and peripheral vascular disease. A summary score 
representing the total number of diabetic complications was then created by summing 
each of these indicator variables. Diabetic complications were therefore incorporated into 
the analyses as a continuous variable with a potential range of 0 to 6. 
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Behavioral Health Services Status 
An integrated behavioral health services program is provided to primary care 
patients receiving medical care with the CommUnityCare clinics. Individuals may 
receive these services based on the referral of their primary care provider. Examples of 
reasons for referral to the integrated behavioral health program include medication 
management assistance, instruction on self-management of behavioral health conditions, 
and other issues related to behavioral healthcare. These services are provided by trained 
behavioral health consultants and psychiatrists who operate in collaboration with the 
patient’s primary care provider. Behavioral health interventions typically consist of five 
to six behavioral health encounters occurring over a variable time period. 
In order to control for the effect of receiving these specialized behavioral health 
services on any of the outcomes evaluated in this study, behavioral health services status 
was incorporated as a covariate in the regression models for Objective 3, Objective 4, and 
Objective 5. For these analyses, individuals were coded as receiving behavioral health 
services if they displayed one of the relevant Current Procedural Terminology (CPT)  
codes at any encounter during the observation period. Behavioral health services status 
was coded as 1 if an individual had any of the following CPT codes associated with a 
clinic encounter: 
 90801 (Psychiatric diagnostic interview examination); 
 90804 (Individual psychotherapy, insight oriented, behavior modifying and/or 
supportive, in an office or outpatient facility, approximately 20 to 30 minutes face-to-
face with the patient); or 
 90805 (Individual psychotherapy, insight oriented, behavior modifying and/or 
supportive, in an office or outpatient facility, approximately 20 to 30 minutes face-to-
face with the patient; with medical evaluation and management services).  
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DATA ANALYSIS 
The purpose of this section is to describe the analytic methods and procedures that 
were employed for this study. The analytic approach and methods are described for each 
objective and the related hypotheses. The a priori alpha level for all analyses was set at 
0.05, and all statistical tests were two-tailed. Data were evaluated for violations of 
assumptions (e.g., presence of multicollinearity, violation of the proportional hazard 
assumption) underlying the associated statistical tests. All statistical analyses were 
conducted using PASW version 18.0. 
 
Objective 1 
Cohort Construction 
The purpose of Objective 1 (Table 2.1) is to evaluate diabetes as a risk factor for 
incident depression among a cohort of indigent primary care patients. The analytic cohort 
for this objective was constructed by identifying individuals with continuous clinic 
eligibility for a period of 24 months, after removing subjects receiving reproductive 
healthcare services and family planning services. The latter subjects were excluded from 
these analyses due to the large number of subjects receiving only reproductive healthcare 
services within the clinics, and to remove potential bias that inclusion of these subjects 
may have introduced. For the purposes of the Objective 1 analyses, the initial 12-month 
period of service eligibility was considered the screening period, and the subsequent 12 
months of service eligibility was considered the follow-up period. 
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Analytic Methods 
For subjects meeting these requirements, encounters during the initial 12 months 
of clinic eligibility were inspected to identify diagnoses and clinical characteristics 
associated with these clinic encounters. In particular, the presence of diagnoses of 
diabetes and depression associated with encounters occurring during the 12-month 
screening period were identified. Individuals with a diagnosis indicative of diabetes or 
depression during the screening period were classified as prevalent cases of these 
conditions. Diagnostic data during the 12-month screening period were also utilized to 
calculate Charlson scores and to identify the presence and number of diabetic 
complications for subjects with a diagnosis of diabetes. 
The follow-up period was defined as the 12 months of clinic service following the 
12-month screening period. Diagnostic data associated with clinic encounters during the 
12-month follow-up period were screened for the presence of diagnoses of diabetes or 
depression in a manner similar to that used for the screening period. 
The prevalence of diabetes and depression was calculated as the total number of 
cases of the respective disorder during the screening period divided by the total number 
of subjects included in the analysis. The 12-month incidence of diabetes during the 
follow-up period was calculated as the total number of new cases of diabetes during the 
follow-up period divided by the number of subjects without a diagnosis of prevalent 
diabetes during the screening period. The 12-month incidence of depression was 
calculated in a similar manner, with the denominator representing the number of 
individuals without a diagnosis of prevalent depression during the screening period.  
In order to evaluate the association between diabetes diagnostic status and 
incident diagnosis of depression, the analytic dataset for Hypothesis 1.1 and Hypothesis 
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1.2 was limited to individuals who did not display a prevalent diagnosis of depression 
during the screening period. 
Hypothesis 1.1 evaluated the bivariate association between prevalent diabetes and 
incident depression during the 12-month evaluation period. Hypothesis 1.1 was formally 
tested via bivariate logistic regression of depression diagnostic status on prevalent 
diabetes diagnostic status. Hypothesis 1.2 evaluated the association between prevalent 
diabetes and incident depression, after statistically controlling for the influence of 
covariates as previously described. Hypothesis 1.2 was tested by multivariate logistic 
regression of incident depression diagnostic status on diabetes diagnostic status with the 
inclusion of the following covariates: age, gender, race/ethnicity, marital status, and 
Charlson score. For each variable included in both logistic regression models, the 
regression coefficient, the standard error of the regression coefficient, the Wald statistic 
and associated p-value, as well as the odds ratio with 95% confidence interval are 
reported.
 94 
Table 2.1 Hypotheses, related study variables, and statistical tests for Objective 1 
 
 
Hypothesis Covariates Statistical Test
Variable Name Variable Type Variable Name Variable Type
H0 1.1 Dichotomous Dichotomous N/A Bivariate
logistic regression
H0 1.2 Dichotomous Age
Gender
Ethnicity
Marital Status
Charlson score
Independent Variable Dependent Variable
Objective 1. Evaluate diabetes as a risk factor for depression among indigent primary care patients.
Diabetes diagnostic 
status
Depression 
diagnostic status
Diabetes diagnostic 
status
Dichotomous Depression 
diagnostic status
Multivariate 
logistic regression
N/A, not applicable
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Objective 2 
Cohort Construction 
The purpose of Objective 2 (Table 2.2) is to evaluate risk factors for an incident 
diagnosis of depression among subjects with pre-existing diabetes. The analytic cohort 
for this objective was identical to that used for Objective 1 with the additional 
requirement that all members of the cohort display a prevalent diagnosis of diabetes 
during the screening period. This cohort of diabetic patients without prevalent depression 
was followed for 12 months after the initial 12-month screening period. Cases of incident 
depression were identified during the 12-month follow-up period using the same 
methodology as described for Objective 1. 
Hemoglobin A1c laboratory data obtained during the screening period were 
incorporated as a variable in the analysis related to Objective 2. A total of 179 of 2394 
subjects included in the cohort for Objective 2 had one or more HbA1c labs reported 
during the screening period. In the case where an individual had only a single HbA1c 
value during the screening period, that data was incorporated into the analysis without 
regard to the time point that the laboratory value was obtained. For individuals with 
multiple HbA1c laboratory values during the screening period, the laboratory test closest 
to the end of the screening period was utilized in the analysis. 
 
Analytic Methods 
A multivariate logistic regression model incorporating the variables of interest 
was constructed. The purpose of this analysis was to evaluate the association between 
individual predictors while controlling for the influence of other variables included in the 
model. This analysis was conducted by regressing incident depression diagnostic status 
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on the following variables simultaneously: age, gender, race/ethnicity, marital status, 
hemoglobin A1c value, number of diabetic complications, and Charlson score. This 
multivariate logistic regression model was used to test the specific hypotheses related to 
Objective 2.
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Table 2.2 Hypotheses, related study variables, and statistical tests for Objective 2 
 
 
 
Hypothesis Statistical Test
Variable Name Variable Type Variable Name Variable Type
H0 2.1 Age Continuous Depression status Dichotomous
H0 2.2 Gender Categorical Depression status Dichotomous Multivariate logistic regression
H0 2.3 Ethnicity Categorical Depression status Dichotomous Multivariate logistic regression
H0 2.4 Marital status Categorical Depression status Dichotomous Multivariate logistic regression
H0 2.5 Hemoglobin A1c 
value
Continuous Depression status Dichotomous Multivariate logistic regression
H0 2.6 No. diabetic 
complications
Continuous Depression status Dichotomous Multivariate logistic regression
H0 2.7 Charlson score Continuous Depression status Dichotomous
Independent Variable Dependent Variable
Multivariate logistic regression
Multivariate logistic regression
Covariates for H0 2.1-2.7: Age, gender, race/ethnicity classification, marital status classification, Hemoglobin A1c, number of diabetic 
complications, Charlson score.
Objective 2. Evaluate risk factors for an incident diagnosis of depression among patients diagnosed with prevalent 
diabetes.
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Objective 3 
Cohort Construction 
The purpose of Objective 3 (Table 2.3) is to evaluate the association between a 
diagnosis of diabetes and antidepressant medication utilization patterns. The analytic 
cohort for this objective was constructed based on identification of an index event of an 
initial prescription for an antidepressant medication. 
To construct this cohort, subjects with sufficient service eligibility and 
prescription claims records were screened for the presence of antidepressant prescription 
claims. The minimum possible length of continuous service eligibility required to be 
screened for inclusion in the cohort for Objective 3 was 18 months. A total of 49 subjects 
had 2 separate periods of service eligibility of 18-months or greater. In these 49 cases the 
most recent 18 month or greater eligibility period served as the evaluation period. 
An initial antidepressant prescription was identified after performing a 6-month 
“look-back” for each antidepressant prescription claim screened. In order to qualify as an 
index antidepressant prescription, it was required that the antidepressant claim was 
preceded by a 6-month antidepressant-free interval. If there were no prescription claims 
for an antidepressant medication in the six months preceding the claim under review, the 
claim was considered an index antidepressant prescription, and the date associated with 
this prescription claim was treated as the index date. For subjects with an index 
antidepressant prescription, a 12-month “look-forward” was conducted to verify that the 
subject had 12 months of continuous clinic eligibility following the index date. 
Once this initial group of subjects meeting the continuous eligibility requirement 
and having an index antidepressant prescription claim was constructed, one additional 
screen based on ICD-9 CM diagnostic codes took place. All subjects who had an ICD-9 
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CM diagnostic code for depression associated with any clinic encounter during the 18-
month observation period (six months pre-index date and 12 months post-index date) 
were identified. All subjects without an ICD-9 CM code indicating a diagnosis of 
depression were excluded from the analytic dataset for Objective 3. This step was 
performed in order to identify individuals receiving antidepressant treatment for 
treatment of documented depression, as opposed to individuals using antidepressant 
medications for other indications (e.g., anxiety disorders). In a similar manner, 
individuals were classified with positive diabetes diagnostic status based on the presence 
of an ICD-9 CM diagnostic code at any point during the observation period. 
 
Analytic Methods 
Demographic and clinical characteristics of all subjects with an index event of an 
initial antidepressant prescription claim are reported. The diagnostic characteristics for 
these subjects in terms of frequency of depression diagnostic status and diabetes 
diagnostic status are likewise reported. The frequency of other psychiatric diagnoses 
associated with antidepressant use among the initial cohort of all subjects with an index 
antidepressant prescription claim is also reported. 
After restriction of the cohort to only subjects with an observed diagnosis of 
depression, the simple frequency of class of antidepressant initially prescribed is 
reported, and these frequencies were compared in the group of patients with a diagnosis 
of diabetes to patients without a diagnosis of diabetes. Likewise, the clinical and 
demographic characteristics of subjects included in the final analytic cohorts are reported 
based on diabetes diagnostic status. 
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Hypothesis 3.1 was tested by means of logistic regression of initial class of 
antidepressant prescription on diabetes diagnostic status and the included covariates. 
Covariates incorporated into this model include: age, gender, ethnicity, marital status, 
behavioral health service status, and the Charlson score. 
Hypotheses 3.2 and 3.3 evaluated the relationship between diabetes diagnostic 
status and antidepressant switch and discontinuation, respectively, during the 12-month 
follow-up period. These analyses were performed by means of logistic regression where 
the outcome (i.e., dichotomous indicator of switch or discontinuation, respectively) was 
the dependent variable. Diabetes diagnostic status was the independent variable of 
interest. Covariates incorporated into this model include: initial antidepressant class, age, 
gender, ethnicity, marital status, behavioral health services status, and the Charlson score. 
Hypotheses 3.4 and 3.5 evaluated the association between diabetic diagnostic 
status and medication possession ratio. Six-month and 12-month MPR were calculated as 
previously described. The relationship between a diagnosis of diabetes and antidepressant 
adherence was evaluated via regression of antidepressant MPR on diabetes diagnostic 
status with appropriate covariates. Hypotheses 3.4 and 3.5 were tested using the 
generalized linear model procedure in PASW with a normal probability distribution and 
the identity link function. 
Hypotheses 3.6 through 3.8 evaluate the relationship between diabetes diagnostic 
status and antidepressant medication persistence. Hypothesis 3.6 formally tested the 
relationship between diabetes diagnostic status and time to antidepressant non-
persistence. The bivariate relationship between diabetes diagnostic status and time to 
antidepressant non-persistence was evaluated via Kaplan-Meier analysis and the 
difference between groups was tested with the log-rank test. Time to antidepressant non-
persistence was evaluated via Cox proportional hazards regression with the inclusion of 
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appropriate covariates. The Cox proportional hazards regression model is a survival 
analysis technique that allows for modeling of time-to-event data in the presence of 
censored cases. Compared to the Kaplan-Meier analysis which evaluates survival time in 
a bivariate manner, the Cox model can be used to test the association between 
independent and dependent variables after controlling for the influence of covariates. 
Hypotheses 3.7 and 3.8 evaluated the relationship between diabetes diagnostic 
status and persistence as a dichotomized variable at 3-month and 12-month time points. 
The relationships between diabetes diagnostic status and 3-month and 12-month 
antidepressant persistence were evaluated using logistic regression of persistence status 
on diabetes diagnostic status after controlling the influence of the included covariates. 
Covariates included in these models include: initial antidepressant class, age, gender, 
ethnicity, marital status, behavioral health services status, and the Charlson score.
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Table 2.3 Hypotheses, related study variables, and statistical tests for Objective 3. 
 
Hypothesis Statistical Test
Variable Name Variable Type Variable Name Variable Type
Objective 3. Evaluate the association between diabetes diagnostic status and antidepressant medication utilization patterns.
H0 3.1 Diabetes status Dichotomous AD class Dichotomous Logistic regression
H0 3.2 Diabetes status Dichotomous AD switch status Dichotomous Logistic regression
H0 3.3 Diabetes status Dichotomous AD discontinuation status Dichotomous Logistic regression
H0 3.4 Diabetes status Dichotomous 6-month AD MPR Continuous Linear regression
H0 3.5 Diabetes status Dichotomous 12-month AD MPR Continuous Linear regression
H0 3.6 Diabetes status Dichotomous Time to AD non-persistence Continuous
H0 3.7 Diabetes status Dichotomous 3-month AD persistence Dichotomous Logistic regression
H0 3.8 Diabetes status Dichotomous 12-month AD persistence Dichotomous Logistic regression
Independent Variable Dependent Variable
Covariates for H0 3.2 through 3.8 : covariates for H0 3.1 model + initial antidepressant class.
Cox proportional hazards survival 
analysis
AD, antidepressant; DM, diabetes mellitus; MPR, medication possession ratio
Covariates for H0 3.1: age, gender, ethnicity, marital status, Charlson score, behavioral health services status.
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Objective 4 
Cohort Construction 
The aim of Objective 4 (Table 2.4) is to evaluate the relationship between class of 
initial antidepressant treatment and antidepressant medication-taking behaviors in 
patients with diabetes receiving antidepressant treatment. In order to meet this objective, 
subjects with an index prescription claim for an antidepressant medication were identified 
in a method identical to that used to construct the cohort for Objective 3. Further, all 
subjects were required to have a diagnosis of diabetes. In order to preserve sufficient 
sample size, rather than limit the cohort to only individuals with a diagnosis of 
depression, depression diagnostic status was included as a covariate in all of the 
Objective 4 analyses. This was done in order to control for the influence of diverse 
indications for antidepressant treatment on the various outcomes of interest. In order to 
frame the interpretation of this included covariate in the intended fashion, the indicator 
for depression diagnostic status was reverse coded such that diagnosis of depression = 0, 
and the lack of a diagnosis of depression = 1. In addition to depression status, the number 
of diagnosed diabetic complications was included as a covariate for the statistical models 
used to test Hypotheses 4.1 to 4.7. 
 
Analytic Methods  
The statistical techniques used to test the hypotheses under Objective 4 were 
similar to those utilized to test Hypotheses 3.2 to 3.8. The primary difference between the 
analyses for Objective 4 and those included under Objective 3 were the analytic cohort 
being limited to subjects with a diagnosis of diabetes, inclusion of number of diabetic 
complications as a covariate, and the independent variable of interest. 
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Hypotheses 4.1 and 4.2 employed logistic regression to evaluate the association 
between class of antidepressant medication initially prescribed and antidepressant switch 
and discontinuation, respectively. Hypotheses 4.3 and 4.4 involved regression of 6- and 
12-month antidepressant MPR, respectively, on class of initial AD medication. 
Hypothesis 4.5 evaluated the relationship between class of initial AD medication and 
time to antidepressant non-persistence via Cox proportional hazards survival analysis. 
Hypotheses 4.6 and 4.7 tested the relationship between initial AD class and 3- and 12-
month AD persistence status, respectively, via the statistical technique of logistic 
regression. Covariates included in all of the models constructed to test the hypotheses 
under Objective 4 were: age, gender, ethnicity, marital status, number of diabetic 
complications, behavioral health services status, depression diagnostic status, and 
Charlson score.
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Table 2.4 Hypotheses, related study variables, and statistical tests for Objective 4 
 
Hypothesis Statistical Test
Variable Name Variable Type Variable Name Variable Type
H0 4.1 AD class Dichotomous AD switch status Dichotomous Logistic regression
H0 4.2 AD class Dichotomous AD discontinuation status Dichotomous Logistic regression
H0 4.3 AD class Dichotomous 6-month AD MPR Continuous Linear regression
H0 4.4 AD class Dichotomous 12-month AD MPR Continuous Linear regression
H0 4.5 AD class Dichotomous Time to AD non-persistence Continuous
H0 4.6 AD class Dichotomous 3-month AD persistence status Dichotomous Logistic regression
H0 4.7 AD class Dichotomous 12-month AD persistence status Dichotomous Logistic regression
Covariates for H0 4.1 - 4.7: age, gender, ethnicity, marital status, depression diagnostic status, number of diabetic complications, 
Charlson score, behavioral health services status.
Objective 5. Evaluate the association between class of initial antidepressant medication treatment and antidepressant 
medication-taking behaviors in patients with type 2 diabetes and comorbid depression.
Cox proportional hazards 
survival analysis
AD, antidepresant; MPR, medication possession ratio.
Independent Variable Dependent Variable
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Objective 5 
Cohort Construction 
The purpose of Objective 5 (Table 2.5) is to evaluate the relationship between 
antidepressant adherence and glycemic control, as measured by HbA1c value. The 
analytic cohort for this objective consisted of subjects with an index antidepressant 
prescription (identified as previously described for Objective 3) and available HbA1c 
laboratory data during the follow-up period. 
 
Analytic Methods 
A limited number of subjects had HbA1c data that could be incorporated into the 
analyses under Objective 5. In order to build a cohort of sufficient size, very limited 
restrictions were placed on the allowable timeframe for incorporation of HbA1c data. 
While the HbA1c values reflect glycemic control over a period of approximately 120 
days preceding measurement, HbA1c were incorporated for all subjects over a broad 
period of follow-up. HbA1c data were incorporated, as available, for any subject with an 
HbA1c measurement after the index event of an initial antidepressant prescription, 
extending beyond the 12-month terminus of the predefined follow-up period. In the case 
where an individual had only a single HbA1c lab after the index date, that data was 
incorporated into the analysis without regard to the time point that the laboratory value 
was obtained. For individuals with multiple HbA1c labs after the index antidepressant 
claim, the laboratory value obtained at the time point closest to the end of 12-month post 
index observation period was utilized in the analysis. In addition, the lack of HbA1c 
laboratory data for subjects during the pre-index screening period necessitated the 
removal of pre-index HbA1c as a covariate for inclusion in the Objective 5 analyses. 
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These methodological limitations, necessary due to limited data availability, are 
acknowledged as a threat the internal validity of the analyses conducted to test 
Hypotheses 5.1 and 5.2. The temporal distribution of HbA1c data utilized for Objective 5 
analyses is presented in the results section. 
Hypotheses 5.1 and 5.2 were tested using the generalized linear model procedure 
with a normal probability distribution and the identity link function. Regression of 
HbA1c values on antidepressant MPR was conducted with age, gender, ethnicity, marital 
status, and Charlson score included as covariates. 
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Table 2.5 Hypotheses, related study variables, and statistical tests for Objective 5 
Hypothesis Statistical Test
Variable Name Variable Type Variable Name Variable Type
H0 5.1 6-month AD MPR Continuous HbA1c Continuous Linear regression
H0 5.2 12-month AD MPR Continuous HbA1c Continuous Linear regression
Independent Variable Dependent Variable
Objective 5. Evaluate the relationship between antidepressant medication adherence and glycemic control.
Covariates for H0 5.1-5.2: age, gender, ethnicity, martial status, behavioral health service status, Charlson score.
AD, antidepressant; DM, diabetes mellitus; MPR, medication possession ratio; HbA1c, hemoglobin A1c
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Power Calculations 
A series of calculations were conducted prior to constructing the study cohorts in 
order to estimate the power of the proposed statistical analyses based on a number of 
assumptions regarding the data. For all power calculations, the alpha-level (probability of 
a type I error) was set to 0.050 and a two-tailed distribution was used. A number of 
assumptions regarding the sample size were made in order to estimate the power of 
certain statistical analyses; therefore, the preliminary analyses presented here were 
treated as a priori power estimates rather than sample size calculations. 
It was initially estimated that there would be data available for 10,000 unique 
subjects for analysis. Based on conservative prevalence estimates for diabetes and 
depression of 10% each, it was anticipated that approximately 1,000 subjects with 
diabetes and 1,000 subjects with depression would be identified. Of these 1,000 subjects 
with diabetes, for the purpose of these preliminary power estimates, it was estimated that 
approximately 200 subjects (20%) would have comorbid diabetes and major depression. 
An incidence rate of 20 new cases of depression per 1,000 patient-years among 
individuals with diabetes, and 10 incident cases per 1,000 patient-years among non-
diabetics was estimated. Based on these assumptions regarding sample size, power 
estimates for the analyses associated with select study hypotheses were conducted with 
SPSS Sample Power 2.0 and are summarized in Table 2.6. 
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Table 2.6 Power estimates for select hypotheses and related statistical tests 
Hypothesis Statistical Test Power Estimate
H0 1.1 Logistic regression
H0 3.4 Linear regression
H0 4.7 Logistic regression Power of 0.70 to detect a difference of 20% in 12-month persistence 
status for subjects receiving SSRI vs. SNRI and atypical antidepressant 
treatment.
Power of 0.99 to detect a 2-fold difference in the incidence of 
depression for subjects with a diagnosis of diabetes compared to those 
without a diagnosis of diabetes.
Power of 0.99 to detect a 0.05 increment to R-squared for the primary 
variable of interest (diagnosis of major depression).
All estimates are based on an alpha-level of 0.050, estimated overall sample size of 10,000, prevalence of diabetes of 
10%, prevalence of depression of 10%, prevalence of depression among individuals with depression of 20%, and 
incidence of depression of 20 and 10 per 1000 pt-years for patients with diabetes and non-diabetics, respectively.  All 
calculations were performed using SPSS Sample Power 2.0.
 111 
Chapter 3: Results 
CHAPTER OVERVIEW 
The purpose of this chapter is to present the results of this research. This chapter 
is organized by objective, with results related to the analysis of each hypothesis 
summarized. 
 
DATA EXTRACTION AND CASE IDENTIFICATION 
Data were extracted for 34,152 subjects who met the criteria for data extraction. 
These subjects had a total of 42,305 unique continuous eligibility periods. The 
distribution of days of service eligibility was tri-modal at 90, 180 and 365 days (Figure 
3.1). The mean, median, and mode of the number of days of continuous service eligibility 
were 368.4 days (± 295.3), 341.0 days (interquartile range: 229), and 365 days, 
respectively. Among these 42,305 unique continuous eligibility periods, 8,699 (20.6%) 
and 5,743 (13.6%) had continuous service eligibility periods of greater than or equal to 
18 and 24 months, respectively. 
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Figure 3.1 Distribution of number of days of continuous service eligibility for subjects 
meeting data extraction criteria 
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OBJECTIVE 1 
Purpose 
The purpose of Objective 1 was to evaluate diabetes diagnostic status as a risk 
factor for incident diagnosis of depression. There were two formal hypotheses tested in 
relationship to Objective 1. 
 
Cohort Description 
Among the 34,152 subjects with eligibility data, total of 2,886 subjects met the 
criteria for inclusion in the objective 1 analytic cohort. The demographic characteristics 
of these subjects are presented in Table 3.1. Overall, subjects were predominantly female 
(72.8%) and classified as White Hispanic (73.5%). In terms of marital status, 
classification as married (37.0%) and single (30.5%) were most common, with a 
substantial proportion of patients displaying missing data or a classification as unknown, 
unreported, or missing (27.1%). 
Diabetes and depression diagnostic status for the 2,886 subjects included in this 
analysis are presented in Table 3.2. Seven hundred and sixty four (26.5%) subjects 
displayed a diagnosis of diabetes during the 12-month screening period. Among these 
subjects, the mean number of diabetic complications was 0.20 ± 1.95. The mean Charlson 
score for these subjects with diabetes during the screening period was 1.36 ± 0.66. Of the 
764 subjects with a diagnosis of diabetes, 206 subjects had HbA1c laboratory test data 
available. The mean HbA1c value for these subjects was 7.86 ± 1.95. A total of 2,122 
subjects did not exhibit a diagnosis of diabetes during the 12-month screening period. 
The 12-month incidence of diabetes during the 12-month follow-up period was 3.8% 
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(n=81). The number of subjects who did not display a diagnosis of diabetes during either 
the 12-month screening period or the 12-month follow-up period was 2,041 (70.7%). 
 
Table 3.1 Summary of demographic characteristics for subjects with 24 months of 
continuous service eligibility 
 
 
Of the 2,886 subjects initially identified, 492 (17.0%) subjects were identified 
who had a diagnosis of depression during the screening period (Table 3.2). There were 
2,394 subjects who did not have a diagnosis of depression during the screening period. 
The 12-month incidence of depression in the overall cohort was 6.8% (n = 163). A total 
Variable  n (%)
Gender
Female 2,101 (72.8%)
Male 785 (27.2%)
Total 2,886 (100.0%)
Race/ethnicity
White (Hispanic) 2,122 (73.5%)
White (non-Hispanic) 394 (13.7%)
Black/African-American 210 (7.3%)
Other† 92 (3.2%)
Unknown‡ 68 (2.4%)
Total 2,886 (100.0%)
Marital status
Single 879 (30.5%)
Married 1,068 (37.0%)
Divorced 74 (2.6%)
Widowed 47 (1.6%)
Legally separated 36 (1.2%)
Life partner 1 (0.0%)
Unknown‡ 781 (27.1%)
Total 2,886 (100.0%)
‡ Unknown includes unknown, unreported, and missing.
† Other includes American Indian/Alaskan native, Asian, Pacific 
Islander (not Hawaiian), Native Hawaiian, and Asian.
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of 2,231 (77.3%) subjects did not have a diagnosis of depression during either the 12-
month screening period or the 12-month follow-up period. 
 
Table 3.2 Depression and diabetes status for subjects identified by study inclusion criteria 
 
 
In order to evaluate the association between diabetes diagnostic status and 
incident diagnosis of depression, individuals with a prevalent diagnosis of depression (n 
= 492) were removed from the analytic dataset for analyses for Hypotheses 1.1 and 1.2. 
This left 2,394 subjects eligible for inclusion in the analyses related to these hypotheses.  
 
Variable n (%)
Depression Status
No depression during observation period 2,231 (77.3%)
Prevalent depression† 492 (17.0%)
New-onset depression‡ 163 (5.6%)
Total 2,886 (100.0%)
Diabetes Status
No diabetes during observation period 2,041 (70.7%)
Prevalent diabetes† 764 (26.5%)
New-onset diabetes‡ 81 (2.8%)
Total 2,886 (100.0%)
‡ Number of subjects displaying a diagnosis during the follow-up period but not the 
screening period
† Number of subjects displaying a diagnosis during the screening period
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Hypothesis 1.1 
H0 1.1: There is no statistically significant association between diabetes diagnostic status 
and incident depression diagnostic status among indigent primary care patients. 
 
Logistic regression was used to evaluate the bivariate relationship between 
prevalent diabetes and incident depression. The raw incidence of depression among 
patients with a diagnosis of diabetes was 5.2 percent (n = 34) and among patients without 
a diagnosis of diabetes the incidence was 7.4 percent  (n = 129). Results of the regression 
model evaluating the bivariate association between diabetes and incident depression are 
presented in Table 3.3.  
 
Table 3.3 Bivariate logistic regression of depression diagnostic status on diabetes 
diagnostic status 
 
 
In the bivariate analysis, the presence of prevalent diabetes was not associated 
with incident depression at a statistically significant level (B = -0.38, p = 0.058, OR 0.69, 
95% CI 0.05-1.01). While the results did not achieve statistical significance, the direction 
of the association indicated a trend towards reduced odds of displaying a diagnosis of 
incident depression for individuals diagnosed with diabetes at baseline. Based on these 
results, H0 1.1 was not rejected. 
 
Variable B SE Wald p-value OR
Prevalent diabetes status -0.38 0.20 3.59 0.058 0.69 0.05 1.01
Constant -2.53 0.09 761.77 < 0.001 0.08
Dependent variable: incident depression status: 0, not present; 1, present.
Model χ2 = 3.824, df = 1, p = 0.051
n = 2394
95% CI
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Exploratory Analyses 
Post-hoc exploratory analyses were conducted to evaluate the association between 
prevalent diabetes and prevalent depression across the study period. These analyses were 
performed in order to evaluate the cross-sectional relationship between depression and 
diabetes during different timeframes. These analyses differed from the a priori analysis 
in that the relationship was evaluated in terms of prevalent cases, as opposed to incident 
cases. Three timeframes were used for identification of prevalent cases: 12-month 
screening period, 12-month follow-up period, and the overall 24-month evaluation 
period. 
The crosstabulations of depression status by diabetes status for each timeframe 
are presented in Tables 3.4, 3.5, and 3.6. The prevalence of depression among subjects 
with a diagnosis of diabetes was lower when compared to non-diabetic subjects during all 
evaluation periods. The prevalence of diabetes among subjects diagnosed with depression 
was lower when compared to subjects without depression for each time period evaluated. 
The Phi correlation coefficient between prevalent diabetes and prevalent depression was 
low, negative, and statistically significant for all timeframes evaluated (n = 2886, 
screening period: rφ = -0.040, p = 0.031; follow-up period: rφ = -0.054, p = 0.004; overall 
timeframe: rφ = -0.041, p = 0.026). 
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Table 3.4 Crosstabulation of depression status by diabetes status for 12-month screening 
period 
 
 
Table 3.5 Crosstabulation of depression status by diabetes status for 12-month follow-up 
period 
 
 
Table 3.6 Crosstabulation of depression status by diabetes status for overall 24-month 
evaluation period 
 
n Column % Row % n Column % Row %
Absent 1741 (82.0%) (72.7%) 653 (85.5%) (27.3%) 2394 (83.0%)
Present 381 (18.0%) (77.4%) 111 (14.5%) (22.6%) 492 (17.0%)
Col. Total 2122 (73.5%) 764 (26.5%) 2886 (100.0%)
χ2 = 4.662, df = 1, p = 0.031
Row Total
Diabetes Status
Absent Present
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n Column % Row % n Column % Row %
Absent 1751 (84.0%) (71.2%) 708 (88.3%) (28.8%) 2459 (85.2%)
Present 333 (16.0%) (78.0%) 94 (11.7%) (22.0%) 427 (14.8%)
Col. Total 2084 (72.2%) 802 (27.8%) 2886 (100.0%)
χ2 = 8.330, df = 1, p = 0.004
Row Total
Diabetes Status
Absent Present
D
e
p
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n
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n Column % Row % n Column % Row %
Absent 1555 (76.2%) (69.7%) 676 (80.0%) (30.3%) 2231 (77.3%)
Present 486 (23.8%) (74.2%) 169 (20.0%) (25.8%) 655 (22.7%)
Col. Total 2041 (70.7%) 845 (29.3%) 2886 (100.0%)
χ2 = 4.949 df = 1, p = 0.026
Row Total
Diabetes Status
Absent Present
D
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Hypothesis 1.2 
H0 1.2: After controlling for age, gender, race/ethnicity, marital status, and Charlson 
score there is no statistically significant association between diabetes diagnostic 
status and incident depression diagnostic status among indigent primary care 
patients. 
 
In addition to evaluation of the bivariate relationship between prevalent diabetes 
and incident depression, a multivariate analysis was conducted evaluating this 
relationship while controlling for the influence of covariates. Covariates included in the 
model were age, gender, race/ethnicity, marital status, and Charlson score. Descriptive 
statistics for covariates included in the model are presented in Table 3.7. 
Results of the multivariate logistic regression analysis are presented in Table 3.8. 
After controlling for age, gender, race/ethnicity, marital status, and Charlson score, 
prevalent diabetes was associated with a lower odds of diagnosis of incident depression 
(B = -0.54, p = 0.021, OR 0.58 95%, CI 0.37 to 0.92). These results indicate that the 
presence of a diagnosis of prevalent diabetes is associated with a reduction in the odds of 
an individual displaying an incident diagnosis of depression during the 12-month follow-
up period by 42 percent. 
Among the covariates included in this model, age (B = 0.22, p = 0.007, OR 1.02, 
95% CI 1.01 to 1.04), male gender (B = -0.51, p = 0.014, OR 0.60, 95% CI 0.40 to 0.90), 
White non-Hispanic race/ethnicity (B = 1.18, p <0.001, OR 3.24, 95% CI 2.13 to 4.94) as 
well as divorced, widowed, or other marital status (B = -0.69, p = 0.001, OR 0.50, 95% 
CI 0.33 to 0.76) were associated with incident depression diagnostic status at a 
statistically significant level. Each year  increase in  age  was associated with  a  2 percent 
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Table 3.7 Descriptive statistics for age, gender, race/ethnicity, marital status and Charlson 
score for subjects included in analyses related to Hypothesis 1.2 
 
 
Variable
Age (mean, SD) 49.12 (11.68) 41.03 (9.69)
Gender (n, %)
Female 439 (67.2%) 1,282 (73.6%)
Male 214 (32.8%) 459 (26.4%)
Total 653 (100.0%) 1,741 (100.0%)
Race/ethnicity (n, %)
White (Hispanic) 511 (78.3%) 1,308 (75.1%)
White (non-Hispanic) 54 (8.3%) 200 (11.5%)
Black/African-American 63 (9.6%) 119 (6.8%)
Other or Unknown† 25 (3.8%) 114 (6.5%)
Total 653 (100.0%) 1,741 (100.0%)
Marital status (n, %)
Single 214 (32.8%) 496 (28.5%)
Married 230 (35.2%) 702 (40.3%)
Other or unknown‡ 209 (32.0%) 543 (31.2%)
Total 653 (100.0%) 1,741 (100.0%)
Charlson score (mean, SD) 1.36 (0.68) 0.20 (0.80)
‡ Other included divorced, widowed, legally separated, and life partner. Unknown includes missing 
and unknown. 
n=653 n=1,741
Diabetes prevalent Diabetes not prevalent
† Other includes American Indian/Alaskan native, Asian, Pacific Islander (not Hawaiian), Native 
Hawaiian, and Asian. Unknown includes unknown, unreported, and missing.
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Table 3.8 Logistic regression of depression diagnostic status on diabetes diagnostic status after controlling for age, gender, 
race/ethnicity classification, marital status classification, and Charlson score 
 
Variable B SE Wald p-value OR
Prevalent diabetes status -0.54 0.23 5.39 0.021 0.58 0.37 0.92
Age 0.22 0.01 7.21 0.007 1.02 1.01 1.04
Male gender -0.51 0.21 6.02 0.014 0.60 0.40 0.90
White non-Hispanic 1.18 0.22 29.98 < 0.001 3.24 2.13 4.94
African-American 0.76 0.32 0.57 0.811 1.08 0.58 2.01
Other race/ethnicity 0.29 0.36 0.67 0.414 1.34 0.67 2.68
Married -0.32 0.20 2.61 0.106 0.72 0.49 1.07
Divorced, widowed, or other -0.69 0.21 10.53 0.001 0.50 0.33 0.76
Charlson score 0.09 0.09 0.87 0.351 1.09 0.91 1.31
Constant -2.78 0.45 37.69 < 0.001 0.06
Model χ2 = 67.256, df = 9, p < 0.001
n = 2394
95% CI
Comparison group for race/ethnicity classifications is White Hispanic; comparison group for marital status classifications 
is Single.
Dependent variable: Incident Depression Status: 0, not present; 1, present.
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increase in the odds of diagnosis of incident depression. Male gender was associated with 
a 40 percent reduced odds of incident diagnosis of depression compared to female 
gender. Relative to subjects classified as White Hispanic, subjects classified as White 
non-Hispanic had a 3.24-fold increased probability of being diagnosed with incident 
depression. Finally, marital status classification as divorced, widowed, other, or unknown 
was associated with a 50 percent decrease in the odds of being diagnosed with incident 
depression during the 12-month follow-up period. H0 1.2 is rejected based on these 
results. 
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Summary 
The results of analyses related to Objective 1 are summarized in Table 3.9. Based 
on the results of analyses as described in this section, H0 1.1 was not rejected. H0 1.2 was 
rejected based on the statistically significant association between diabetes diagnostic 
status and incident depression status in the multivariate model. The results of the 
multivariate logistic regression model indicate that a diagnosis of diabetes is associated 
with decreased likelihood of observing an incident diagnosis of depression in this cohort 
of indigent care patients.
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Table 3.9 Summary of hypothesis testing related to Objective 1 
 
Hypothesis Covariates Statistical Test Result
Variable Name Variable Type Variable Name Variable Type
H0 1.1 Dichotomous Dichotomous N/A Bivariate
logistic regression
H0 1.2 Dichotomous Age
Gender
Ethnicity
Marital Status
Comorbidity index
Independent Variable Dependent Variable
Objective 1. Evaluate diabetes as a risk factor for depression among indigent primary care patients.
Diabetes diagnostic 
status
Depression 
diagnostic status
Failed to reject
RejectedDiabetes diagnostic 
status
Dichotomous Depression 
diagnostic status
Multivariate 
logistic regression
N/A, not applicable
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OBJECTIVE 2 
Purpose 
The purpose of Objective 2 was to evaluate the association between demographic 
and clinical factors and incident depression among patients diagnosed with diabetes. 
There were seven formal hypotheses tested in relationship to Objective 2. 
 
Cohort description 
The analytic cohort for Objective 2 was based on the cohort utilized for analysis 
of hypotheses 1.1 and 1.2, with the additional restriction that all subjects display 
prevalent diabetes during the screening period. This procedure resulted in the 
identification of 653 subjects eligible for inclusion in the Objective 2 analysis. Further, 
the requirement that HbA1c values obtained during the screening period were available 
for analysis reduced the analytic cohort to 179 subjects. Among these 179 subjects there 
were 7 (3.9%) cases of new-onset depression during the 12 months of follow-up. The 
demographic and clinical characteristics of these patients are presented in Table 3.10.  
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Table 3.10 Demographic and clinical characteristics of 179 subjects with a prevalent 
diagnosis of diabetes, no diagnosis of depression during the screening period, and 
available hemoglobin A1c data 
 
 
Variable  
Age (mean, SD) 49.37 (10.00)
Gender (n, %) 
Female 121 (67.6%)
Male 58 (32.4%)
Total 179 (100.0%)
Race/ethnicity (n, %) 
White (Hispanic) 142 (79.3%)
White (non-Hispanic) 8 (4.5%)
Black/African-American 21 (11.7%)
Other† 4 (2.2%)
Unknown‡ 4 (2.2%)
Total 179 (100.0%)
Marital status (n, %) 
Single 56 (31.3%)
Married 64 (35.8%)
Divorced 6 (3.4%)
Widowed 8 (4.5%)
Legally separated 4 (2.2%)
Unknown‡ 41 (22.9%)
Total 179 (100.0%)
Charlson Score (mean, SD) 1.31 (0.06)
Hemoglobin A1c (mean, SD) 7.68 (1.89)
No. diabetic complications (mean, SD) 0.21 (0.47)
‡ Unknown includes unknown, unreported, and missing.
† Other includes American Indian/Alaskan native, Asian, Pacific 
Islander (not Hawaiian), Native Hawaiian, and Asian.
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Hypotheses 2.1 to 2.7 
H0 2.1: After controlling for the influence of covariates, there is no statistically 
significant association between age and depression diagnostic status in patients 
with a diagnosis of diabetes. 
H0 2.2: After controlling for the influence of covariates, there is no statistically 
significant association between gender and depression diagnostic status in 
patients with a diagnosis of diabetes. 
H0 2.3: After controlling for the influence of covariates, there is no statistically 
significant association between race/ethnicity and depression diagnostic status in 
patients with a diagnosis of diabetes. 
H0 2.4: After controlling for the influence of covariates, there is no statistically 
significant association between marital status and depression diagnostic status in 
patients with a diagnosis of diabetes. 
H0 2.5: After controlling for the influence of covariates, there is no statistically 
significant association between baseline HbA1c level and depression diagnostic 
status in patients with a diagnosis of diabetes. 
H0 2.6: After controlling for the influence of covariates, there is no statistically 
significant association between the diabetic complications and depression 
diagnostic status in patients with a diagnosis of diabetes. 
H0 2.7: After controlling for the influence of covariates, there is no statistically 
significant association between the Charlson score and depression diagnostic 
status in patients with a diagnosis of diabetes. 
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Hypotheses 2.1-2.7 were evaluated by means of multivariate logistic regression 
with incident depression diagnostic status as the dependent variable. Age, gender, 
ethnicity, marital status, HbA1c, number of diabetic complications present, and the 
Charlson score were simultaneously entered into the regression model. The results of the 
multivariate model are presented in Table 3.11. None of the variables included in the 
model demonstrated a statistically significant association with diagnosis of incident 
depression. Among the variables included in the model, only age (B = -0.08, p = 0.093, 
OR 0.92, 95% CI 0.84 to 1.01) and African-American race/ethnicity (B = 1.71, p = 0.086, 
OR 5.51, 95% CI 0.79 to 38.67) were associated with a p-value < 0.10. Therefore, H0 2.1 
through H0 2.7 were not rejected. 
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Table 3.11 Logistic regression of incident depression diagnostic status on age, gender, race/ethnicity classification, marital 
status classification, hemoglobin A1c, number of diabetic complications, and Charlson score in a cohort of subjects with 
prevalent diabetes 
 
Variable B SE Wald p-value OR
Age -0.08 0.05 2.82 0.093 0.92 0.84 1.01
Male gender -1.05 1.17 0.80 0.370 0.35 0.04 3.48
White non-Hispanic -18.58 12381.74 < 0 .01 0.999 0.00 NR NR
African-American 1.71 0.99 2.95 0.086 5.51 0.79 38.67
Other race/ethnicity 1.73 1.45 1.42 0.233 5.63 0.33 96.11
Married 0.35 1.05 0.11 0.739 1.42 0.18 11.17
Divorced, widowed, or other 0.31 1.15 0.07 0.785 1.37 0.14 13.13
Hemoglobin A1c -0.10 0.21 0.23 0.628 0.90 0.60 1.36
No. diabetic complications 0.33 1.04 0.10 0.752 1.39 0.18 10.72
Charlson score 0.43 0.69 0.39 0.532 1.54 0.40 6.03
Constant 0.11 3.09 0.00 0.972 1.11
Model χ2 = 9.289, df = 10, p = 0.505
n = 179
NR, not reported
95% CI
Dependent variable: Incident Depression Status: 0, not present; 1, present.
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is 
Single.
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Exploratory Analyses 
Post-hoc exploratory analyses were conducted to evaluate factors associated with 
a prevalent diagnosis of depression among subjects with a prevalent diagnosis of 
diabetes. Individuals were classified as having diabetes and/or depression if they 
demonstrated a diagnostic code for either disorder at any point over the 24-month 
timeframe. Depression diagnostic status was regressed on age, gender, ethnicity, marital 
status, and Charlson score for patients with a diagnosis of diabetes. HbA1c value was not 
incorporated in this exploratory analysis due to the impact on sample size. A total of 845 
subjects with a diagnosis of diabetes during the 24-month observation timeframe were 
identified. This regression analysis revealed a statistically significant association between 
male gender and depression diagnostic status (B = -0.63, p = 0.003, OR 0.53, 95% CI 
0.35 to 0.81), and White non-Hispanic race/ethnicity and depression diagnostic status (B 
= 1.15, p < 0.001, OR 3.16, 95% CI 1.95 to 5.13) (Table 3.12). None of the other 
variables included in the exploratory analysis achieved statistical significance. 
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Table 3.12 Logistic regression of depression diagnostic status on age, gender, race/ethnicity classification, marital status 
classification, number of diabetic complications, and Charlson score in a cohort of subjects with prevalent diabetes 
 
 
Variable B SE Wald p-value OR
Age < 0.01 0.01 0.27 0.606 1.00 0.99 1.02
Male gender -0.63 0.22 8.56 0.003 0.53 0.35 0.81
White non-Hispanic 1.15 0.25 21.71 < 0.001 3.16 1.95 5.13
African-American -0.44 0.38 1.36 0.243 0.64 0.31 1.35
Other race/ethnicity -0.22 0.51 0.18 0.673 0.81 0.30 2.19
Married -0.18 0.23 0.60 0.438 0.83 0.53 1.32
Divorced, widowed, or other 0.36 0.22 2.77 0.096 1.43 0.94 2.18
No. diabetic complications 0.21 0.24 0.75 0.386 1.23 0.77 1.96
Charlson score -0.13 0.14 0.85 0.355 0.88 0.66 1.16
Constant -0.91 0.57 2.55 0.111 0.40
Model χ2 = 44.915, df = 9, p = < 0.001
n = 845
95% CI
Dependent variable: Incident Depression Status: 0, not present; 1, present.
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
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Summary 
The results of the tests of hypotheses 2.1 through 2.7 are summarized in Table 
3.13. Age, gender, race/ethnicity, marital status, HbA1c value, number of diabetic 
complications, and comorbidity score were evaluated for their association with an 
incident diagnosis of depression among diabetic subjects. None of the factors evaluated 
were associated with incident diagnosis of depression. Based on the results of this 
analysis, H0 2.1 through H0 2.7 were not rejected. Post-hoc exploratory analysis revealed 
that female gender and White non-Hispanic race/ethnicity were associated with increased 
odds of prevalent diagnosis of depression among subjects with a diagnosis of diabetes. 
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Table 3.13 Summary of hypothesis testing related to Objective 2 
Hypothesis Statistical Test Result
Variable Name Variable Type Variable Name Variable Type
H0 2.1 Age Continuous Depression status Dichotomous Failed to Reject
H0 2.2 Gender Categorical Depression status Dichotomous Multivariate logistic regression Failed to Reject
H0 2.3 Ethnicity Categorical Depression status Dichotomous Multivariate logistic regression Failed to Reject
H0 2.4 Marital status Categorical Depression status Dichotomous Multivariate logistic regression Failed to Reject
H0 2.5 Hemoglobin A1c 
value
Continuous Depression status Dichotomous Multivariate logistic regression Failed to Reject
H0 2.6 No. diabetic 
complications
Continuous Depression status Dichotomous Multivariate logistic regression Failed to Reject
H0 2.7 Charlson score Continuous Depression status Dichotomous Failed to Reject
Independent Variable Dependent Variable
Multivariate logistic regression
Multivariate logistic regression
Objective 2. Evaluate risk factors for an incident diagnosis of depression among patients diagnosed with prevalent 
diabetes.
Covariates for H0 2.1-2.7: Age, gender, race/ethnicity classification, marital status classification, Hemoglobin A1c, number of diabetic complications, Charlson 
score.
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OBJECTIVE 3 
Purpose 
The purpose of Objective 3 is to evaluate the association between diabetes 
diagnostic status and antidepressant medication utilization patterns among subjects with a 
diagnosis of depression. There were eight formal hypotheses tested in relationship to 
Objective 3. 
 
Cohort Description 
Individuals were identified for inclusion in the analytic cohort for Objective 3 
based on continuous service eligibility and antidepressant exposure, as described in 
Chapter 2. Based on these procedures, 455 subjects were identified with an index 
antidepressant prescription claim and sufficient continuous clinic service. 
Demographic characteristics for these subjects are presented in Table 3.14. This 
cohort was primarily female (83.1%). In terms of race/ethnicity, the cohort was 
predominantly classified as White Hispanic (73.2%). The distribution of marital status 
was relatively balanced between single (36.5%), married (37.4%), and other/unknown 
(26.1%). A total of 205 subjects (45.1%) received specialized behavioral health services 
within the clinics. 
The frequency of type of antidepressant medication at index is presented in Table 
3.15. The most frequently observed index antidepressant medications were from the SSRI 
class: sertraline (49.5%), fluoxetine (13.0%), escitalopram (13.4%), and paroxetine 
(6.6%). Among the SNRI medications, the overall frequency was 5.7 percent for 
duloxetine and 3.3 percent for venlafaxine. The atypical antidepressants bupropion and 
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mirtazapine were observed for 5.3 percent and 1.1 percent of index antidepressant claims, 
respectively. 
Table 3.14 Demographic characteristics for subjects meeting continuous service 
eligibility criteria and having an index prescription claim for an antidepressant 
medication 
 
 
Variable n (%)
Gender
Female 378 83.1%
Male 77 16.9%
Total 455 100.0%
Race/Ethnicity
White (Hispanic) 333 73.2%
White (non-Hispanic) 75 16.5%
Black/African American 31 6.8%
Other† 6 1.3%
Unknown‡ 10 2.2%
Total 455 100.0%
Marital Status
Single 166 36.5%
Married 170 37.4%
Divorced 10 2.2%
Widowed 4 0.9%
Legally Separated 6 1.3%
Unknown‡ 99 21.8%
Total 455 100.0%
‡ Unknown includes unknown, unreported, and missing
† Other includes American Indian/Alaskan native, Asian, 
Pacific Islander (not Hawaiian), Native Hawaiian, and Asian
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Table 3.15 Antidepressant medication at index for individuals with an index event of an 
initial antidepressant prescription claim and meeting continuous clinic service eligibility 
criteria 
 
 
 
Diagnostic descriptive statistics for subjects with an index event of an initial 
antidepressant prescription claim are presented in Table 3.16. A diagnosis of depression 
was present for 60.9% (n = 277) of patients with an index prescription for an 
antidepressant medication. The other psychiatric diagnoses most frequently associated 
with an index prescription claim for an antidepressant medication were anxiety disorders 
(19.3%, n = 88) and bipolar disorder (3.5%, n = 16).  
 
Antidepressant medication n (%)
SSRI
Sertraline 225 49.5%
Fluoxetine 59 13.0%
Escitalopram 61 13.4%
Paroxetine 30 6.6%
Citalopram 10 2.2%
SNRI
Duloxetine 26 5.7%
Venlafaxine 15 3.3%
Atypical Antidepressants
Bupropion 24 5.3%
Mirtazapine 5 1.1%
Total 455 100.0%
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin 
norepinephrine reuptake inhibitor
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Table 3.16 Depression and diabetes diagnostic status for subjects with an index event of 
an initial antidepressant prescription claim and meeting continuous clinic eligibility 
criteria. 
 
 
 
The analytic cohort for the hypotheses under Objective 3 was further restricted, as 
described in Chapter 2, to patients diagnosed with depression. This left 277 subjects 
eligible for inclusion in the final analytic cohort used to test hypotheses 3.1 to 3.8. Of 
these 277 subjects, 57 (20.6%) had a diagnosis of diabetes. Descriptive statistics for these 
277 subjects with an index event of initial antidepressant prescription and a diagnostic 
status indicating the presence of depression are presented in Table. 3.17. The mean 
Charlson score was 1.39 (± 0.59) among subjects with a diagnosis of diabetes, and 0.16 
(± 0.61) among those without a diagnosis of diabetes. Table 3.18 presents the frequency 
of type of antidepressant medication by diabetes status. 
Variable n (%)
Depresson diagnostic status
Not present 178 39.1%
Present 277 60.9%
Total 455 100.0%
Diabetes diagnostic status
Not present 346 76.0%
Present 109 24.0%
Total 455 100.0%
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Table 3.17 Demographic characteristics for subjects with in index event of an initial 
antidepressant prescription claim and meeting continuous service eligibility criteria. 
 
Variable
n (%) n (%)
Gender
Female 43 75.4% 186 84.5%
Male 14 24.6% 34 15.5%
Total 57 100.0% 220 100.0%
Race/Ethnicity
White (Hispanic) 42 73.7% 156 70.9%
White (non-Hispanic) 10 17.5% 48 21.8%
Black/African American 4 7.0% 9 4.1%
Other† 1 1.8% 2 0.9%
Unknown‡ 0 0.0% 5 2.3%
Total 57 100.0% 220 100.0%
Marital Status
Single 20 35.1% 81 36.8%
Married 14 24.6% 82 37.3%
Divorced 4 7.0% 2 0.9%
Widowed 0 0.0% 1 0.5%
Legally Separated 2 3.5% 1 0.5%
Unknown‡ 17 29.8% 53 24.1%
Total 57 100.0% 220 100.0%
Behavioral health services status
Not present 15 26.3% 88 40.0%
Present 42 73.7% 132 60.0%
Total 57 100.0% 220 100.0%
‡ Unknown includes unknown, unreported, and missing
Diabetes present Diabetes not present
† Other includes American Indian/Alaskan native, Asian, Pacific Islander (not Hawaiian), Native 
Hawaiian, and Asian
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Table 3.18 Antidepressant medication at time of index for subjects with an index event of 
initial antidepressant prescription claim and meeting continuous clinic service eligibility 
criteria 
 
Variable
n (%) n (%)
SSRI
Sertraline 32 56.1% 113 51.4%
Fluoxetine 14 24.6% 26 11.8%
Escitalopram 4 7.0% 28 12.7%
Paroxetine 0 0.0% 12 5.5%
Citalopram 2 3.5% 5 2.3%
SNRI
Duloxetine 4 7.0% 8 3.6%
Venlafaxine 1 1.8% 9 4.1%
Atypical Antidepressants
Bupropion 0 0.0% 17 7.7%
Mirtazapine 0 0.0% 2 0.9%
Total 57 100.0% 220 100.0%
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor
Diabetes Not PresentDiabetes
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Hypothesis 3.1 
H0 3.1: There is no statistically significant relationship between diabetes diagnostic status 
and type of initial antidepressant (i.e., SSRI, non-SSRI) prescribed for patients 
with depression. 
 
Testing of Hypothesis 3.1 was conducted via logistic regression with initial class 
of antidepressant medication as the dependent variable. The primary independent variable 
of interest in this analysis is diabetes diagnostic status, with covariate control for relevant 
variables as discussed in Chapter 2. The results of the logistic regression are summarized 
in Table 3.19. 
SSRI medications were prescribed for 83.6 percent (n = 184) of patients without a 
diagnosis of diabetes, compared to 91.2 percent (n = 52) of subjects with a diagnosis of 
diabetes. After controlling for the influence of the included covariates, diabetes 
diagnostic status was associated with the initial class of antidepressant medication 
prescribed at a statistically significant level (B= -2.03, p = 0.002, OR 0.13, 95% CI 0.04 
to 0.48). Based on the coding of the dependent variable with SSRI = 0 and non-SSRI = 1, 
this analysis indicates that subjects with a diagnosis of diabetes were less likely than their 
non-diabetic counterparts to receive initial treatment with a non-SSRI medication. 
Among the included covariates, only age was found to be associated with initial 
antidepressant class (B = 0.04, p = 0.046, OR 1.04, 95% CI 1.00 - 1.08). Each year 
increase in age was associated with a 4 percent increase in the odds of receiving a non-
SSRI antidepressant as initial treatment.  Based on these results, H0 3.1 is rejected.
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Table 3.19 Logistic regression of class of initial antidepressant medication on diabetes diagnostic status, age, gender, 
race/ethnicity classification, marital status classification, Charlson score, and behavioral health service status in a cohort of 
subjects with an index event of an initial antidepressant medication claim and a diagnosis of depression 
Variable B SE Wald p-value OR
Diabetes status -2.03 0.67 9.28 0.002 0.13 0.04 0.48
Age 0.04 0.02 3.98 0.046 1.04 1.00 1.08
Male gender 0.61 0.47 1.67 0.196 1.84 0.73 4.61
White non-Hispanic 0.48 0.45 1.11 0.292 1.61 0.66 3.91
African-American -0.16 0.84 0.04 0.847 0.85 0.16 4.44
Other race/ethnicity 0.50 1.04 0.23 0.633 1.64 0.21 12.62
Married -1.13 0.63 3.24 0.072 0.32 0.09 1.11
Divorced, widowed, or other 0.78 0.42 3.48 0.062 2.18 0.96 4.94
Charlson score 0.52 0.28 3.40 0.065 1.68 0.97 2.93
Behavioral health service status 0.81 0.48 2.84 0.092 2.24 0.88 5.75
Constant -4.25 0.98 18.77 < 0.001 0.01
Dependent variable: initial antidepressant class: 0, SSRI; 1, non-SSRI.
Model χ2 = 43.881, df = 10, p < 0.001
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
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Hypothesis 3.2 
H0 3.2: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant switch status 
in patients with depression. 
 
Testing of Hypothesis 3.2 was conducted via logistic regression with 
antidepressant switch status as the dependent variable. The primary independent variable 
of interest in this analysis is diabetes diagnostic status, with covariate control for relevant 
variables as discussed in Chapter 2. The results of the logistic regression are summarized 
in Table 3.20. 
A total of 45 patients in the cohort (n = 277) exhibited a switch in their 
antidepressant regimen based on the definitions described in Chapter 2. Patients with 
diabetes displayed an antidepressant switch in 10.4 percent (n = 6) of cases, while 
patients without a diagnosis of diabetes had an antidepressant switch in 17.7 percent (n = 
39) of cases. After controlling for the influence of the covariates, there was no 
statistically significant association between diabetes status and antidepressant switch 
status (B = -0.082, p = 0.179, OR 0.44, 95% CI 0.13 - 1.45). Among the covariates, only 
reception of specialized behavioral health services was associated with antidepressant 
switch status (B = 0.96, p = 0.023, OR 2.61, 95% CI 1.14 - 5.98). Reception of 
behavioral health services was associated with a 2.61-fold increase in the odds of 
observing an antidepressant switch. Based on these results, these analyses failed to reject 
H0 3.2.
 143 
Table 3.20 Logistic regression of antidepressant switch status on diabetes diagnostic status, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service status, and initial class of antidepressant 
medication in a cohort of subjects with an index event of an initial antidepressant medication claim and a diagnosis of 
depression 
Variable B SE Wald p-value OR
Diabetes status -0.82 0.61 1.80 0.179 0.44 0.13 1.45
Age < 0.01 0.02 0.07 0.798 1.00 0.96 1.03
Male gender -0.02 0.45 0.00 0.962 0.98 0.40 2.37
White non-Hispanic 0.68 0.45 2.25 0.134 1.97 0.81 4.76
African-American 1.07 0.71 2.30 0.129 2.92 0.73 11.64
Other race/ethnicity -0.26 1.12 0.06 0.813 0.77 0.09 6.90
Married 0.65 0.47 1.92 0.165 1.91 0.77 4.75
Divorced, widowed, or other 0.41 0.43 0.91 0.341 1.51 0.65 3.51
Charlson score 0.11 0.28 0.15 0.700 1.11 0.64 1.94
Behavioral health service status 0.96 0.42 5.17 0.023 2.61 1.14 5.98
Class of index AD medication 0.32 0.45 0.50 0.480 1.38 0.57 3.33
Constant -2.67 11.16 11.16 0.001 0.07
Dependent variable: Antidepressant switch status: 0, no switch; 1, switch.
Model χ2 = 15.921, df = 11, p = 0.144
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
AD, antidepressant.
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Hypothesis 3.3 
H0 3.3: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 
discontinuation status in patients with depression. 
 
Hypothesis 3.3 was evaluated via logistic regression with antidepressant 
discontinuation status as the dependent variable. The primary independent variable of 
interest in this analysis is diabetes diagnostic status, with covariate control for relevant 
variables as discussed in Chapter 2. The results of the logistic regression are summarized 
in Table 3.21. 
A total of 197 subjects (71.1%) discontinued antidepressant treatment based on 
the definition of discontinuation as described in Chapter 2, with 71.9 percent of subjects 
with a diagnosis of diabetes (n = 41) and 70.9 percent of subjects without diabetes (n = 
156) discontinuing initial antidepressant treatment. Diabetes diagnostic status was not 
associated with antidepressant discontinuation after controlling for the influence of the 
included covariates (B = 0.28, p = 0.542, OR 1.33, 95% CI 0.53 - 3.31). Among the 
covariates, only reception of behavioral health services was associated with a statistically 
significant relationship with antidepressant discontinuation status (B = -0.78, p = 0.016, 
OR 0.46, 95% CI 0.24 - 0.86). Reception of behavioral health services was associated 
with a 54 percent reduction in the odds of observing an antidepressant discontinuation 
among the subjects evaluated. Based on these analyses, H0 3.3 was not rejected.
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Table 3.21 Logistic regression of antidepressant discontinuation status on diabetes diagnostic status, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service status, and initial class of antidepressant 
medication in a cohort of subjects with an index event of an initial antidepressant medication claim and a diagnosis of 
depression 
Variable B SE Wald p-value OR
Diabetes status 0.28 0.47 0.37 0.542 1.33 0.53 3.31
Age -0.01 0.01 0.68 0.410 0.99 0.96 1.02
Male gender 0.18 0.38 0.21 0.644 1.19 0.56 2.53
White non-Hispanic -0.70 0.37 3.62 0.057 0.50 0.24 1.02
African-American -0.74 0.62 1.42 0.233 0.48 0.14 1.61
Other race/ethnicity 0.12 0.86 0.02 0.885 1.13 0.21 6.06
Married -0.01 0.36 0.00 0.988 0.99 0.49 2.01
Divorced, widowed, or other 0.15 0.34 0.20 0.654 1.17 0.59 2.29
Charlson score -0.07 0.08 0.08 0.782 0.94 0.59 1.49
Behavioral health service status -0.78 0.33 5.84 0.016 0.46 0.24 0.86
Class of index AD medication 0.10 0.40 0.06 0.802 1.11 0.50 2.43
Constant 1.98 0.63 10.04 0.002 7.25
Dependent variable: Antidepressant discontinuation: 0, no discontinuation; 1, discontinuation.
Model χ2 = 17.855, df = 11, p = 0.085
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
AD, antidepressant.
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Hypothesis 3.4 
H0 3.4: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 6-month 
MPR. 
 
Hypothesis 3.4 was evaluated via implementation of the generalized linear model 
with 6-month medication possession ratio (MPR) as a continuous dependent variable. 
The primary independent variable of interest in this model was diabetes diagnostic status. 
The unadjusted mean 6-month MPR was 0.65 (± 0.28) for patients with a diagnosis of 
diabetes and 0.53 (± 0.30) for subjects without a diagnosis of diabetes. 
The results of the multivariate analysis are presented in Table 3.22. After 
controlling for the influence of covariates, diabetes diagnostic status was not associated 
with 6-month MPR (B = 0.101, p = 0.088). Among the covariates, age (B = 0.004, p = 
0.021) and behavioral health service status (B = 0.082, p = 0.033) were associated with 6-
month MPR at a statistically significant level. Based on these analyses, each year 
increase in age was associated with an increase in the 6-month antidepressant MPR of 
0.004 units. In addition, reception of behavioral health services was associated with a 
0.082 unit increase in the 6-month MPR. None of the other covariates were associated 
with 6-month MPR. Based on the results of this model, H0 3.4 was not rejected. 
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Table 3.22 Regression of 6-month medication possession ratio on diabetes diagnostic 
status, age, gender, race/ethnicity classification, marital status classification, Charlson 
score, behavioral health service status, and initial class of antidepressant medication in a 
cohort of subjects with an index event of an initial antidepressant medication claim and a 
diagnosis of depression 
 
Variable B SE Wald Chi-Square p-value
Intercept 0.339 0.076 20.04 <0.001
Diabetes status 0.101 0.059 2.92 0.088
Age 0.004 0.002 5.33 0.021
Male gender -0.050 0.050 0.98 0.321
White non-Hispanic 0.018 0.049 0.14 0.713
African-American -0.106 0.087 1.50 0.221
Other race/ethnicity -0.153 0.107 2.03 0.154
Married 0.028 0.045 0.40 0.528
Divorced, widowed, or other -0.070 0.044 2.52 0.113
Charlson score 0.001 0.030 < 0.01 0.986
Behavioral health service status 0.082 0.039 4.54 0.033
Class of index AD medication -0.001 0.053 < 0.01 0.991
Dependent variable: 6-month medication possession ratio
Model χ2 = 27.294, df = 11, p = 0.004
n = 277
AD, antidepressant.
Comparison group for race/ethnicity classification is White Hispanic; comparison group for 
marital status classification is Single.
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Hypothesis 3.5 
H0 3.5: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and antidepressant 12-month 
MPR. 
 
Hypothesis 3.5 was evaluated via implementation of the generalized linear model 
with antidepressant 12-month MPR as the dependent variable. The primary independent 
variable of interest in this model was diabetes diagnostic status, with age, gender, 
race/ethnicity, marital status, Charlson score, behavioral health service status, and class 
of index antidepressant medication entered as covariates. The unadjusted mean 12-month 
MPR was 0.49 (± 0.32) for patients with a diagnosis of diabetes and 0.36 (± 0.29) for 
subjects without a diagnosis of diabetes.  
The results of the multivariate analysis are presented in Table 3.23. After 
controlling for the influence of the included covariates, diabetes diagnostic status was 
associated with 12-month MPR at a statistically significant level (B = 0.130, p = 0.024). 
Among the covariates, only age was associated with 12-month MPR (B = 0.004, p = 
0.011). Each year increase in age was associated with a 0.004 unit increase in the 12-
month MPR. While behavioral health service status was not associated with 12-month 
MPR at the a priori alpha level of 0.05, there was a trend towards statistical significance 
observed for this variable (B = 0.074, p = 0.052). H0 3.5 was rejected, based on the 
results of this analysis. 
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Table 3.23 Regression of 12-month medication possession ratio on diabetes diagnostic 
status, age, gender, race/ethnicity classification, marital status classification, Charlson 
score, behavioral health service status, and initial class of antidepressant medication in a 
cohort of subjects with an index event of an initial antidepressant medication claim and a 
diagnosis of depression 
 
 
Variable B SE Wald Chi-Square p-value
Intercept 0.157 0.074 4.46 0.035
Diabetes status 0.130 0.058 5.09 0.024
Age 0.004 0.002 6.40 0.011
Male gender -0.052 0.049 1.14 0.285
White non-Hispanic 0.034 0.048 0.50 0.479
African-American -0.108 0.085 1.62 0.203
Other race/ethnicity -0.060 0.105 0.33 0.568
Married 0.021 0.044 0.23 0.628
Divorced, widowed, or other -0.050 0.043 1.33 0.250
Charlson score -0.018 0.030 0.35 0.553
Behavioral health service status 0.074 0.038 3.79 0.052
Class of index AD medication < 0.001 0.052 < 0.01 0.997
Dependent variable: 12-month medication possession ratio.
Model χ2 = 27.880, df = 11, p = 0.003
n = 277
AD, antidepressant.
Comparison group for race/ethnicity classification is White Hispanic; comparison group for 
marital status classification is Single.
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Hypothesis 3.6 
H0 3.6: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and time to antidepressant non-
persistence status. 
 
Hypothesis 3.6 evaluated time to antidepressant non-persistence using survival 
analysis methodology. As a preliminary evaluation of the bivariate association between 
diabetes diagnostic status and time to antidepressant non-persistence, Kaplan-Meier 
survival analysis was conducted. In this bivariate analysis, the median persistence time 
for patients with a diagnosis of diabetes was 90.0 days, compared to 60.0 days among 
patients without a diagnosis of diabetes. This difference was significant (log-rank p-value 
= 0.002). 
Survival analysis was then performed using the Cox proportional hazards 
regression model. In this model, diabetes diagnostic status was the independent variable 
of interest and time to antidepressant non-persistence was the dependent variable. Age, 
gender, race/ethnicity, Charlson score, behavioral health services status, and class of 
initial antidepressant medication were entered as covariates. The results of this model are 
presented in Table 3.24. The graphical survival functions are presented in Figure 3.2. 
Based on this model, diabetes diagnostic status was not associated with time to non-
persistence at a statistically significant level (B = -0.37, p = 0.094, HR 0.69, 95% CI 0.45 
- 1.06). None of the covariates included in the model were associated with time to 
antidepressant non-persistence at a statistically significant level. On the basis of these 
results, H0 3.6 was not rejected.
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Table 3.24 Cox proportional hazards regression of time to antidepressant non-persistence on diabetes diagnostic status, age, 
gender, race/ethnicity classification, marital status classification, Charlson score, behavioral health service status, and initial 
class of antidepressant medication in a cohort of subjects with an index event of an initial antidepressant medication claim and 
a diagnosis of depression 
Variable B SE Wald p-value HR
Diabetes status -0.37 0.22 2.81 0.094 0.69 0.45 1.06
Age -0.01 0.01 1.63 0.201 0.99 0.98 1.00
Male gender 0.09 0.18 0.24 0.626 1.09 0.77 1.55
White non-Hispanic 0.04 0.18 0.06 0.804 1.05 0.74 1.49
African-American 0.17 0.31 0.29 0.591 1.18 0.65 2.16
Other race/ethnicity 0.02 0.40 0.00 0.966 1.02 0.47 2.22
Married 0.04 0.16 0.06 0.811 1.04 0.76 1.43
Divorced, widowed, or other 0.21 0.16 1.69 0.193 1.24 0.90 1.71
Charlson score < 0.01 0.12 0.00 0.988 1.00 0.80 1.25
Behavioral health service status -0.18 0.14 1.76 0.184 0.83 0.64 1.09
Class of index AD medication 0.11 0.19 0.33 0.568 1.12 0.77 1.62
Dependent variable: time to antidepressant non-persistence.
Model χ2 = 14.547, df = 11, p = 0.204
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
AD, antidepressant.
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Figure 3.2 Survival function for Cox proportional hazards regression of time to 
antidepressant non-persistence on diabetes diagnostic status, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service 
status, and initial class of antidepressant medication in a cohort of subjects with an index 
event of an initial antidepressant medication claim and a diagnosis of depression 
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Hypothesis 3.7 
H0 3.7: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and 3-month antidepressant 
persistence status. 
 
The association between diabetes status and 3-month antidepressant persistence 
was evaluated via logistic regression with persistence status as the dependent variable and 
diabetes diagnostic status as the primary variable of interest. Covariates included in the 
model were age, gender, race/ethnicity, marital status, Charlson score, behavioral health 
service status, and initial antidepressant medication. 
The unadjusted frequency of 3-month persistence with initial antidepressant 
treatment was 73.7 percent (n = 42) for subjects with a diagnosis of diabetes, and 44.5 
percent (n = 98) for subjects without a diagnosis of diabetes. The results of the analyses 
related to Hypothesis 3.7 are presented in Table 3.25. After controlling for the influence 
of the included covariates, diabetes status was associated with a 3.83-fold increase in 
odds of antidepressant persistence at 3 months (B = 1.34, p = 0.004, OR 3.83, 95% CI 
1.55 - 9.48). None of the covariates displayed a statistically significant association with 
3-month persistence. H0 3.7 was rejected on the basis of these results.
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Table 3.25 Logistic regression of 3-month persistence status on diabetes diagnostic status, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service status, and initial class of antidepressant 
medication in a cohort of subjects with an index event of an initial antidepressant medication claim and a diagnosis of 
depression 
Variable B SE Wald p-value OR
Diabetes status 1.34 0.46 8.43 0.004 3.83 1.55 9.48
Age 0.02 0.01 1.98 0.160 1.02 0.99 1.04
Male gender -0.18 0.37 0.24 0.622 0.84 0.41 1.71
White non-Hispanic -0.07 0.36 0.04 0.851 0.93 0.46 1.89
African-American 0.37 0.66 0.31 0.576 1.44 0.40 5.22
Other race/ethnicity -0.53 0.77 0.47 0.494 0.59 0.13 2.68
Married 0.15 0.32 0.21 0.650 1.16 0.61 2.19
Divorced, widowed, or other -0.52 0.32 2.55 0.110 0.60 0.32 1.12
Charlson score -0.13 0.24 0.29 0.591 0.88 0.55 1.40
Behavioral health service status 0.27 0.28 0.94 0.333 1.31 0.76 2.27
Class of index AD medication -0.28 0.38 0.55 0.457 0.75 0.36 1.59
Constant -0.90 0.55 2.66 0.103 0.41
Dependent variable: 3-month antidepressant persistence: 0, non-persistent; 1, persistent.
Model χ2 = 25.499, df = 11, p = 0.008
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
AD, antidepressant.
 155 
Hypothesis 3.8 
H0 3.8: After controlling for appropriate covariates, there is no statistically significant 
relationship between diabetes diagnostic status and 12-month antidepressant 
persistence status. 
 
The purpose of Hypothesis 3.8 was to test the association between diabetes 
diagnostic status and 12-month antidepressant persistence (the dependent variable in this 
analysis). Covariates included in the logistic regression model were identical to those 
included in the analyses for Hypothesis 3.7. 
The frequency of 12-month persistence was 7.0 percent (n = 4) for patients with a 
diagnosis of diabetes, and 2.3 percent (n = 5) for subjects without a diagnosis of diabetes. 
Results of the analysis related to Hypothesis 3.8 are presented in Table 3.26. After 
including the influence of the covariates into the model, diabetes diagnostic status was 
not associated with 12-month antidepressant persistence at a statistically significant level 
(B = 0.52, p = 0.663, OR 1.67, 95% CI 0.17 - 16.94). None of the covariates included in 
the model displayed a statistically significant association with 12-month antidepressant 
persistence. Based on these results, H0 3.8 was not rejected. 
 
Summary 
The results of analyses related to hypotheses 3.1 through 3.8 are summarized in 
Table 3.26. Among the hypotheses related to Objective 3, hypotheses 3.1, 3.5, and 3.7 
were rejected.
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Table 3.26 Logistic regression of 12-month persistence status on diabetes diagnostic status, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service status, and initial class of antidepressant 
medication in a cohort of subjects with an index event of an initial antidepressant medication claim and a diagnosis of 
depression 
 
 
Variable B SE Wald p-value OR
Diabetes status 0.52 1.18 0.19 0.663 1.67 0.17 16.94
Age 0.02 0.04 0.33 0.568 1.02 0.95 1.09
Male gender 0.15 0.94 0.02 0.874 1.16 0.19 7.26
White non-Hispanic -0.03 0.87 0.01 0.972 0.97 0.17 5.38
African-American -18.69 10885.58 < 0.01 0.999 < 0.01 NR NR
Other race/ethnicity -17.81 13811.02 < 0.01 0.999 < 0.01 NR NR
Married -1.52 1.70 1.70 0.192 0.22 0.02 2.15
Divorced, widowed, or other -0.29 0.13 0.13 0.713 0.75 0.16 3.52
Charlson score 0.24 0.13 0.13 0.714 1.27 0.36 4.51
Behavioral health service status 1.40 1.61 1.61 0.205 4.06 0.46 35.51
Class of index AD medication -0.75 0.41 0.41 0.519 0.47 0.05 4.59
Constant -5.08 7.78 7.78 0.005 0.01
Dependent variable: 12-month antidepressant persistence: 0, non-persistent; 1, persistent.
Model χ2 = 10.510, df = 11, p = 0.485
n = 277
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is 
Single.
AD, antidepressant; NR, not reported.
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Table 3.27 Summary of hypothesis testing related to Objective 3 
Hypothesis Statistical Test Result
Variable Name Variable Type Variable Name Variable Type
Objective 3. Evaluate the association between diabetes diagnostic status and antidepressant medication utilization patterns.
H0 3.1 Diabetes status Dichotomous AD class Dichotomous Logistic regression
H0 3.2 Diabetes status Dichotomous AD switch status Dichotomous Logistic regression
H0 3.3 Diabetes status Dichotomous AD discontinuation status Dichotomous Logistic regression
H0 3.4 Diabetes status Dichotomous 6-month AD MPR Continuous Linear regression
H0 3.5 Diabetes status Dichotomous 12-month AD MPR Continuous Linear regression
H0 3.6 Diabetes status Dichotomous Time to AD non-persistence Continuous
H0 3.7 Diabetes status Dichotomous 3-month AD persistence Dichotomous Logistic regression
H0 3.8 Diabetes status Dichotomous 12-month AD persistence Dichotomous Logistic regression
Rejected
Independent Variable Dependent Variable
Rejected
Failed to reject
Failed to reject
Failed to reject
Covariates for H0 3.2 through 3.8 : covariates for H0 3.1 model + initial antidepressant class.
Cox proportional hazards survival 
analysis
Failed to reject
Rejected
Failed to reject
AD, antidepressant; DM, diabetes mellitus; MPR, medication possession ratio
Covariates for H0 3.1: age, gender, ethnicity, marital status, Charlson score, behavioral health services status.
 158 
OBJECTIVE 4 
Purpose 
The purpose of Objective 4 is to evaluate the association between class of initial 
antidepressant medication treatment and antidepressant medication-taking behaviors in 
patients with diabetes. There were seven formal hypotheses tested in relation to Objective 
4. 
 
Cohort Description 
Based on these procedures as detailed previously in Chapter 2, the analytic cohort 
for this objective included 109 subjects with a diagnosis of diabetes. Of these 109 
subjects, 57 subjects were found to have a diagnosis of depression while 52 subjects did 
not have a diagnosis of depression in the medical record. For all of the subsequent 
analyses under Objective 4, the primary independent variable of interest (initial 
antidepressant class) was coded as SSRI = 0, non-SSRI = 1. Of the 109 subjects included 
in this cohort, there were a total of 93 subjects initiated on an SSRI antidepressant 
medication and 16 subjects initiated on a non-SSRI. Among the 16 subjects initiated on a 
non-SSRI medication, 11 were initiated on a serotonin norepinephrine reuptake inhibitor 
and 5 were initiated on bupropion. Clinical and demographic characteristics for the 109 
subjects included in the analysis related to Objective 4 are presented in Table 3.28. 
Fifty-two subjects (55.9%) in the SSRI group and 5 subjects (31.3%) in the non-
SSRI group had a recorded diagnosis of depression. Fourteen (15.1%) and two (2.2%) of 
the subjects in the SSRI group, and two (12.5%) and one (6.3%) of the subjects in the 
non-SSRI group had diagnoses of anxiety disorders and bipolar disorder, respectively. 
Among patients initiated on SSRI treatment, 42 (45.2%) received specialized behavioral 
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health services while 6 (37.5%) initiated on non-SSRI treatment received these clinical 
services. The mean Charlson score was 1.45 (± 0.70) among patients initiated on SSRI 
medications, and 1.31 (± 0.48) for subjects initiated on other antidepressant medications. 
The mean number of diabetic complications was low in both groups (SSRI 0.41 ± 0.63; 
non-SSRI: 0.38 ± 0.62)  
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Table 3.28 Demographic and clinical characteristics by initial antidepressant medication 
class for subjects with an index event of an initial antidepressant prescription and a 
diagnosis of diabetes 
 
Variable
n (%) n (%)
Gender
Female 71 76.3% 9 56.3%
Male 22 23.7% 7 43.8%
Total 93 100.0% 16 100.0%
Race/Ethnicity
White (Hispanic) 73 78.5% 5 31.3%
White (non-Hispanic) 9 9.7% 4 25.0%
Black/African American 8 8.6% 5 31.3%
Other† 1 1.1% 2 12.5%
Unknown‡ 2 2.2% 0 0.0%
Total 93 100.0% 16 100.0%
Marital Status
Single 30 32.3% 6 37.5%
Married 36 38.7% 4 25.0%
Divorced 3 3.2% 1 6.3%
Widowed 1 1.1% 0 0.0%
Legally Separated 3 3.2% 0 0.0%
Unknown‡ 20 21.5% 5 31.3%
Total 93 100.0% 16 100.0%
Behavioral health services status
Not present 51 54.8% 10 62.5%
Present 42 45.2% 6 37.5%
Total 93 100.0% 16 100.0%
‡ Unknown includes unknown, unreported, and missing
SSRI non-SSRI
† Other includes American Indian/Alaskan native, Asian, Pacific Islander (not Hawaiian), Native 
Hawaiian, and Asian
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Hypothesis 4.1 
H0 4.1: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and antidepressant 
switch status after controlling for appropriate covariates. 
 
The purpose of Hypothesis 4.1 is to evaluate the association between initial class 
of antidepressant medication and antidepressant switch status among patients with 
diabetes. The hypothesis was tested via logistic regression of antidepressant switch status 
on class of initial antidepressant treatment. Covariates included in the model were age, 
gender, ethnicity, Charlson score, number of diabetic complications, behavioral health 
services status, and an indicator for treatment indication other than depression (coded 
such that diagnosis of depression = 0; no diagnosis of depression observed = 1). 
The raw frequency of subjects who were classified as undergoing an 
antidepressant switch was 9.7 percent (n=9) for subjects initiated on an SSRI medication 
and 12.5 percent (n=2) for subjects initiated on a non-SSRI medication. The results of the 
multivariate logistic regression of switch status on initial class of antidepressant are 
presented in Table 3.29. After controlling for the covariates, there was no statistically 
significant relationship observed between initial antidepressant treatment and 
antidepressant switch during the follow-up period (B = -0.50, p = 0.638, OR 0.61, 95% 
CI 0.08 - 4.81). The only covariate which demonstrated a statistically significant 
association with antidepressant switch status was number of diabetic complications (B = 
1.48, p = 0.042, OR 4.40, 95% CI 1.05 - 18.40). Each unit increase in the number of 
diabetic complications was associated with a 4.40-fold increase in odds of observing an 
antidepressant switch. Based on the results of this analysis, H0 4.1 was not rejected.
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Table 3.29 Logistic regression of antidepressant switch status on class of initial antidepressant medication, age, gender, 
race/ethnicity classification, marital status classification, Charlson score, number of diabetic complications, behavioral health 
service status, and depression status in a cohort of diabetic subjects with an index event of an initial antidepressant medication 
claim 
Variable B SE Wald p-value OR
non-SSRI medication -0.50 1.05 0.22 0.638 0.61 0.08 4.81
Age 0.02 0.04 0.37 0.540 1.02 0.95 1.11
Male gender 0.55 0.74 0.55 0.458 1.73 0.41 7.30
Race/ethnicity other than White Hispanic 1.04 0.84 1.53 0.216 2.83 0.54 14.79
Married 1.48 1.08 1.89 0.169 4.40 0.53 36.27
Divorced, widowed, or other 0.90 1.01 0.80 0.370 2.47 0.34 17.76
Charlson score -1.33 0.93 2.02 0.155 0.26 0.04 1.65
No. diabetic complications 1.48 0.73 4.12 0.042 4.40 1.05 18.40
Behavioral health service status 1.26 1.25 1.01 0.316 3.51 0.30 40.90
Diagnosis other than depression 0.55 1.22 0.20 0.655 1.73 0.16 19.03
Constant -4.58 2.52 3.30 0.069 0.01
Dependent variable: Antidepressant switch status: 0, no switch; 1, switch.
Model χ2 = 10.769, df = 10, p = 0.376
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is Single.
95% CI
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Hypothesis 4.2 
H0 4.2: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and antidepressant 
discontinuation status after controlling for appropriate covariates. 
 
The purpose of Hypothesis 4.2 is to evaluate the association between initial 
antidepressant medication class and antidepressant discontinuation status observed over 
one year of follow-up. As with the analysis of Hypothesis 4.1, the primary independent 
variable of interest was initial antidepressant medication class. Covariates included in the 
logistic regression model testing this hypothesis were identical to those included in the 
analysis of Hypothesis 4.1.  
The discontinuation rate was 76.3 percent (n=71) among patients initiated on an 
SSRI and 75.0 percent (n = 12) among patients initiated on a non-SSRI medication. 
Results of the logistic regression model used to test Hypothesis 4.2 are presented in Table 
3.30. There was no association observed between initial class of antidepressant 
medication and antidepressant discontinuation (B = 0.02, p = 0.983, OR 1.02, 95% CI 
0.24 - 4.25). Among the covariates included in the model, only age was found to be 
associated with antidepressant discontinuation status (B = -0.05, p = 0.048, OR 0.95, 95% 
CI 0.90 - 1.00). Each year increase in age was associated with a 5 percent reduction in 
odds of antidepressant discontinuation. Based on the results of this analysis, H0 4.2 was 
not rejected.
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Table 3.30 Logistic regression of antidepressant discontinuation status on class of initial antidepressant medication, age, 
gender, race/ethnicity classification, marital status classification, Charlson score, number of diabetic complications, behavioral 
health service status, and depression status in a cohort of diabetic subjects with an index event of an initial antidepressant 
medication claim 
Variable B SE Wald p-value OR
non-SSRI medication 0.02 0.73 0.00 0.983 1.02 0.24 4.25
Age -0.05 0.03 3.90 0.048 0.95 0.90 1.00
Male gender 0.06 0.56 0.01 0.920 1.06 0.35 3.17
Race/ethnicity other than White Hispanic -0.16 0.57 0.08 0.782 0.85 0.28 2.61
Married 0.47 0.61 0.59 0.441 1.60 0.48 5.35
Divorced, widowed, or other 0.22 0.58 0.15 0.702 1.25 0.40 3.85
Charlson score 0.19 0.49 0.15 0.702 1.20 0.46 3.13
No. diabetic complications -0.11 0.52 0.04 0.838 0.90 0.33 2.47
Behavioral health service status -0.25 0.62 0.17 0.683 0.78 0.23 2.62
Diagnosis other than depression 0.35 0.65 0.29 0.591 1.42 0.40 5.07
Constant 3.49 1.59 4.79 0.029 32.65
Dependent variable: Antidepressant discontinuation status: 0, no discontinuation; 1, discontinuation.
Model χ2 = 7.229, df = 10, p = 0.704
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is Single.
95% CI
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Hypothesis 4.3 
H0 4.3: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 6-month 
antidepressant MPR after controlling for appropriate covariates. 
 
The purpose of Hypothesis 4.3 is to evaluate the association between initial class 
of antidepressant medication treatment and 6-month antidepressant MPR. This hypothesis 
was tested via the generalized linear model with MPR treated as a continuous outcome 
variable. The primary independent variable of interest was class of initial antidepressant 
treatment. Covariates included in this model are identical to those utilized in the logistic 
regression models testing hypotheses 4.1 and 4.2.  
The unadjusted mean 6-month MPR was 0.56 (± 0.29) for subjects initiated on an 
SSRI medication, and 0.57 (± 0.32) for those subjects initiated on a non-SSRI 
medication. The results of the regression model used to test Hypothesis 4.3 are presented 
in Table 3.31. There was no association observed between class of initial antidepressant 
treatment and 6-month MPR after controlling for the influence of covariates (B = 0.048, p 
= 0.549). None of the covariates included in the model were found to demonstrate a 
statistically significant association with 6-month MPR. Based on the results of this 
analysis, H0 4.3 was not rejected. 
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Table 3.31 Regression of 6-month medication possession ratio on class of initial 
antidepressant medication, age, gender, race/ethnicity classification, marital status 
classification, Charlson score, number of diabetic complications, behavioral health 
service status, and depression status in a cohort of diabetic subjects with an index event 
of an initial antidepressant medication claim 
 
Variable B SE Wald Chi-Square p-value
Intercept 0.620 0.149 17.23 <0.001
non-SSRI medication 0.048 0.079 0.36 0.549
Age 0.001 0.003 0.03 0.871
Male gender -0.068 0.062 1.21 0.271
Race/ethnicity other than White Hispanic -0.002 0.065 0.00 0.978
Married -0.034 0.066 0.26 0.608
Divorced, widowed, or other 0.087 0.066 1.76 0.185
Charlson score -0.058 0.052 1.26 0.261
No. diabetic complications 0.055 0.055 0.98 0.323
Behavioral health service status 0.077 0.068 1.29 0.256
Diagnosis other than depression -0.121 0.069 3.01 0.083
Dependent variable: 6-month medication possession ratio.
Model χ2 = 21.222, df = 10, p = 0.020
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
 167 
Hypothesis 4.4 
H0 4.4: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 12-month 
antidepressant MPR after controlling for appropriate covariates. 
 
Hypothesis 4.4 tested the association between class of initial antidepressant 
medication and 12-month antidepressant MPR. The methodology utilized to test this 
hypothesis was identical to that used to test Hypothesis 4.3, with the exception that the 
dependent variable in this model was 12-month MPR, as opposed to 6-month MPR in the 
previous hypothesis.  
The unadjusted mean 12-month MPR was 0.39 (± 0.30) for subjects initiated on 
an SSRI medication, and 0.42 (± 0.31) for those subjects initiated on a non-SSRI 
medication. The results of the regression model used to test Hypothesis 4.4 are presented 
in Table 3.32. There was no association demonstrated between class of initial 
antidepressant treatment and 12-month MPR, after controlling for the influence of the 
included covariates (B = 0.063, p = 0.440). Diagnosis other than depression was the only 
covariate that demonstrated a statistically significant association with 12-month MPR (B 
= -0.152, p = 0.034). The lack of an observed diagnosis of depression was associated with 
a 0.15 unit reduction in 12-month MPR. Based on these results, H0 4.4 was not rejected. 
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Table 3.32 Regression of 12-month medication possession ratio on class of initial 
antidepressant medication, age, gender, race/ethnicity classification, marital status 
classification, Charlson score, number of diabetic complications, behavioral health 
service status, and depression status in a cohort of diabetic subjects with an index event 
of an initial antidepressant medication claim 
 
 
Variable B SE Wald Chi-Square p-value
Intercept 0.328 0.154 4.53 0.033
non-SSRI medication 0.063 0.082 0.60 0.440
Age 0.004 0.003 2.74 0.098
Male gender -0.054 0.063 0.72 0.395
Race/ethnicity other than White Hispanic -0.026 0.067 0.15 0.699
Married -0.096 0.068 1.98 0.159
Divorced, widowed, or other 0.027 0.068 0.16 0.693
Charlson score -0.058 0.053 1.19 0.276
No. diabetic complications 0.050 0.057 0.77 0.380
Behavioral health service status 0.053 0.070 0.58 0.445
Diagnosis other than depression -0.152 0.072 4.51 0.034
Dependent variable: 12-month medication possession ratio.
Model χ2 = 23.417, df = 10, p = 0.009
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status 
classification is Single.
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Hypothesis 4.5 
H0 4.5: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and time to 
antidepressant non-persistence status after controlling for appropriate 
covariates. 
 
Hypothesis 4.5 evaluated the association between initial class of antidepressant 
medication prescribed and time to antidepressant non-persistence. The relationship 
between initial antidepressant class and time to non-persistence was first evaluated in a 
bivariate manner, via Kaplan-Meier analysis. The median time to non-persistence with 
antidepressant treatment was 90 days for patients initiated on an SSRI medication and 55 
days for patients initiated on a non-SSRI medication. This difference was not statistically 
significant with a log-rank p-value of 0.810. 
After the preliminary bivariate association was evaluated, Cox proportional 
hazard regression was used to determine the relationship between class of initial 
antidepressant medication prescribed and time to antidepressant non-persistence after 
controlling for covariates. Covariates included in the model were age, gender, 
race/ethnicity, Charlson score, number of diabetic complications, behavioral health 
service status, and depression diagnostic status. The results of the model used to test 
Hypothesis 4.5 are presented in Table 3.33. The graphical survival function is presented 
in Figure 3.3 After controlling for the influence of the included covariates, there was no 
association observed between initial class of antidepressant and time to antidepressant 
non-persistence (B = 0.05, p = 0.877, HR 1.05, 95% CI 0.54 - 2.05). None of the included 
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covariates demonstrated a statistically significant association with time to antidepressant 
non-persistence. H0 4.5 was not rejected based on the results of this analysis.
 171 
 
Table 3.33 Cox proportional hazards regression of time to antidepressant non-persistence on class of initial antidepressant 
medication, age, gender, race/ethnicity classification, marital status classification, Charlson score, number of diabetic 
complications, behavioral health service status, and depression status in a cohort of diabetic subjects with an index event of an 
initial antidepressant medication claim 
Variable B SE Wald p-value HR
non-SSRI medication 0.05 0.34 0.02 0.877 1.05 0.54 2.05
Age < 0.01 0.01 0.21 0.650 1.00 0.97 1.02
Male gender 0.01 0.26 0.00 0.982 1.01 0.60 1.67
Race/ethnicity other than White Hispanic -0.02 0.27 0.00 0.956 0.99 0.58 1.68
Married 0.24 0.26 0.86 0.353 1.28 0.76 2.14
Divorced, widowed, or other -0.07 0.27 0.07 0.797 0.93 0.54 1.60
Charlson score 0.16 0.22 0.54 0.461 1.18 0.76 1.81
No. diabetic complications -0.18 0.23 0.63 0.426 0.83 0.53 1.30
Behavioral health service status -0.34 0.29 1.40 0.237 0.71 0.40 1.25
Diagnosis other than depression 0.21 0.28 0.54 0.462 1.23 0.71 2.13
Dependent variable: time to antidepressant discontinuation
Model χ2 = 9.448, df = 10, p = 0.487
n = 109
95% CI
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is Single.
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Figure 3.3 Survival Function for Cox proportional hazards regression of time to 
antidepressant non-persistence on initial antidepressant class, age, gender, race/ethnicity 
classification, marital status classification, Charlson score, behavioral health service 
status, depression diagnostic status in a cohort of subjects with an index event of an initial 
antidepressant medication claim and a diagnosis of depression 
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Hypothesis 4.6 
H0 4.6: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 3-month 
antidepressant persistence status after controlling for appropriate covariates. 
 
The association between initial antidepressant medication and 3-month 
antidepressant persistence was evaluated via logistic regression. The dependent variable 
in this analysis was 3-month persistence evaluated as a dichotomous outcome variable 
with 3-month persistence coded as 1, and 3-month non-persistence coded as 0. The 
covariates included in this model are identical to the previous analyses under objective 4. 
The 3-month persistence rate was 63.4 percent (n = 59) for subjects initiated on an 
SSRI medication, and 43.8 percent (n = 7) for subjects initiated on a non-SSRI 
medication. Results of the multivariate logistic regression of 3-month persistence status 
on class of index antidepressant medication are presented in Table 3.34. After controlling 
for covariates, there was no statistically significant association between class of initial 
antidepressant medication and 3-month persistence with antidepressant treatment (B = -
0.84, p = 0.191, OR 0.43, 95% CI 0.12 - 1.52). There was no statistically significant 
relationship between any of the included covariates and 3-month antidepressant 
persistence. Based on the results of this analysis, H0 4.6 was not rejected.
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Table 3.34 Logistic regression of 3-month antidepressant persistence status on class of initial antidepressant medication, age, 
gender, race/ethnicity classification, marital status classification, Charlson score, number of diabetic complications, behavioral 
health service status, and depression status in a cohort of diabetic subjects with an index event of an initial antidepressant 
medication claim 
Variable B SE Wald p-value OR
non-SSRI medication -0.84 0.64 1.71 0.191 0.43 0.12 1.52
Age -0.01 0.02 0.17 0.684 0.99 0.95 1.03
Male gender 0.05 0.50 0.01 0.928 1.05 0.39 2.81
Race/ethnicity other than White Hispanic 0.43 0.55 0.63 0.428 1.54 0.53 4.53
Married 0.22 0.54 0.17 0.680 1.25 0.43 3.60
Divorced, widowed, or other 0.23 0.55 0.17 0.679 1.25 0.43 3.65
Charlson score -0.38 0.41 0.84 0.359 0.68 0.30 1.54
No. diabetic complications 0.15 0.45 0.12 0.732 1.17 0.48 2.81
Behavioral health service status 0.14 0.56 0.07 0.795 1.16 0.39 3.45
Diagnosis other than depression -1.02 0.56 3.31 0.069 0.36 0.12 1.08
Constant 1.65 1.27 1.70 0.192 5.23
Dependent variable: 3-month antidepressant persistence: 0, non-persistent; 1, persistent
Model χ2 = 11.786, df = 10, p = 0.300
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is Single.
95% CI
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Hypothesis 4.7 
H0 4.7: Among subjects with diabetes, there is no statistically significant relationship 
between type of initial antidepressant medication treatment and 12-month 
antidepressant persistence status after controlling for appropriate covariates. 
 
The association between initial antidepressant medication and 12-month 
persistence was evaluated via logistic regression. The dependent variable in this analysis 
was 12-month persistence evaluated as a dichotomous outcome variable. The covariates 
included in this model are identical to the previous analyses under Objective 4.  
The 12-month persistence rate was 4.3 percent (n = 4) for subjects initiating on 
SSRI treatment and 12.5 percent (n = 2) for subjects initiating on a non-SSRI 
antidepressant treatment. Results of the multivariate logistic regression of 12-month 
persistence status on class of index antidepressant medication are presented in Table 3.35. 
There was no statistically significant association between class of initial antidepressant 
medication and 12-month persistence with antidepressant treatment after controlling for 
covariates (B = 0.03, p = 0.594, OR 1.03, 95% CI 0.92 - 1.16). Among the covariates, the 
only statistically significant association observed was for number of diabetic 
complications (B = 2.62, p = 0.014, OR 13.71, 95% CI 1.71 - 109.85). Each unit increase 
in the number of observed diabetic complications was associated with a 13.71-fold 
increase in the odds of 12-month antidepressant persistence. Based on the results of this 
analysis, H0 4.7 was not rejected. 
Summary 
The results of analyses related to Objective 4 are summarized in Table 3.36. None 
of the null hypotheses tested under Objective 4 were rejected.
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Table 3.35 Logistic regression of 12-month antidepressant persistence status on class of initial antidepressant medication, age, 
gender, race/ethnicity classification, marital status classification, Charlson score, number of diabetic complications, behavioral 
health service status, and depression status in a cohort of diabetic subjects with an index event of an initial antidepressant 
medication claim 
Variable B SE Wald p-value OR
non-SSRI medication 0.03 0.06 0.28 0.594 1.03 0.92 1.16
Age -0.14 1.45 0.01 0.923 0.87 0.05 14.79
Male gender -0.40 1.27 0.10 0.753 0.67 0.06 8.04
Race/ethnicity other than White Hispanic -18.90 5827.44 <0.01 0.997 <0.01 NR NR
Married -0.45 1.09 0.17 0.683 0.64 0.08 5.46
Divorced, widowed, or other -2.14 1.43 2.24 0.134 0.12 0.01 1.93
Charlson score 0.98 1.38 0.50 0.478 2.66 0.18 40.02
No. diabetic complications 2.62 1.06 6.08 0.014 13.71 1.71 109.85
Behavioral health service status 0.91 1.40 0.42 0.516 2.48 0.16 38.49
Diagnosis other than depression 0.26 1.46 0.03 0.857 1.30 0.07 22.66
Constant -3.01 3.64 0.68 0.409 0.05
Dependent variable: 12-month antidepressant persistence: 0, non-persistent; 1, persistent
Model χ2 = 15.422, df = 10, p = 0.117
n = 109
Comparison group for race/ethnicity classification is White Hispanic; comparison group for marital status classification is Single.
95% CI
NR, not reported.
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Table 3.36 Summary of hypothesis testing related to Objective 4 
 
Hypothesis Statistical Test Result
Variable Name Variable Type Variable Name Variable Type
H0 4.1 AD class Dichotomous AD switch status Dichotomous Logistic regression
H0 4.2 AD class Dichotomous AD discontinuation status Dichotomous Logistic regression
H0 4.3 AD class Dichotomous 6-month AD MPR Continuous Linear regression
H0 4.4 AD class Dichotomous 12-month AD MPR Continuous Linear regression
H0 4.5 AD class Dichotomous Time to AD non-persistence Continuous
H0 4.6 AD class Dichotomous 3-month AD persistence status Dichotomous Logistic regression
H0 4.7 AD class Dichotomous 12-month AD persistence status Dichotomous Logistic regression Failed to reject
Failed to reject
Failed to reject
Failed to reject
Failed to reject
Failed to reject
Failed to reject
Covariates for H0 4.1 - 4.7: age, gender, ethnicity, marital status, diabetes diagnostic status, number of diabetic complications, 
Charlson score, behavioral health services status.
Objective 5. Evaluate the association between class of initial antidepressant medication treatment and antidepressant 
medication-taking behaviors in patients with type 2 diabetes and comorbid depression.
Cox proportional hazards 
survival analysis
AD, antidepresant; MPR, medication possession ratio.
Independent Variable Dependent Variable
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OBJECTIVE 5 
The purpose of Objective 5 is to evaluate the relationship between antidepressant 
adherence and glycemic control, as measured by HbA1c value. There were two formal 
hypotheses tested under Objective 5. 
 
Cohort Description 
The analytic cohort for this objective consisted of subjects with an index 
antidepressant prescription and available HbA1c lab values during the follow-up period. 
There were a total of 106 subjects who met these criteria and were included in these 
analyses. Demographic characteristics for these subjects are presented in Table 3.37. The 
mean age of subjects included in these analyses was 49.88 (±9.60) years. Mean follow-up 
HbA1c value was 7.41 (± 1.74), and the mean Charlson score was 1.16 (±0.73). Eighty-
three percent (n = 88) of subjects were treated with SSRI medications. Overall, sertraline 
was the most frequently observed antidepressant medication (50.0%), followed by 
fluoxetine (15.1%), escitalopram (11.3%), duloxetine (7.5%), bupropion (7.5%), 
paroxetine (5.7%) venlafaxine (1.9%) and citalopram (0.9%). The distribution of time in 
days between index antidepressant prescription claim and date of HbA1c observation is 
presented in Figure 3.4. 
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Table 3.37 Demographic characteristic for subjects with an HbA1c test during the follow-
up period and an index event of an initial antidepressant prescription claim 
 
Variable n (%)
Gender
Female 85 80.2%
Male 21 19.8%
Total 106 100.0%
Race/Ethnicity
White (Hispanic) 80 75.5%
White (non-Hispanic) 10 9.4%
Black/African American 12 11.3%
Other† 2 1.9%
Unknown‡ 2 1.9%
Total 106 100.0%
Marital Status
Single 37 34.9%
Married 39 36.8%
Divorced 4 3.8%
Widowed 1 0.9%
Legally Separated 2 1.9%
Unknown‡ 23 21.7%
Total 106 100.0%
‡ Unknown includes unknown, unreported, and missing
† Other includes American Indian/Alaskan native, Asian, 
Pacific Islander (not Hawaiian), Native Hawaiian, and Asian
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Figure 3.4 Distribution of time in days between index antidepressant prescription claim 
and hemoglobin A1c observation 
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Hypothesis 5.1 
H0 5.1: After controlling for appropriate covariates, there is no statistically significant 
relationship between 6-month antidepressant medication MPR and follow-up 
HbA1c. 
 
The association between 6-month antidepressant MPR and HbA1c value during 
follow-up was evaluated via the generalized linear model with HbA1c incorporated as a 
continuous outcome variable. The primary variable of interest was 6-month MPR. 
Covariates included in this analysis were age, gender, ethnicity, marital status, behavioral 
health services status, and Charlson comorbidity score. 
The mean 6-month MPR was 0.57 (± 0.29). The Pearson correlation between 6-
month MPR and HbA1c was r = 0.22 with a p-value of 0.018. Results of the statistical 
model testing Hypothesis 5.1 are presented in Table 3.38. After controlling for the 
influence of covariates, a statistically significant association was observed for 6-month 
antidepressant medication MPR and follow-up HbA1c (B = 1.69, p = 0.004). A 0.10 unit 
(10 percentage point) increase in 6-month MPR was associated with a 0.17 unit increase 
in HbA1c level. Age was the only covariate associated with post-index HbA1c (B = -
0.03, p = 0.043), indicating that each year increase in age was associated with a 0.03 unit 
reduction in HbA1c value. Hypothesis 5.1 was rejected based on these results. 
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Table 3.38 Linear regression of post-index hemoglobin A1c value on 6-month 
antidepressant medication possession ratio, age, gender, race/ethnicity classification, 
marital status classification, behavioral health services status, and Charlson score in a 
cohort of diabetic subjects with an index event of an initial antidepressant medication 
claim 
 
 
Variable B SE Wald Chi-Square p-value
Intercept 7.89 0.96 67.68 <0.001
6-month MPR 1.69 0.59 8.25 0.004
Age -0.03 0.02 4.08 0.043
Male gender -0.25 0.42 0.35 0.556
White non-Hispanic -0.66 0.57 1.35 0.245
African-American -0.01 0.53 0.00 0.989
Other race/ethnicity -0.52 0.85 0.38 0.540
Married 0.32 0.40 0.63 0.427
Divorced, widowed, or other 0.06 0.40 0.02 0.875
Behavioral health service status -0.34 0.33 1.03 0.309
Charlson score 0.37 0.22 2.71 0.100
Dependent variable: post-index HbA1c.
Model χ2 = 16.649, df = 10, p = 0.082
n = 106
Comparison group for race/ethnicity classification is White Hispanic; comparison group for 
marital status classification is Single.
MPR, medication possession ratio
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Hypothesis 5.2 
H0 5.2: After controlling for appropriate covariates, there is no statistically significant 
relationship between 12-month antidepressant medication MPR and follow-up 
HbA1c. 
 
The association between 12-month antidepressant MPR and HbA1c value during 
follow-up was evaluated. The methodology utilized to test this hypothesis was identical 
to that used for Hypothesis 5.1, with the only exception being that the primary 
independent variable of interest for Hypothesis 5.2 was 12-month antidepressant MPR. 
Covariates included in this analysis were age, gender, ethnicity, marital status, behavioral 
health services status, and Charlson comorbidity score. 
The mean 12-month antidepressant MPR was 0.39 (± 0.30). The Pearson 
correlation between 12-month MPR and HbA1c was r = 0.22 and was statistically 
significant (p = 0.026). Results of the statistical model testing Hypothesis 5.2 are 
presented in Table 3.39. After controlling for the influence of the included covariates, a 
statistically significant association was observed between 12-month antidepressant 
medication MPR and follow-up HbA1c (B = 1.61, p = 0.005). For every 0.10 unit (10 
percentage point) increase in 12-month MPR, HbA1c was increased by 0.16 in the 
regression model. Age was the only covariate with a statistically significant association 
with HbA1c (B = -0.04, p = 0.015), indicating that each year increase in age was 
associated with a 0.04 unit reduction of HbA1c. Hypothesis 5.2 was rejected based on 
these results. 
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Summary 
The results of hypothesis testing associated with Objective 5 are presented in 
Table 3.40. Both hypotheses 5.1 and 5.2 were rejected based on the results previously 
described. 
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Table 3.39 Linear regression of post-index hemoglobin A1c value on 12-month 
antidepressant medication possession ratio, age, gender, race/ethnicity classification, 
marital status classification, behavioral health service status, and Charlson score in a 
cohort of diabetic subjects with an index event of an initial antidepressant medication 
claim 
 
 
 
Variable B SE Wald Chi-Square p-value
Intercept 8.49 0.89 90.52 <0.001
12-month MPR 1.61 0.57 8.04 0.005
Age -0.04 0.02 5.86 0.015
Male gender -0.21 0.42 0.25 0.616
White non-Hispanic -0.62 0.57 1.18 0.278
African-American -0.02 0.53 0.00 0.963
Other race/ethnicity -0.15 0.84 0.03 0.856
Married 0.39 0.40 0.92 0.337
Divorced, widowed, or other 0.11 0.40 0.08 0.782
Behavioral health service status -0.27 0.33 0.70 0.403
Charlson score 0.33 0.22 2.22 0.136
Dependent variable: post-index HbA1c.
Model χ2 = 16.459, df = 10, p = 0.087
n = 106
Comparison group for race/ethnicity classification is White Hispanic; comparison group for 
marital status classification is Single.
MPR, medication possession ratio
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Table 3.40 Summary of hypothesis testing related to Objective 5 
 
 
 
 
Hypothesis Statistical Test Result
Variable Name Variable Type Variable Name Variable Type
H0 5.1 6-month AD MPR Continuous HbA1c Continuous Linear regression Rejected 
H0 5.2 12-month AD MPR Continuous HbA1c Continuous Linear regression Rejected 
Independent Variable Dependent Variable
Objective 5. Evaluate the relationship between antidepressant medication adherence and glycemic control.
Covariates for H0 5.1-5.2: age, gender, ethnicity, martial status, behavioral health service status, Charlson score.
DM, diabetes mellitus, MPR, medication possession ratio.
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Chapter 4: Discussion 
OVERVIEW 
The purpose of this chapter is to discuss the results and implications of this study. 
The study goals are briefly summarized in the following section, followed by a discussion 
of the results for each of the objectives and their related hypotheses. 
 
STUDY GOALS 
The overall goal of this study was to evaluate the relationships between diabetes 
and depression, with a specific focus on epidemiology and antidepressant medication-
taking behaviors. There were 5 primary aims of this study: 
1) To evaluate diabetes as a risk factor for incident diagnosis of depression among a 
cohort of indigent care patients; 
2) To determine the relationship between demographic and clinical factors and 
incident depression among diabetic patients; 
3) To examine the association between diabetes and antidepressant medication 
utilization patterns among patients with depression; 
4) To evaluate the association between class of initial antidepressant medication 
treatment and antidepressant medication-taking behaviors among patients with 
diabetes; and 
5) To determine the relationship between antidepressant medication adherence and 
glycemic control in patients with diabetes. 
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OBJECTIVE 1: DIABETES AS A RISK-FACTOR FOR DEPRESSION 
The purpose of Objective 1 was to evaluate the association between prevalent 
diabetes and incident diagnosis of depression among a group of indigent primary care 
patients. A total of 2,394 subjects without prevalent depression were identified. Subjects 
included in this analysis were primarily classified as female (71.8%) and White Hispanic 
(75.9%). In comparison, the total clinic population over the same timeframe (n = 34,152) 
was classified as 69.4 percent female and 67.3 percent White Hispanic. 
The prevalence of diabetes during the 12-month screening period was 26.5 
percent. The prevalence found in this study of indigent primary care patients is higher 
than the prevalence observed in the general population.
64,199,200
 The 12-month incidence 
of diabetes during the follow-up period was 3.8 percent. The incidence of diabetes in this 
population is also higher than that observed in the general population.
201
 Of note, a high 
proportion of subjects included in this study were classified as White Hispanic 
race/ethnicity, a known risk factor for diabetes.
65
 
Estimates of the point prevalence of depression vary by treatment setting, 
increasing as you move from the general population (2-4%) to the primary care setting(5-
10%), to the inpatient setting (6-14%).
202
 The prevalence of depression in the current 
study was 17.0 percent during the 12-month screening period. In comparison, the lifetime 
prevalence of depression in the general population has been estimated to be 16.2 
percent.
26
 
Over the entire 24-month observation period, the cross-sectional prevalence of 
depression among subjects with a diagnosis of diabetes was 20.0 percent. This compares 
to the overall prevalence of depression among diabetic patients estimated by Anderson et 
al. at 25.3 percent.
115
 Of note, all of the studies included in the analysis conducted by 
Anderson et al. evaluated depression by either self-report rating scale or diagnostic 
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interview. The current study utilized ICD-9 CM diagnostic codes to identify diagnosis of 
depression. 
The overall incidence of depression was 6.8 percent during the 12-month follow-
up period, which is higher than the estimated incidence of depression from the Baltimore 
Epidemiological Catchment Area study (1.6%).
203
 The 12-month incidence of depression 
was 5.2 percent for patients with a diagnosis of diabetes and 7.4 percent for patients 
without a prevalent diagnosis of diabetes. After controlling for relevant clinical and 
demographic factors, prevalent diabetes was found to have a negative association with a 
diagnosis of incident depression during 12 months of follow-up. The odds for a diagnosis 
of incident depression were 42 percent lower among subjects with a diagnosis of 
prevalent diabetes compared to those without a diagnosis of diabetes. Bivariate analysis, 
not controlling for covariate influence, displayed a trend towards a negative association 
between diabetes and incident depression (p = 0.052); however, the analysis did not result 
in a statistically significant association.  
Exploratory cross-sectional bivariate correlations were evaluated to assess the 
correlation between diabetes and depression during the screening period, the follow-up 
period, and the overall observation timeframe. The purpose of these post-hoc exploratory 
analyses was to determine whether the relationship between incident depression and 
diabetes diagnostic status was an artifact related to rapid screening and identification of 
depression among patients with diabetes during the screening period. For each of these 
timeframes evaluated, the bivariate correlation between diagnosis of diabetes and 
depression was low, negative, and statistically significant. These exploratory analyses 
confirm that the relationship between prevalent diabetes and depression diagnostic status 
was consistently inverse across all timeframes evaluated, and whether depression was 
evaluated in terms of incident or prevalent cases. 
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In the multivariate regression model, greater age, female gender, and White non-
Hispanic race/ethnicity were associated with increased odds of diagnosis of depression. 
These findings are similar to other research that has found these factors associated with 
risk for depression.
7,8
 In the multivariate model evaluating depression diagnostic status, 
male gender was associated with a 40 percent decrease in odds of diagnosis of depression 
during follow-up (i.e., female gender was associated with a 1.6-fold increase in odds of 
an incident diagnosis of depression during follow-up). White non-Hispanic race/ethnicity 
was associated with 3.24-fold increased odds of diagnosis of depression compared to 
individuals classified as White Hispanic. This latter finding is presented within the 
context of previous research suggesting under-recognition and under-treatment of 
depression among Hispanic patients.
120,204-206
 Of particular relevance, Shah and Huffman 
found that screening rates for depression among Hispanic patients with diabetes was 
extremely low despite a high prevalence of depression in this population.
120
 
It is possible that factors related to treatment that were not measured in the current 
study may have affected the outcome. In a large, multiyear study evaluating the 
relationship between prevalent diabetes and incident depression, Golden et al. found that 
diabetic patients receiving treatment for diabetes had an increased risk of incident 
depression, but not untreated diabetic patients.
123
 In addition, there was no relationship 
found between impaired fasting blood glucose status and an incident diagnosis of 
depression. Although in the study conducted by Golden et al. the estimates of risk 
attributable to prevalent diabetes did not achieve statistical significance, the point 
estimate for the odds of incident depression was < 1.0 for both untreated diabetes (OR 
0.73, 95% CI 0.41-1.30) and impaired fasting blood glucose (OR 0.80, 95% CI 0.63-
1.02). The current analyses did not incorporate diabetes treatment status as a covariate in 
the model. Research suggests that not only treatment status, but simple awareness of a 
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diagnosis of diabetes may increase the risk for depression
125
. Health beliefs, disease state 
knowledge, and insight may be important factors in terms of understanding the 
association between diabetes and depression, especially among indigent care patients. 
A number of other factors may help explain the findings of the current study. 
Perhaps most noteworthy is that the cohort of subjects included in these analyses were 
drawn from a population of indigent care patients in a primary care setting. Individuals 
included in this cohort were primarily classified as White Hispanics, with relatively 
limited representation of White non-Hispanics and African-Americans. Previous research 
conducted by Zhang et al. found no increase in the prevalence of depression among 
Hispanic men and women diagnosed with diabetes .
117
 Other research has found a higher 
prevalence of depression among Hispanics diagnosed with diabetes in a community 
sample and in a primary care setting.
118,119
 These studies assessed depression and severity 
of depression by administration of validated rating scale instruments, while the current 
study utilized diagnostic coding in the electronic patient medical record. As mentioned 
previously, diagnosis and treatment of depression among minority patients in general, 
and Hispanics in particular, have been shown to be inadequate.
120,204-206
 The use of 
diagnostic coding to identify depression, rather than direct clinical assessment may have 
resulted in an underestimate of the presence of depression in this patient population. 
It is also possible that the period of follow-up was not sufficient to capture 
incident diagnoses of depression among patients with diabetes. Research that has found 
an association between diabetes and incident depression covered a significantly longer 
time-frame (3.1 years) than the current 12-month analysis.
123
 However, other research 
using an even longer period of follow-up (4.5 years) did not find a relationship between 
diabetes and incident depression.
207
 In addition, recent research published in August, 
2010 suggests that new-onset depressive symptoms related to diabetes may not emerge 
 192 
for a prolonged period of time, over a year, after diagnosis of diabetes.
208
 The current 
timeframe was dictated by data availability. As future data becomes available from the 
data sources used for this study, it may be worthwhile to reevaluate the association 
between diabetes and incident depression using a longer follow-up period. 
Another factor that may have influenced the results of these analyses is related to 
the continuous service criterion. In order to be included in the analytic cohort for this 
analysis, individuals were required to have 24 months of continuous service eligibility. 
Since eligibility determinations are tied to presentation at the clinic for services, there 
may be a systematic bias among patients with longer periods of service eligibility 
compared to those with shorter periods. Patients who are relatively healthy require fewer 
clinic services, present to the clinic less frequently, and thus are more likely to have 
significant lapses in continuous service eligibility. Patients with chronic medical 
conditions, on the other hand, may present to the clinic more frequently for medical care 
and may be more likely to establish a sufficient period of continuous service eligibility.  
The continuous service criterion utilized for this study may have resulted in 
patients with more chronic and severe medication conditions such as asthma, 
cardiovascular disease, and other chronic medical conditions being included in the 
analytic cohort with a high frequency. Many of these chronic medical conditions have 
been associated with increased risk for mood disorders.
209,210
 While this study attempted 
to control for the influence of medical comorbidity via inclusion of the Charlson score as 
a covariate, a number of conditions with a relatively well established association with 
increased risk for depression are not captured by the Charlson score (e.g., hepatitis C 
infection). It is possible that the presence of such medical conditions associated with 
depression among non-diabetic subjects included in these analyses may have biased the 
study results. 
 193 
Summary 
The unadjusted 12-month incidence of depression among diabetes patients was 
5.2 percent for patients with a diagnosis of diabetes and 7.4 percent for patients without 
diabetes. Among this cohort of indigent care patients, after controlling for covariates, 
prevalent diabetes was associated with reduced odds of an incident diagnosis of 
depression during 12 months of follow-up. Greater age, female gender and White non-
Hispanic ethnicity were associated with increased odds of incident depression, while 
marital status classification of divorced, widowed or other was associated with reduced 
odds of incident diabetes diagnostic status. Factors related to the demographic make-up 
of the cohort, the duration of study follow-up, and the continuous service eligibility 
requirement may have influenced the observed results. 
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OBJECTIVE 2: RISK FACTORS FOR A DIAGNOSIS OF DEPRESSION AMONG PATIENTS 
WITH DIABETES 
The purpose of Objective 2 was to identify risk factors for a diagnosis of 
depression among patients with diabetes. A total of 179 subjects with diabetes were 
included in the logistic regression model. Age, gender, ethnicity, marital status, HbA1c 
level, number of diabetic complications, and Charlson score were evaluated for their 
association with incident diagnosis of diabetes. 
In the multivariate analysis, none of the factors evaluated were associated with an 
incident diagnosis of depression at a statistically significant level. Among the factors 
evaluated, only age and African-American race achieved a p-value less than 0.10 (p = 
0.093 and p = 0.083, respectively). In terms of directionality, the odds ratio for age was < 
1.0, while the odds ratio for classification as African-American was > 1.0. While neither 
of these factors were associated with an incident diagnosis of depression at a statistically 
significant level, younger age has been associated with increased prevalence of 
depression among diabetic patients.
119,211-213
 African-American race/ethnicity has 
likewise been associated with increased risk for depression among diabetic patients.
213
 
Previous research has linked obesity, smoking status, and educational level with 
increased risk of depression; however, these data were not available for inclusion in the 
current study. 
212,213
   
Of note, the sample size for this analysis was limited to 179 subjects with 
available HbA1c laboratory values during the screening period. The restriction of the 
sample size available for this analysis may have resulted in insufficient power to detect 
meaningful differences in odds of a diagnosis of incident depression. The pre-study 
power analysis assumed identification of a sample size of 1,000 subjects with diabetes for 
this analysis. The primary factors resulting in the small sample size available for these 
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analyses was the 24-month continuous service eligibility requirement and the lack of 
HbA1c data for the majority of subjects with a prevalence diagnosis of diabetes. 
The analyses related to Objective 1 found that diabetes was inversely associated 
with incident diagnosis of depression. In the analysis related to Objective 2, a relatively 
small number of cases of incident depression during the 12-month follow-up were 
observed. Among the 179 subjects included in this analysis, only 7 (3.9%) displayed an 
incident diagnosis of depression during the 12-month follow-up period. Logistic 
regression is sensitive to the number of events observed relative to the number of 
variables included in the model. A low event observed/variables ratio may result in bias 
in the regression coefficients, large variance estimates, improper coverage of the 
confidence intervals, and paradoxical associations.
214
 The low event rate likely adversely 
affected the stability and validity of the logistic model utilized for these analyses. 
Post-hoc exploratory analyses were conducted evaluating risk factors for a 
diagnosis of prevalent depression in a cross-sectional manner over the entire 24-month 
study period. Individuals were classified as having a diagnosis of diabetes and/or 
depression if they demonstrated a diagnostic code for either disorder at any point over the 
24-month timeframe. Depression diagnostic status was regressed on age, gender, 
ethnicity, marital status, and Charlson score for patients with a diagnosis of diabetes. 
HbA1c value was not incorporated in this exploratory analysis due to the impact on 
sample size. A total of 845 subjects with a diagnosis of diabetes were identified. Female 
gender and White non-Hispanic race/ethnicity classification were associated with 
increased odds of a prevalent diagnosis of depression. None of the other variables 
included in the exploratory analysis achieved statistical significance. Female gender and 
White non-Hispanic race/ethnicity were also found to be associated with increased odds 
of incident depression in the analyses related to Objective 1. These findings are 
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compatible with previous research that has found that the factors associated with 
increased risk for depression among diabetic patients are similar to the factors that 
increase risk for depression in the general population.
115
 While this post-hoc analysis was 
only exploratory, and no definitive conclusions can be reached based on these data, these 
data may assist in the development of future research questions evaluating the 
epidemiological relationship between diabetes and depression. 
 
Summary 
No statistically significant association was observed between any of the 
demographic and clinical factors evaluated and incident depression diagnostic status. The 
restricted sample size and the low frequency of observed cases of incident depression 
during follow-up likely adversely affected the stability and validity of the a priori 
analysis. The results of exploratory analyses evaluating the association between 
demographic and clinical factors associated with a prevalent diagnosis of depression 
among subjects with diabetes may be useful to inform future research in this area. In 
these exploratory analyses, female gender and classification as White non-Hispanic were 
associated with increased odds of a prevalent diagnosis of depression. 
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OBJECTIVE 3: DIABETES AND ANTIDEPRESSANT MEDICATION-TAKING BEHAVIORS 
The purpose of Objective 3 was to evaluate the association between diabetes 
diagnosis status and antidepressant medication-taking behaviors. Diagnosis of diabetes 
was found to be associated with increased odds of receiving an SSRI vs. a non-SSRI 
medication as initial antidepressant treatment. There was no association between diabetes 
diagnostic status and either antidepressant switch or discontinuation. Diagnosis of 
diabetes was associated with an increase in 12-month antidepressant medication 
adherence, but not 6-month adherence. Among the persistence outcomes evaluated, only 
3-month persistence was associated with diabetes diagnostic status. Individuals with a 
diagnosis of diabetes were 3.83-fold more likely to be classified as persistent with initial 
antidepressant treatment at 3 months.  
In this evaluation, diagnosis of diabetes was associated with increased likelihood 
of receiving an SSRI treatment as the initial medication treatment for depression. A 
number of studies have evaluated the acute phase efficacy of antidepressant treatment for 
depression in patients with diabetes.
157-162
 One of these studies evaluated the use of 
nortriptyline,
157
 and one evaluated the use of bupropion.
158
 No controlled studies have 
evaluated the use of SNRI medications such as duloxetine and venlafaxine as an acute 
phase treatment for depression in diabetic patients. While these latter medications have 
demonstrated efficacy as treatment for diabetic complications such as peripheral 
neuropathy in patients without depression, there is a lack of research data to inform their 
use targeting core psychopathology associated with depression in this patient 
population.
215,216
 
In this evaluation, the difference observed in terms of initial antidepressant 
prescribing patterns was driven by the “atypical antidepressants” bupropion and 
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mirtazapine.  Among subjects without a diagnosis of diabetes, 8.5 percent of subjects 
were initiated on either bupropion (n = 17) or mirtazapine (n = 2), while among subjects 
with diabetes, there were no individuals initiated on these medications. The rate of SNRI 
treatment among patients without diabetes (7.7%) was similar to that among patients with 
diabetes (8.8%). The observed differences in initial antidepressant prescribing patterns 
among diabetic compared to non-diabetic patients may represent a number of clinical 
considerations including: the evidence base (or lack thereof) for specific agents in this 
setting, metabolic side effect profile associated with certain agents, efficacy for treatment 
of co-occurring conditions, cost considerations, or individual patient-level clinical 
considerations. 
A total of 45 patients (16.2%) overall switched their antidepressant regimen over 
12 months of observation. This rate is slightly higher than the switch rate measured in a 
demographically similar group of patients over a 3-month period (13%).
217
 Patients with 
a diagnosis of diabetes switched antidepressant treatment in 10.4 percent of cases 
compared to 17.7 percent among patients without a diagnosis of diabetes. There was no 
statistically significant association observed between diabetes diagnostic status and 
antidepressant switch. 
Overall, 71.1 percent (n = 197) of subjects discontinued antidepressant treatment 
within 12 months of initiation. The discontinuation rate in this study was much higher 
than the 3-month discontinuation rate observed by Bull et al. at 20 percent.
217
 The higher 
discontinuation rate is likely due to the significantly longer period of follow-up in the 
current study. Among patients with diabetes, 71.9 percent discontinued antidepressant 
treatment, while 70.9 percent of subjects without a diagnosis of diabetes were observed to 
discontinue treatment. Again, there was no statistically significant association observed 
between diabetes diagnostic status and antidepressant discontinuation. 
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In the multivariate models, reception of behavioral health services was associated 
with both antidepressant switch and antidepressant discontinuation, although in different 
directions. Behavioral health services are add-on services provided to patients within the 
clinics on a referral basis. Physicians can refer patients for these services, which are 
provided by psychiatrists and clinical social workers and include interventions targeting 
specific behavioral health needs including medication management. Reception of these 
services was associated with a 2.61-fold increase in the odds of antidepressant medication 
switch. While no data were available to determine the clinical rationale for switching 
medications, this association may represent more active case and medication 
management for patients receiving these specialized services. Participation in the 
behavioral health program was also associated with a 54 percent reduction in odds of 
antidepressant discontinuation. Similar findings in other studies suggest that behavioral 
health interventions may be associated with decreased rate of discontinuation of 
antidepressant treatment.
217,218
 
Medication adherence was evaluated in terms of the medication possession ratio 
calculated with a fixed interval denominator. Medication possession ratio during both a 
6- and 12-month period after index was evaluated. After covariate control, diabetes 
diagnostic status was associated with a higher level of medication adherence at 12-
months (p = 0.024), but the relationship did not achieve statistical significance at the 6-
month evaluation (p = 0.088). Greater age was associated with increased medication 
adherence for both the 6-month and 12-month evaluations. Increased age has been 
associated with higher rates of psychotropic medication adherence in some studies, but 
not others.
219-221, 222
 Behavioral health services status was associated with higher 6-month 
medication adherence. In the model evaluating 12-month medication adherence, 
behavioral health services status did not achieve statistical significant at the p = 0.05 
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level, but a trend towards statistical significance was observed (p = 0.052). As previously 
discussed, engaging with specialty behavioral health interventions may be associated 
with increased medication adherence. This effect may be mediated by enhanced 
medication education, coping strategy education, and more frequent clinical assessment 
and interaction for patients receiving these services. 
Antidepressant medication persistence was evaluated in terms of time to 
antidepressant non-persistence as well as dichotomous persistence status at 3- and 12-
month  intervals. There was no relationship observed between diabetic diagnostic status 
and time to antidepressant non-persistence. Diagnosis of diabetes was associated with an 
increase in 3-month persistence (OR 3.83, p = 0.004), but not persistence at 12 months 
(OR 1.67, p = 0.663). 
The persistence findings may be related to differences in physician prescribing 
patterns for patients with chronic medical conditions such as diabetes. In particular, a 
greater proportion of diabetic patients received a 90-day supply of their initial 
antidepressant medication fill than did patients without a diagnosis of diabetes. A total of 
61.4 percent (n = 35) of subjects with a diagnosis of diabetes had an initial antidepressant 
prescription claim with a days supply ≥ 90 days, compared to 27.7 percent (n = 61) of 
subjects without a diagnosis of diabetes. The observation that the difference in 3-month 
persistence was not maintained at the 12-month interval suggests that the difference in 
level of persistence observed at 3 months was related to the observed differences in the 
initial days supply prescribed rather than differences in patient-level medication-taking 
behaviors.  
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Summary 
A total of 277 subjects receiving antidepressant therapy and with an associated 
diagnosis of depression were included in objective 3 analyses. Subjects with a diagnosis 
of diabetes were more likely to receive an SSRI antidepressant medication as their initial 
treatment compared to a non-SSRI medication. This observation appeared to be related to 
a lower frequency of prescribing the atypical antidepressants bupropion and mirtazapine 
among diabetic patients. There was no association observed between diabetes diagnostic 
status and either antidepressant switch or antidepressant discontinuation. Diabetes 
diagnostic status was associated with a higher level of medication adherence at 12 
months, but not at 6 months. There was no association between diabetes diagnostic status 
and time to non-persistence or 12-month antidepressant persistence. The association 
between diabetes diagnostic status and 3-month persistence appears to have been driven 
by differences in antidepressant prescribing patterns, specifically the initial days supply 
of medication prescribed. Among patients receiving medication treatment for depression, 
reception of specialized behavioral health services within the primary care setting was 
associated with higher likelihood of switching antidepressant medications, and lower 
likelihood of discontinuing antidepressant treatment. In addition, participation in 
specialized behavioral health services was associated with higher 6-month medication 
adherence, but the difference observed in 12-month medication adherence did not achieve 
statistically significant levels. Future research should evaluate the effects of specialized 
behavioral health services in the primary care setting on medication-taking behaviors for 
patients with depression. 
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OBJECTIVE 4: CLASS OF ANTIDEPRESSANT TREATMENT AND ANTIDEPRESSANT 
MEDICATION-TAKING BEHAVIORS 
The association between class of initial antidepressant treatment and subsequent 
antidepressant medication-taking behaviors among diabetic patients was evaluated. Based 
on review of the literature, this study represents the first evaluation of medication-taking 
behaviors based on initial class of antidepressant prescribed among diabetic patients with 
depression. None of the a priori hypotheses tested under this objective were rejected. 
After restricting the analytic cohort to only subjects with a diagnosis of diabetes, 109 
subjects were included in the analysis. Of these subjects, the majority (n=93) were 
initiated on SSRI medication treatment.  
The number of subjects who exhibited an antidepressant switch were similar in 
both groups (SSRI: 9.7%, n = 9; non-SSRI 12.5%, n = 2). Antidepressant switch status 
was not associated with initial class of antidepressant medication at a statistically 
significant level. In the multivariate model, number of diabetic complications was 
associated with a 4.40-fold increase in odds of antidepressant switch. The mean number 
of diabetic complications was higher among patients who switched antidepressant 
medications compared to those who did not switch (switch: 0.73 ± 0.90; no switch: 0.37 
± 0.58).  
It is possible that antidepressant medications may be used in this patient 
population to directly treat diabetic complications, specifically diabetic peripheral 
neuropathy. If an individual with neuropathy was initiated on an antidepressant 
medication that is not effective for treatment of neuropathy, they may be more likely to 
switch treatment to another antidepressant medication with an indication for this 
comorbidity. Among the cohort of 109 subjects included in this analysis, a diagnosis 
indicative of diabetic peripheral neuropathy was observed in 8.3 percent (n=9) of subjects 
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overall. The frequency of diabetic neuropathy was 27.3 percent (n = 3) among subjects 
who switched treatment, and 6.1 percent (n = 6) among subjects who did not switch 
treatment. 
Among the 3 subjects with diagnostic coding indicative of neuropathy and who 
subsequently switched treatment, two were initiated on escitalopram and one on 
duloxetine. One of the subjects initiated on escitalopram switched treatment to 
duloxetine, the other to fluoxetine. The subject initiated on duloxetine switched treatment 
to bupropion. While data suggest variable levels of efficacy for a variety of 
antidepressant medications in the treatment of neuropathy, duloxetine has an FDA 
approval for this indication.
223
 
The 12-month discontinuation rate was 76.3 percent (n = 71) among subjects 
initiated on SSRI treatment and 75.0 percent (n = 12) among subjects initiated on SNRI 
treatment. After covariate control, there was no statistically significant relationship 
between initial class of antidepressant treatment and antidepressant discontinuation. 
Among the included covariates, only younger age was associated with antidepressant 
discontinuation at a statistically significant level. 
Initial class of antidepressant treatment was not associated with either 6- or 12-
month medication adherence as measured by interval-based MPR. The unadjusted 6-
month MPR was 0.56 ± 0.29 for subjects initiated on an SSRI and 0.57 ± 0.32 for 
subjects initiated on a non-SSRI antidepressant medications. The 12-month MPR was 
0.39 ± 0.30 for subjects initiated on an SSRI and 0.42 ± 0.31 for those initiated on a non-
SSRI. Among the covariates, only diagnosis other than depression was associated with 
12-month MPR; no covariates were associated with 6-month MPR. Diagnosis other than 
depression was associated with a statistically significant decrease in 12-month MPR. 
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Among diabetic patients initiated on antidepressant treatment, the lack of a diagnosis of 
depression present is associated with a 0.15 reduction in antidepressant MPR. 
Persistence with antidepressant medication was evaluated as both a continuous 
measure of time to non-persistence and dichotomous 3- and 12-month persistence 
measures. There was no statistically significant relationship observed between initial 
class of antidepressant medication or any of the included covariates and time to anti-
depressant non-persistence. Among diabetic patients, the 3-month persistence level was 
63.4 percent for subjects initiated on SSRI treatment and 43.8 percent for subjects who 
were initiated on a non-SSRI treatment. There was no statistically significant relationship 
observed between class of initial antidepressant medication or any of the included 
covariates on 3-month persistence status. The 12-month persistence rate was 4.3 percent 
for subjects started on SSRI treatment and 12.5 percent for subjects started on a non-
SSRI medication. After controlling for the included covariates, class of initial 
antidepressant was not associated with 12-month persistence. Among the covariates, 
number of diabetic complications was associated with increased likelihood of persistence 
with antidepressant treatment at 12-months, but not at 3-months.  
The statistical power of these analyses may have been insufficient to detect 
significant differences in the outcomes evaluated. In order to assess the power of these 
analyses, post-hoc power analysis was conducted using SPSS Sample Power 2.0. For the 
linear regression of 12-month MPR on antidepressant class at initiation and the included 
covariates, power was estimated based on an observed increment of 0.189 to R-square for 
the inclusion of the 9 covariates as a single set in the model, and an increment to R-
square of 0.01 for the primary dependent variable of interest (initial class of 
antidepressant medication). Based on a sample size of 110, this analysis reveals a power 
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of 0.20 to detect the increment to R-square observed by inclusion of initial class of 
antidepressant medication prescribed into the model.  
Likewise, a post-hoc power analysis was conducted using the observed data from 
the logistic regression of 3-month antidepressant persistence status on initial class on 
antidepressant medication treatment. Using a model with only initial class of 
antidepressant medication included as an independent variable (i.e. inclusion of no 
covariates in the model), and the observed frequencies of 3-month persistence, a sample 
size of 110 with a 2-tailed alpha level of 0.05 yields a power of 0.29.  
 
Summary 
In summary, the analyses employed for this study failed to reject all of the null 
hypotheses related to Objective 4. Post-hoc power estimates confirm that the small 
sample size resulted in insufficient power to reject the null hypothesis based on the 
observed differences for both the linear regression model evaluating 12-month MPR and 
the logistic regression model evaluating 3-month persistence. Among the covariates 
included in the analyses for Objective 4, number of diabetic complications was associated 
with increased odds of antidepressant switch, and increased odds of 12-month 
antidepressant persistence. Future research should focus on evaluating the relationship 
between diabetic complications and antidepressant medication-taking behaviors among 
patients with a diagnosis of diabetes.  
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OBJECTIVE 5: ANTIDEPRESSANT ADHERENCE AND GLYCEMIC CONTROL 
Hemoglobin A1c values were available for 106 subjects initiated on 
antidepressant medication. The overall mean hemoglobin A1c for these subjects was 7.41 
± 1.74. Higher level of antidepressant adherence was associated with increased HbA1c 
values during the follow-up period. The positive association between antidepressant MPR 
and HbA1c was consistent in analyses of both 6- and 12-month MPR, and after 
controlling for age, gender, ethnicity, marital status, behavioral health service status, and 
comorbidity score.  
A number of studies have evaluated the effect of antidepressant treatment on 
glycemic control. Results from these studies suggest that improvements in glycemic 
control are most closely related to the extent of depressive symptom response. Lustman et 
al. found that nortriptyline treatment was associated with improvements in depressive 
symptom severity; however, path analysis revealed a direct hyperglycemic effect 
attributable to treatment.
157
 According to this analysis, while nortriptyline treatment was 
associated with a hyperglycemic effect, improvement in depressive symptoms with 
treatment was associated with an indirect beneficial effect on glycemic control. While 
this study indicates that antidepressant treatment (and specifically nortriptyline treatment) 
may be associated with hyperglycemia, tricyclic antidepressants were not included in the 
medication adherence analyses of the current study.   
In a placebo-controlled acute phase depression study, fluoxetine treatment was 
not associated with a statistically significant change in HbA1c level.
160
 In this study, 
depressive symptom remission was likewise not associated with glycemic control. In a 
long-term maintenance study with sertraline, recovery from depression during acute 
phase treatment was associated with improved glycemic control; however, during the 
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maintenance phase of the study, there was no difference observed between sertraline-
treated patients and those receiving placebo in terms of glycemic control.
163
 Likewise, 
clinical response to bupropion was associated with improvements in glycemic control 
during open-label acute phase treatment, but no changes in glycemic control were 
observed during the maintenance phase of treatment.
158
 These prospective studies all 
incorporated measures of depressive symptom severity, and evaluated the association 
between improvement in symptoms of depression and glycemic control. The current 
research did not utilize clinical symptom severity measurements, and was only able to 
evaluate the relationship between increased levels of antidepressant medication exposure 
and glycemic control.  
A number of recent studies have evaluated antidepressant medication exposure 
and its association with hyperglycemia, specifically new-onset diabetes. Brown et al. 
found an increased risk for new-onset diabetes for patients taking SSRI/TCA 
combination therapy compared to TCA monotherapy.
170
 In this study, SSRI monotherapy 
was associated with lower risk of observing new-onset diabetes compared to TCA 
monotherapy. Rubin et al. found that antidepressant medication exposure was a risk 
factor for developing new-onset diabetes among a group of subjects with high risk for 
developing diabetes.
171
 Intermittent antidepressant exposure was not associated with a 
statistically significant increase in odds of diabetes diagnosis, while continuous 
antidepressant use was associated with a significant increase in risk. Research conducted 
by Andersohn et al. likewise suggests that the extent of antidepressant exposure is a key 
factor in risk of diabetes associated with antidepressant exposure.
172
 
The findings of the current study suggest that increased level of antidepressant 
exposure may be associated with impaired glycemic control. A number of factors may 
explain the association between antidepressant medication exposure and hyperglycemia 
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among diabetic patients. First, higher levels of antidepressant exposure may be a marker 
for increased severity of depressive symptomatology. The association between depressive 
symptomatology and hyperglycemia in diabetic patients has been established in a number 
of studies.
55
 The relationship between depressive symptoms and hyperglycemia has been 
attributed to physiological factors, psychosocial factors, and self-care behaviors.
126
 
Second, antidepressant medication use may be associated with metabolic side 
effects that alter glycemic control in diabetic patients. Raeder et al. found that SSRI use 
was associated with obesity and hypercholesterolemia, and that this effect varied based 
on the specific medication evaluated.
174
 It is not unexpected that there would be 
variability in the relationship between antidepressant use and metabolic side effects based 
on the specific pharmacological properties of the various agents. Paroxetine and 
mirtazapine, for example, have been associated with weight gain in patients treated for 
depression.
31,224
 The current study did not evaluate the relationship between 
antidepressant exposure and hyperglycemia based on the individual agent used. SSRI 
medications accounted for the vast majority (83.0%) of antidepressant treatment in this 
analysis. Sertraline was the most frequently prescribed individual antidepressant 
medication overall (50.0%). 
A significant limitation in this analysis was the lack of control for pre-index 
HbA1c levels. Inclusion of these data would have limited the sample size for this analysis 
to 24 subjects. In addition, this analysis was unable to incorporate HbA1c measures from 
a precisely defined time point during the follow-up period. Hemoglobin A1c data were 
collected during the course of usual care within the clinics, and were incorporated as 
available into this analysis. The period of time post-index during which HbA1c values 
were available was broad. The mean number of days between initial prescription claim 
for an antidepressant medication and observation of HbA1c value was 428 (± 169) days 
 209 
with a range of 122 to 1,100. This broad timeframe, although necessary to achieve a 
sufficient sample size, represents a significant threat to the internal validity of this 
analysis. 
 
Summary 
Higher level of antidepressant medication adherence was associated with 
increased HbA1c levels. A number of factors may explain the observed relationship. 
Increased levels of antidepressant medication exposure may represent a marker for 
depressive disease state severity. In addition, specific antidepressant medication may be 
associated with effects on metabolic factors that affect glycemic control. The current 
analysis is limited in that HbA1c values were observed over a broad period of time post 
initiation of antidepressant treatment.  
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LIMITATIONS 
Clinic service eligibility  
Data for subjects included in this study were obtained from the existing 
administrative and clinic records for patients receiving care within the clinic network. In 
order for a subject to be included in the various components of this study, the individual 
was required to display a period of continuous service eligibility. This requirement was 
necessitated by the nature of the study design, which followed subjects from an index 
event occurring in the past, and evaluating clinical outcomes over a predetermined period 
of time after that event. 
An indigent clinic network served as the source of data for this research. Service 
eligibility is based on income level and the Federal Poverty Index guidelines. When an 
individual is determined to be eligible for clinic services, he/she are assigned a period of 
service eligibility that may last for between 3 and 12 months. After the end of the initial 
period of eligibility, the individual must undergo a new determination of eligibility in 
order to continue receiving care within the clinic. The period of time between the lapse in 
service coverage and the renewal of coverage is variable and is associated with clinical 
follow-up. That is, once an individual’s initial period of service eligibility expires, his/her 
service eligibility is not automatically reviewed at the conclusion of the period, but rather 
is only re-evaluated once the individual presents for services after the expiration of their 
service coverage. For these reasons, there are a number of situations that may result in a 
temporary lapse of service coverage, including failure to meet eligibility requirements 
and failure to present to the clinic for services once eligibility has terminated. In order to 
construct a study cohort of subjects with continuous clinic eligibility, a gap of 90 days 
between discrete eligibility periods was allowed. 
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The continuous service eligibility requirement resulted in a significant reduction 
in the number of subjects with data available for analysis. Initially, 34,512 subjects were 
identified who had clinic data available for extraction; however, after applying the 
continuous service eligibility criteria, the number of subjects available for inclusion in the 
analytic cohort for Objective 1 was 2,886. Likewise, the number of subjects included in 
the analytic cohort for Objectives 3 through 5, which required 18 months of continuous 
service eligibility and an index antidepressant prescription claim, was only 455. Applying 
diagnostic confirmation of the presence of depression further reduced the number of 
subjects with an index antidepressant claim to 277. Further reductions in sample size 
were observed for the analyses related to Objective 5, which required HbA1c data during 
the follow-up period after an index antidepressant prescription claim. 
It is not completely clear in what way individuals with long periods of continuous 
eligibility differ systematically from individuals with short periods of continuous 
eligibility, and how the selection of individuals with longer periods of continuous service 
eligibility may have biased the study cohorts. It is possible that a longer permissible 
“service gap” between service periods would have resulted in a less significant reduction 
in the sample size available for study inclusion. The 90 day “gap period” was determined 
with the input and feedback of clinic administrators and information technology 
personnel familiar with the operational environment of the clinic. While a longer gap 
period would have increased the available sample size, it would have also allowed for 
subjects receiving care in other indigent clinic networks for a substantial portion of the 
observation period to be included in the analyses. 
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Use of Secondary Databases for Clinical Research 
The use of administrative and healthcare claims data as a resource for medical 
outcomes research in non-experimental studies is common; however, there are a number 
of considerations and limitations to the use of these data.
225,226
 Data for the current study 
were collected from a range of health information systems, including administrative, 
clinical, and pharmacy records. Administrative data, including eligibility determinations 
and clinic encounters, were utilized. In addition, clinical data such as diagnoses and 
laboratory test results were incorporated into this research. In terms of pharmacy data, 
prescription claims from community and onsite pharmacies were utilized. 
As opposed to research utilizing only prescription claims, a strength of this study 
was the ability to incorporate patient-level diagnostic and clinical data. Although the 
inclusion of these data allowed for analysis of the relationship between medication 
utilization and clinical status (e.g., HbA1c values), these analyses were limited due to 
lack of availability of HbA1c data for the vast majority of subjects. In addition, very few 
subjects with HbA1c data in the post-index period had pre-index values that could be 
incorporated in the model, as discussed previously. Therefore, inclusion of clinical data 
as an outcome measure was a “double-edged sword,” contributing its own unique 
limitations.  
 
Data Validity 
A significant limitation to the use of secondary data is the threat to validity posed 
by missing, incomplete, or inaccurate data within the information technology systems. 
Data for some subjects may be missing or incomplete due to inherent limitations of the 
database system (e.g., a limit on the number of diagnoses recorded for each clinic 
encounter), patient-specific factors related to healthcare consumption (e.g., using an “out-
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of-network” provider), or error or oversight on the part of clinic staff (e.g. erroneous 
coding or data input). In addition, variables which may affect study outcomes (e.g., 
income level, smoking status, body weight, family history) may not be available in 
administrative or clinical database systems in an extractable form. 
 
Diagnostic Data 
While the ability to incorporate diagnostic data into this research offers some 
advantages, the use of administrative claims data to establish medical diagnosis is not 
without limitation. First, due to limitations inherent in the design of the systems utilized 
for this study, a maximum of four diagnostic codes can be associated with a given clinic 
encounter. Therefore, some diagnoses may not be captured during a given encounter 
when, in fact, the diagnosis was present. Diagnoses captured in the system may also 
change over time; for example, a diagnosis may be recorded in one encounter but not 
another occurring at a later time point. In addition, diagnoses present in administrative 
records may be representative of a variety of factors influencing healthcare provider 
behavior, rather than purely clinical considerations.
227
 
The validity of database diagnostic codes is site-, provider-, and disease state-
specific.
225
 Research suggests that diagnostic codes may have variable validity for 
different psychiatric conditions. Rawson et al. found a high level of agreement between 
administrative data and individual medical charts for patients with schizophrenia, but 
lower concordance for patients for depression.
228
 Rawson speculates that their finding 
may be related to the severity and/or specificity of certain psychiatric diagnoses 
compared to others. Medical disorders, and especially psychiatric disorders, that are more 
severe and more precisely defined may be more likely to be accurately captured in 
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diagnostic codes present in administrative data. There has been no systematic evaluation 
of diagnostic data reliability and validity reported for the CommUnity care clinic setting. 
 
Prescription Claims 
In addition to the factors mentioned previously affecting all secondary healthcare 
databases, there are a number of factors unique to the evaluation of medication adherence 
based on prescription claims data. The validity of adherence and persistence measures 
based on prescription claims data are predicated on a number of assumptions. First, it is a 
fundamental assumption that the patient actually takes the medication that he/she receives 
from the pharmacy. Prescription claims are only an indication that the individual received 
the prescription medication from the pharmacy, not necessarily that the individual 
ingested the medication. In this manner, prescription claims data are only a surrogate for 
medication-taking. While the use of medication claims data to measure adherence and 
persistence is based on these fundamental assumptions, measures based on claims data 
may be less susceptible to recall bias or inaccuracy than self-report measures.
227
 Second, 
evaluation of medication adherence based on claims data assumes comprehensiveness of 
the prescription data. That is, that all prescription medication fills are captured in the 
claims database. Medication provision for individuals who receive medications from 
other sources (e.g., samples) is not captured in the prescription claims database. In the 
current study setting, patients with prescription claims were receiving medical assistance 
to assist them in paying for their prescription medication. This does not, however, 
completely remove the possibility that patients with prescription assistance were utilizing 
medications procured through sources outside the scope of study data collection. 
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Generalizability 
The population from which the study cohorts were constructed was an indigent 
primary care population. Results from the current research may not be applicable to 
patients treated in other clinical settings. Patients who were included in the current study 
were classified, by nature of their eligibility for services, as being at or below 200% of 
the Federal Poverty Index Guidelines. Patients from lower socioeconomic levels have 
higher rates of many medical conditions, including chronic medical conditions such as 
diabetes.
229-232
 The relationship between socioeconomic status and health is complex, but 
may be related to education, environmental factors, health beliefs, access to healthcare 
resources or a variety of other factors.
233-236
 
In addition, the patient population evaluated in this study was classified 
predominantly as White Hispanic and female gender. These factors may limit the 
generalizability of the study results to populations of patients representing differing 
demographic makeup. In addition, all subjects in this study were receiving care in a 
regional community clinic network located in Central Texas, which may limit the 
generalizability to other geographical regions.  
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FUTURE RESEARCH 
This study represents an evaluation of the relationships between diabetes and 
depression and antidepressant medication utilization patterns among indigent patients 
receiving community healthcare services. This area, specifically research in underserved 
populations, is an area of medical outcomes research with room for substantial growth. 
Factors associated with medical outcomes in the non-indigent patient population may not 
be generalizable to the indigent care population and their unique needs. Continued 
research in this specific population is necessary in order to help clinicians and researchers 
understand these needs, and in order to design and implement tailored interventions for 
these traditionally underserved patient populations. 
In terms of the specific area addressed by this study, future research is needed to 
explore the epidemiological relationship between diabetes and depression in this patient 
population. Future research in this area should specifically evaluate the association 
between race/ethnicity and epidemiological and clinical outcomes associated with 
diabetes and depression. While research has been conducted evaluating cultural and racial 
factors associated with a variety of psychiatric disorders and their treatment, very little 
research has been conducted specifically in these areas with patients displaying co-
occurring diabetes and depression. In light of the increased risk for both diabetes and 
depression among minority groups such as Hispanics, research that increases the 
understanding and ability of medical providers to communicate healthcare information in 
a culturally competent manner is essential. Research establishing the unique 
phenomenology of depression among minority patient populations with depression may 
assist in understanding the results of the current research, as well as previous research 
suggesting culture-specific epidemiology of depression among diabetic patients. 
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The role and outcomes associated with integrated behavioral health services in the 
primary care setting should be addressed by future research. The current study found that 
behavioral health interventions were associated with outcomes related to medication-
taking behaviors. Studies that focus on this specific relationship, and other clinical 
outcomes associated with integrated behavioral health interventions, are necessary. 
The association between antidepressant medication exposure and glycemic 
control in diabetic patients deserves further research. Research suggests that 
antidepressant exposure may increase risk for development of new-onset diabetes, and 
the current research suggests that a relationship may exist between antidepressant 
exposure and hyperglycemia in diabetic patients. An ideal research design would allow 
for the incorporation of measures of depressive symptom severity and both pre- and post-
index measures of glycemic control. The current study was limited in that post-index 
glycemic control was evaluated over an extended period of time, and pre-index HbA1c 
values were not available for a sufficient number of patients. In addition, the current 
study did not control for depressive symptom severity. A comprehensive clinical data 
resource will be required to rigorously evaluate this relationship. Alternatively, in light of 
the limitations of secondary database systems, prospectively collected data would appear 
to be the best method available to address this research topic.  
A pressing issue as relates to the current research is the need for characterizing the 
data sources utilized for this study. Specifically, there is a need to evaluate the data 
integrity, reliability, and validity of the administrative and clinical database sources 
within the clinic network. In addition, analyses evaluating the relationship between 
demographic and clinical factors associated with continuous clinic service eligibility are 
needed.  
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One significant limitation of the current study was the requirement for continuous 
clinic services eligibility within a single community healthcare “network.” As advances 
in health information technology and medical data sharing among indigent healthcare 
networks evolves, future research should account for the transient and intermittent nature 
of medical care that exists in this patient population. Studies need to be designed to take 
into account the difficulty in constructing substantial cohorts of patients with longitudinal 
data. In the future, programs that attempt to facilitate communication between disparate 
clinic networks may allow for broader determinations of continuous care across multiple 
clinic networks, and may allow for tracking individuals as they transition in and out of 
inter-network clinic care. 
To the extent that outcomes evaluations are necessary to provide “real-world” 
assessment of clinical outcomes and clinic quality improvement feedback, a sufficient 
health information infrastructure is necessary that meets the administrative needs of the 
clinic setting, as well as the requirements necessary to facilitate rigorous outcomes 
research. While the use of clinical information obtained from administrative databases is 
common in outcomes research, there is often a balance between study considerations and 
issues related to data validity and reliability. The current research study was limited by 
the lack of clinical data available for outcomes research. As our health information 
technology evolves, researchers should be involved in the design of these systems to the 
extent that their input will inform creation of information systems that not only serve the 
interests of administrative and clinical staff, but can be utilized to produce clinically 
meaningful and valid outcomes evaluations.  
In addition to establishing improvements in the area of health information 
technology and enhanced researcher interface to these systems, future research in this 
area should integrate prospective outcomes evaluations within community clinics. 
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Prospective evaluations will allow researchers to address and account for many of the 
limitations inherent to retrospective evaluations such as the current study.  
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CONCLUSION 
This study evaluated the associations between diabetes, depression, and 
antidepressant medication-taking behaviors among indigent care patients. Diabetes was 
found to be associated with decreased odds of observing an incident diagnosis of 
depression. Greater age, female gender, and White non-Hispanic ethnicity were 
independent risk factors for a diagnosis of depression among clinic patients evaluated. No 
statistically significant relationships were observed for any of the demographic or clinical 
factors and incident depression among diabetic patients in the a priori risk factor 
analyses. Exploratory analyses revealed that demographic factors including gender and 
ethnicity may be associated with increased risk of diabetic patients developing 
depression. 
Despite a significant amount of research linking diabetes with increased risk for 
depression, the current study found that a diagnosis of diabetes was associated with 
decreased probability of observing a clinical diagnosis of depression among patients 
receiving care in an indigent primacy care setting. In terms of the relevance of these 
findings to clinical practice, these findings suggest that under-recognition and under-
diagnosis of depression in the indigent care setting may be a significant problem. 
Systematic screening for common psychiatric conditions such as depression is important 
in the primary care setting, and may be especially important among patients with chronic 
medical conditions such as diabetes. 
Diabetes was associated with higher rates of initial SSRI prescribing for the 
treatment of depression, but was not associated with either switch or discontinuation of 
antidepressant treatment. Differences observed in antidepressant medication adherence 
and adherence in the current study may have been driven by differences in prescribing 
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patterns among diabetic patients compared to non-diabetic patients, specifically in terms 
of a greater days supply of medication associated with the initial antidepressant 
prescription claim for diabetic patients. Class of initial antidepressant medication did not 
appear to be associated with any of the medication-taking outcomes evaluated, although 
this may have been related to small sample size and insufficient study power. 
This study found an association between higher levels of antidepressant adherence 
and worsened glycemic control in diabetic patients. These findings suggest that an 
increased level of antidepressant exposure is not only associated with new-onset diabetes, 
but may also be associated with impaired glycemic control among patients who already 
have diabetes. These findings, however, are limited due to the period of time during 
which HbA1c data were observed and the lack of control for baseline HbA1c level, and 
will need to be replicated in future studies. 
Results of the current study suggest that a prevalent diagnosis of diabetes is 
associated with a reduced risk for a diagnosis of new-onset depression in indigent care 
patients. Further research is necessary to evaluate the effect that chronic comorbid 
medical conditions such as diabetes may have on antidepressant medication-taking 
behaviors, and relationship between antidepressant exposure and glycemic control. 
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APPENDIX A. RETROSPECTIVE STUDIES OF MEDICATION ADHERENCE IN DIABETES BASED ON PHARMACY CLAIMS DATA 
 
Author, year n Medications Adherence Persistence
Venturini, 1999 786 SU No. of days out of medication/sum of days in all intervals 83% High: 43.9% N/A
Morisky survey Medium: 41.9%
Low: 14.2%
Boccuzzi, 2001 85,888 Adherence: sum of days supply/duration of therapy 12 month adherence: N/A 12 month persistence:
MET: 76.4% MET: 60.3%
SU: 80.1 % SU: 56.2%
TZD: 83.0% TZD: 43.2%
AGI: 70.4% AGI: 31.1%
MET: 69.8% MET: 48.1%
Catalan, 2001 Young: 216 Acarbose Ever-renew: 73%, 80% N/A 79 days, 101 days
Seniors: 366 Compliant-renew: 60%, 65%
Dailey, 2002 23400 1 year follow-up: N/A 1 year follow-up:
SU: 64.64% SU: 183.1 days
MET: 65.06% MET: 183.8 days
SU + MET: 44.42% SU + MET: 111.1 days
2 year follow-up 2 year follow-up
SU: 60.54% SU: 274.3 days
MET: 63.07% MET: 296.7 days
SU + MET: 35.76% SU + MET: 121.9 days
Dezii, 2002 992 Glipizide QD: 60.5% N/A 12 month persitence:
BID: 52.0% QD: 44.4%
Persistence: number of days with continous medical BID: 35.8%
Drug Utilization Measure(s)
Categorical 
Adherence
persistence: continuous access to ≥ 1 days' supply of 
medication
Ever-renew: frequency of renewal of index prescription at 
any point during follow-up period
ODM and/or 
insulin
SU, MET, TZD, 
AGI, MEG
Compliant-renew: frequency of renewal of index 
prescription with a gap equivalent to 1/2 the days supply 
Persistence: Number of days between first fill and first 
failure to refill prescription
Adherence: sums of days' supply/number of days in follow-
up period
Persistence: Number of days with continuous medication 
therapy, with a grace period between fills equal to 0.5 
times the days supply of the preceding fill
Adherence: sum of the days supply/days in observation 
period
n, number of subjects; N/A, not applicable or not reported; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglidinide ; ODM, any oral 
diabetic medication
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APPENDIX A. RETROSPECTIVE STUDIES OF MEDICATION ADHERENCE IN DIABETES BASED ON PHARMACY CLAIMS DATA 
(CONTINUED) 
 
 
Author, year n Medications Adherence Persistence
Donnan, 2002 2849 SU or MET Sum of the days' supply/days in observation period N/A SU: 31% N/A
MET: 34%
Evans,  2002 2537 SU or MET Sum of days' supply/days in study period SU: 93.7% SU: 63% N/A
MET: 85.4% MET: 50%
Mellkian, 2002 1815 SU+MET Combination tablet: 77.0% N/A N/A
two-tablet treatment: 54.0%
Morningstar, 2002 3358 SU or MET CMA: 86% N/A N/A
CMG: 16%
CMOS: 3%
Schectman, 2002 810 Days supply/days in treament interval Overall MPR: 79.7% N/A N/A
Whites: 82.0%
Blacks: 76.5% (p=0.0002 vs. whites)
Spoelstra, 2002 411 SU, MET, 85.3% N/A N/A
Balkrishnan, 2003 775 ODM, insulin, Sum of days supply/days in treatment period N/A N/A
Kogut, 2004 1067 SU, MET N/A SU: 87.9% N/A
MET: 81.9%
CMA: sum of day's supply between the first and last 
fill/sum of days' between first and last fill
CMG: accumulated gap days/total number of days 
between the first and last fill
CMOS: accumulated oversupply days/total nubmer of days 
between first and last fill
Drug Utilization Measure(s)
Categorical 
Adherence
n, number of subjects; N/A, not applicable or not reported; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglidinide ; ODM, any oral 
diabetic medication
SU, MET, AGI, 
TZD
71-78% each year over 5 
year period
Days supply of medication/days in study period, days 
supply of medication/nubmer of days between first and 
last fill
Total number of days with medication/number of days of 
observation
Sum of the days' supply/number of days between first and 
last fill
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APPENDIX A. RETROSPECTIVE STUDIES OF MEDICATION ADHERENCE IN DIABETES BASED ON PHARMACY CLAIMS DATA 
(CONTINUED) 
 
Author, year n Medications Adherence Persistence
Lau, 2004 900 SU, MET, TZD, N/A 71.2% N/A
Pladevall, 2004 677 MET MET: 57% N/A N/A
Hertz, 2005 6090 SU, MET, MEG, Adherence: sum of days supply/observation period N/A 53.8% Early non-persistence: 10.5%
Early non-persistence: failure to fill a second prescription 12 month non-persistence: 37.0%
Persistence: length of time between first fill and and the 
Lawrence, 2006 2741 SU, MET Sum of days supply/days in evaluation period SU: 76% N/A N/A
MET: 69%
Ho, 2007 11532 SU, MET, TZD Sum of days supply/observation period N/A 79.7% N/A
Adams, 2008 1806 ODM Milligrams dispensed/amount prescribed per month At 6 months N/A N/A
Whites: 78.3%
Blacks: 72.7%
At 12 months:
Whites: 77.6%
Blacks: 71.7%
Rozenfeld, 2008 2741 SU, MET, AGI, Sum of days supply/duration of therapy Overall MPR: 81.3% Overall: 65.4% N/A
SU: 81.8% SU: 65.8%
MET: 80.7% MET: 63.9%
TZD: 82.0% TZD: 69.4%
Sum of days supply/number of days between 1st and last 
fill
Number of days with gaps in medication refill/number of 
days in observation period
n, number of subjects; N/A, not applicable or not reported; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglidinide ; ODM, any oral 
diabetic medication
Drug Utilization Measure(s)
Categorical 
Adherence
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APPENDIX B. STUDIES EVALUATING THE RELATIONSHIP BETWEEN DIABETIC MEDICATION ADHERENCE AND GLYCEMIC 
CONTROL 
 
 
Author, year n Design
Diabetic 
Medications Data Source
Adherence 
Measure Findings Covariates
Schectman, 2002 810 SU MPR Age
MET Gender
TZD Ethnicity
AGI Income/copay
No. oral agents
Insulin use
No. HbA1c levels
No. encounters
Continuity index
Guilliausseau, 2003 11896 SU NR None
MET
AGI
Krapek, 2004 301 SU Survey, clinic data Morisky survey Age 
MET Gender
AGI Ethnicity
TZD No. diabetic medications
Presence of DM complications
Duration of DM
BMI
Education level
Practice site
Type of insurance
Retrospective 
cohort
Pharmacy claims, 
clinic data
10% increase in MPR associated with 0.16% 
lower HbA1c (p< 0.0001) and a 0.13% 
greater decrease in HbA1c (p < 0.0001) over 
15 month study period.
Prospective 
cohort
HbA1c significantly lower among subjects 
reporting no missed doses of medication 
compared to those reporting missing more 
than one dose per week (7.1 vs. 8.5%, 
p<0.01).
n, number of subjects; NR, not reported; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglitinide ; DM, diabetes mellitus; MPR, 
medication possession ratio; SBP, systolic blood pressure; BMI, body mass index; ODM, oral diabetic medication regimen
Patient self-
report
Prospective 
cohort
Good adherence (Morisky score ≥ 3) 
associated with a 10% decrease in total 
HbA1c (p<0.001)
 227 
APPENDIX B. STUDIES EVALUATING THE RELATIONSHIP BETWEEN DIABETIC MEDICATION ADHERENCE AND GLYCEMIC 
CONTROL (CONTINUED) 
 
Author, year n Design
Diabetic 
Medications Data Source
Adherence 
Measure Findings Covariates
Pladevall, 2004 677 MET CMG Age
Gender
Ethnicity
BMI
No. total medications
No. outcome measures
Lawrence, 2006 2995 SU Pharmacy claims MPR None
MET
Adams, 2008 1806 NS Clinic data MPR Race
Age 
Gender
Comorbidity
SBP
Cholesterol level
BMI 
Baseline HbA1c
Baseline medications
No. of physician visits
Test strip use
Therapy intensification
Medication adherence
Rozenfeld, 2008 2741 SU Pharmacy claims MPR Age
MET Gender
TZD Baseline HbA1c
AGI Chronic disease score
MEG Medication burden
Provider demographics
ODM regimen
Retrospective 
cohort
10% increase in adherence associated with 
a 0.1% decrease in HbA1c (p = 0.0004)
n, number of subjects; NR, not reported; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; AGI, alpha-glucosidase inhibitor; MEG, meglitinide ; DM, diabetes mellitus; MPR, 
medication possession ratio; SBP, systolic blood pressure; BMI, body mass index; ODM, oral diabetic medication
Retrospective 
cohort
Pharmacy claims, 
clinic data
10% increase in nonadherence associated 
with a 0.14% increase in HbA1c (p<0.01)
Retrospective 
cohort
Negative correlation between HgA1c and 
MPR for both SU (r=-0.295, p<0.001) and 
MET (-0.285, p<0.001).
Retrospective 
cohort
10% increase in MPR associated with 
decrease in HbA1c (blacks, -0.02%; whites 
0.03%; p-values not reported) 
 228 
APPENDIX C. STUDY DATA MATRIX: DATA SOURCES AND DATA ELEMENTS 
Dataset   NHIS Eligibility Labs
file Community Class A
Demographic data
Study ID
Age x
Gender x
Ethnicity x
Marital status x
Primary care provider x
Dates of eligibility x
Visit/Encounter data
Encounter type x
Location x
Physician x
Date of service x
Diagnosis codes x
Procedure codes x
Lab data
Test x x
Lab date x x
Lab result x x
Ordering provider x x
Prescription data
RX fill date x x
Dispense date x x
Original date x x
Prescriber x x
NDC x x
Drug label x x
Quantity x x
Days supply x x
Refills allowed x x
Fill number x x
NHIS, NextGen Health Information System; NDC, National Drug Code.
Pharmacy
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APPENDIX D. STUDY VARIABLES, VARIABLE CODING, VARIABLE TYPE, AND SOURCE 
 
Variable Value(s) Type Source
Variables of interest
Diagnosis of depression 0 = diagnosis not present; 1 = diagnosis present Dichotomous NHIS
Diagnosis of diabetes 0 = diagnosis not present; 1 = diagnosis present Dichotomous NHIS
Antidepressant MPR range = 0-1 Continuous EPR
Time to AD non-persistence Continuous (days) Continuous EPR
Antidepressant class 0 = SSRI; 1 = non-SSRI Dichotomous EPR
Antidepressant switch 0 = no switch; 1 = switch Dichotomous EPR
Antidepressant discontinuation 0 = no discontinuation; 1 = discontinuation Dichotomous EPR
Glycemic control Continuous (Hemoglobin A1c %) Continuous Laboratory
Covariates
Age Continuous, possible range 18-64 Continuous NHIS
Gender 0 = female; 1 = male Dichotomous NHIS
Ethnicity 0 = White Hispanic; 1 = non-White Hispanic; 2 = African-American; 3 = Other or Unknown Categorical NHIS
Marriage status 0 = Single; 1 = Married; 2 = Other or Unknown Categorical NHIS
Behavioral health service status 0 = not receiving services; 1 = receiving  services Dichotomous NHIS
Diabetic complications Continuous (number of complications) Continuous NHIS
Charlson score Continuous, possible range 0-7 Continuous NHIS
Ethnicity† 0 = White Hispanic; 1 = other race/ethnicity Dichotomous NHIS
Diagnosis of depression† 0 = diagnosis present; 1 = diagnosis not present Dichotomous NHIS
NHIS, NextGen health information system; EPR, electronic pharmacy records; AD, antidepressant; MPR, medication possession ratio; SSRI, selective serotonin 
reuptake inhibitor.
† incorporated as a covariate for Objective 4 analyses only
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APPENDIX E. DIAGNOSES, WEIGHTS, AND ICD-9 CM DIAGNOSTIC CODES FOR DIAGNOSES USED TO CALCULATE CHARLSON 
SCORE 
 
 
Diagnosis Charlson weight ICD-9 code(s)
Myocardial infarction 1 410.xx, 412.xx
Congestive heart failure 1
Peripheral vascular disease 1 440.xx, 441.xx, 442.xx, 443.xx, 447.1x, 785.4x
Cerebrovascular disease 1
Dementia 1 290.xx, 331.0x-331.2x
Chronic pulmonary disease 1 415.0x, 416.8x-416.9x, 491.xx-494.xx, 496.xx
Rheumatological disease 1 710.xx, 714.xx
Peptic ulcer disease 1 531.xx - 534.xx
Mild liver disease 1 571.2x, 571.5x-571.6x, 571.8x-571.9x
Diabetes 1 250.0x-250.3x
Diabetes with complications 2 250.4x-250.9x
Paralysis 2 342.xx, 344.xx
Renal disease 2 585.xx-586.xx
Any malignancy, including  2
leukemia and lymphoma
Moderate to severe liver disease 3 572.2x-572.4x, 456.0x-456.2x
Metastatic solid tumor 6 196.xx-199.xx
Acquired immune deficiency 6 042.xx-044.xx
syndrome
402.01, 402.11, 402.91, 425.xx, 428.xx, 429.3x, 
404.01, 404.03, 404.11, 404.13, 404.91, 404.93
362.34, 430.xx-436.xx, 437.0x-437.1x, 437.9x, 438.xx, 
781.4x, 784.3x, 997.0x
140.xx-171.xx, 174.xx-195.xx, 200.xx-208.xx, 273.0x, 
273.3x
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APPENDIX F. DIABETIC COMPLICATIONS AND ASSOCIATED ICD-9 CM DIAGNOSTIC 
CODES 
 
Diagnosis ICD-9 code(s)
Retinopathy 
Diabetic ophthalmologic disease 250.5x
Background retinopathy 362.01
Other retinopathy 362.1x
Retinal edema 362.83
Cystiod macular degeneration 362.53
Other retinal disorders 362.81, 362.82
Proliferative retinopathy 362.02
Retinal detachment 361.xx
Blindness 369.xx
Vitreous hemorrhage 379.23
Nephropathy 
Diabetic nephropathy 250.4x
Acute glomerulonephritis 580.xx
Nephrotic syndrome 581.xx
Hypertension, nephrosis 581.81
Chronic glomerulonephritis 582.xx
Nephritis/nephropathy 583.xx
Chronic renal failure 585.xx
Renal failure NOS 586.xx
Renal insufficiency 593.9x
Neuropathy
Diabetic neuropathy 250.6x, 356.9x
Amyotrophy 358.1x
Cranial nerve palsy 951.0x, 951.1x, 951.3x
Mononeuropathy 354.xx, 355.xx
Charcot’s arthropathy 713.5x
Polyneuropathy 357.2x
Neurogenic bladder 596.54
Autonomic neuropathy 337.0x, 337.1x
Gastroparesis/diarrhea 545.5x, 536.3x
Orthostatic hypotension 458.0x
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APPENDIX F. DIABETIC COMPLICATIONS AND ASSOCIATED ICD-9 CM DIAGNOSTIC 
CODES (CONTINUED) 
 
  
Diagnosis ICD-9 code(s)
Cerebrovascular
Transient cerebral ischemia 435.xx
Stroke 431.xx, 433.xx, 434.xx, 436.xx
Cardiovascular 
Atherosclerosis 440.xx
Other ischemic heart disease 411.xx
Angina pectoris 413.xx
Other chronic ischemic heart disease 414.xx
Myocardial infarction 410.xx
Ventricular fibrillation, arrest 427.1x, 427.3x
Atrial fibrillation, arrest 427.4x, 427.5x
Other arteriosclerotic cardiovascular disease 429.2x
Old myocardial infarction 412.xx
Heart failure 428.xx
Atherosclerosis, severe 440.23, 440.24
Aortic aneurysm/dissection 441.xx
Peripheral vascular disease 
Diabetic peripheral vascular disease 250.7x
Other aneurysm 442.3x
Peripheral vascular disease 443.81, 443.9x
Foot wound + complication 892.1x
Claudication, intermittent 443.9x
Embolism/thrombosis 444.22
Gangrene 785.4x
Gas gangrene 000.4x
Ulcer of lower limbs 707.1x
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